










Attitude and Intention to Abuse Controlled Prescription Drugs: 












A dissertation presented in partial fulfillment  
of the requirements for the degree of  
Doctor of Philosophy 
(Social and Administrative Sciences) 








Associate Professor Steven R Erickson, Co-Chair 
Professor Karen B Farris, Co-Chair 
Professor Richard P Bagozzi 
Professor Rajesh Balkrishnan, University of Virginia 










© David Malewski 


















Dr. Richard Bagozzi 
Dr. Rajesh Balkrishnan 
Dr. Steven Erickson 
Dr. Karen Farris 
Dr. Mark Ilgen 
 
Sumit Chhabra  
Peter Batra 
Dr. Anthony Chiodo 
The University of Michigan (U of M) 
University of Michigan Health System (UMHS) Spine Clinic Staff  
UMHS Spine Clinic Patients 
U of M College of Pharmacy Staff Volunteers 
U of M College of Pharmacy 
U of M Rackham Graduate School 
Duellman Graduate Student Research Fund 









Table of Contents 
 
Dedication ...................................................................................................................................... ii 
Acknowledgements ...................................................................................................................... iii 
List of Tables ............................................................................................................................... vii 
List of Figures ............................................................................................................................... ix 
List of Appendices ......................................................................................................................... x 
Abstract ......................................................................................................................................... xi 
Chapter 1: ...................................................................................................................................... 1 
Introduction, Objectives and Significance .................................................................................. 1 
Introduction ................................................................................................................................. 1 
Objectives .................................................................................................................................... 5 
Significance ................................................................................................................................. 7 
Innovation.................................................................................................................................... 8 
Chapter 2: .................................................................................................................................... 10 
Literature Review and Theoretical Models .............................................................................. 10 
Protection Motivation Theory ................................................................................................... 10 
Protection Motivation Theory and Substance Use Disorders ................................................... 13 
Theory of Planned Behavior ..................................................................................................... 15 
Theory of Planned Behavior and Substance Use Disorders ...................................................... 16 
Moderation, Mediation, and Conditional Indirect Effects ........................................................ 23 
The Use of Vignettes ................................................................................................................. 24 
Literature Review Discussion ................................................................................................... 27 
Proposing a New Behavioral Model – Protection Motivation – Theory of Planned Behavior 28 
Protection Motivation Theory Contribution .............................................................................. 30 
Theory of Planned Behavior Contribution ................................................................................ 30 
Moderation, Mediation, and Conditional Indirect Effects Contribution ................................... 31 
Chapter 3: .................................................................................................................................... 34 
Research Methodology ............................................................................................................... 34 
Specific Aims ............................................................................................................................ 34 
 
v 
Aim 1 ..................................................................................................................................... 34 
Aim 1 Research Questions .................................................................................................... 34 
Aim 2 ..................................................................................................................................... 34 
Aim 2 Hypotheses ................................................................................................................. 34 
Pre-test Survey .......................................................................................................................... 36 
Subject Sample/Patient Screening ............................................................................................. 36 
Qualitative Study Design .......................................................................................................... 37 
Interview Recruitment ............................................................................................................ 37 
Interview Design .................................................................................................................... 38 
Quantitative Study Design ........................................................................................................ 39 
Survey Recruitment ................................................................................................................ 39 
Measures and Analysis .............................................................................................................. 41 
Measures: Qualitative ........................................................................................................... 41 
Analysis: Qualitative ............................................................................................................. 42 
Measures: Quantitative ......................................................................................................... 43 
Analysis: Quantitative ........................................................................................................... 55 
Chapter 4: .................................................................................................................................... 58 
Results .......................................................................................................................................... 58 
Results: Qualitative ................................................................................................................... 58 
Recruitment ............................................................................................................................ 58 
Demographics ........................................................................................................................ 59 
Interview Findings ................................................................................................................. 60 
Interview Summary Findings ................................................................................................. 65 
Interview Significant Themes................................................................................................. 66 
Results: Quantitative ................................................................................................................. 67 
Recruitment ............................................................................................................................ 67 
Demographics ........................................................................................................................ 67 
Nonresponse bias ................................................................................................................... 69 
Control vs Test Groups: Vignette manipulation .................................................................... 69 
Hayes’ Regression Model 4 – What are the basic mediation relationships? ........................ 75 
Hayes’ Regression Model 7 – Demonstrating conditional indirect effects ........................... 79 
 
vi 
Chapter 5: Discussion ................................................................................................................. 89 
Main Findings of Overall Study ................................................................................................ 89 
Qualitative Theme Interpretations......................................................................................... 89 
Significance of the Vignette Manipulation ............................................................................ 93 
Significance of Regression Findings ..................................................................................... 96 
Test of the Theoretical Model ................................................................................................. 100 
Hypotheses predictions ........................................................................................................ 101 
Health Policy and Clinical Implications.................................................................................. 106 
Policy Implications .............................................................................................................. 107 
Clinical Implications ........................................................................................................... 108 
Study Limitations and Alternative Strategies.......................................................................... 109 
Generalizability ................................................................................................................... 109 
Language and cultural barriers .......................................................................................... 109 
Perceived behavioral control still to be tested .................................................................... 110 
Substance of choice ............................................................................................................. 111 
Recall bias and social desirability ....................................................................................... 111 
Type I error .......................................................................................................................... 112 
Future Research ....................................................................................................................... 113 
Future changes to study instruments ................................................................................... 113 
Future research suggestions and directions ........................................................................ 113 
Conclusion ............................................................................................................................... 115 






List of Tables 
 
Table 4.1 Qualitative Study Subject Characteristics ..................................................................... 59 
Table 4.2 Reviewer One: Patient Responses ................................................................................ 61 
Table 4.3 Reviewer Two: Patient responses ................................................................................. 63 
Table 4.4 Descriptive Data ........................................................................................................... 68 
Table 4.5 Non-response Bias Data................................................................................................ 69 
Table 4.6 Chi-square: Perceived Severity ..................................................................................... 71 
Table 4.7 Chi-square: Perceived Vulnerability ............................................................................. 71 
Table 4.8 Chi-square: Intrinsic Rewards ...................................................................................... 72 
Table 4.9 Chi-square: Extrinsic Rewards ..................................................................................... 72 
Table 4.10 Chi-square: Subjective Norms .................................................................................... 73 
Table 4.11 Chi-square: Attitude .................................................................................................... 73 
Table 4.12 Chi-square: Intention .................................................................................................. 74 
Table 4.13 Chi-square: Risk of Addiction .................................................................................... 74 
Table 4.14 Chi-square: Self-Efficacy ........................................................................................... 75 
Table 4.15 Prescription Misuse Types and Combinations............................................................ 76 
Table 4.16 Model 4 Intention Full Model - Often & Dose – Abbreviated* ................................. 77 
Table 4.17 Model 4 Intention Full Model - Withdrawal & Feel Good – Abbreviated* ............... 78 
Table 4.18 Model 4 Theory of Reasoned Action All Misuse Types – Abbreviated* .................. 79 
Table 4.19 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Often & Dose Misuse – Abbreviated* .......................................................................................... 81 
Table 4.20 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Withdrawal & Feel Good – Abbreviated* .................................................................................... 82 
Table 4.21 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M1) and Attitude(M2) 
 Intention(Y) Withdrawal & Feel Good – Abbreviated* .......................................................... 83 
Table 4.22 Model 7 Self-Efficacy(W) with Perceived Severity(M)  Intention(Y) Withdrawal 
Misuse – Abbreviated* ................................................................................................................. 84 
Table 4.23 Model 7 Self-Efficacy(W) with Intrinsic Rewards(M)  Intention(Y) Often and Dose 
Misuse – Abbreviated* ................................................................................................................. 85 
Table 4.24 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M)  Intention(Y) 
Withdrawal and Feel Good Misuse – Abbreviated* ..................................................................... 86 
Table 4.25 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M1) and Attitude(M2)  
Intention(Y) All Type Misuse – Abbreviated* ............................................................................. 87 
Table 4.26 Model 7 Risk of Addiction(W) with All Mediators and Intention(Y) All Misuse 
Types  - Abbreviated* ................................................................................................................... 88 
Table B.1 Reviewer One: Interview coding ............................................................................... 158 
Table B.2 Reviewer Two: Interview coding ............................................................................... 159 
 
viii 
Table B.3 Model 4 Attitude Full Model - Often & Dose............................................................ 161 
Table B.4 Model 4 Attitude Full Model - Withdraw & Feel Good ............................................ 163 
Table B.5 Model 4 Intention Full Model - Often & Dose .......................................................... 165 
Table B.6 Model 4 Intention Full Model - Withdrawal & Feel Good ........................................ 167 
Table B.7 Model 4 Theory of Reasoned Action All Misuse Types ............................................ 169 
Table B.8 Model 6 Perceived Vulnerability Often & Dose ........................................................ 171 
Table B.9 Model 6 Perceived Vulnerability Withdrawal & Feel Good ..................................... 173 
Table B.10 Model 6 Perceived Severity Often & Dose .............................................................. 175 
Table B.11 Model 6 Perceived Severity Withdrawal & Feel Good ........................................... 176 
Table B.12 Model 6 Perceived Intrinsic Rewards Often & Dose ............................................... 177 
Table B.13 Model 6 Perceived Intrinsic Rewards Withdrawal & Feel Good ............................ 179 
Table B.14 Model 6 Perceived Extrinsic Rewards Often & Dose .............................................. 181 
Table B.15 Model 6 Perceived Extrinsic Rewards Withdrawal & Feel Good ........................... 183 
Table B.16 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Attitude(Y) 
Often & Dose Misuse.................................................................................................................. 186 
Table B.17 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Often & Dose Misuse.................................................................................................................. 188 
Table B.18 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Attitude(Y) 
Withdrawal & Feel Good ............................................................................................................ 190 
Table B.19 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Withdrawal & Feel Good ............................................................................................................ 192 
Table B.20 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M1) and Attitude(M2) 
 Intention(Y) Withdrawal & Feel Good .................................................................................. 194 
Table B.21 Model 7 Self-Efficacy(W) with Perceived Severity(M)  Attitude(Y) Often Misuse
..................................................................................................................................................... 196 
Table B.22 Model 7 Self-Efficacy(W) with Perceived Severity(M)  Intention(Y) Withdrawal 
Misuse ......................................................................................................................................... 198 
Table B.23 Model 7 Self-Efficacy(W) with Intrinsic Rewards(M)  Attitude(Y) Often and Dose 
Misuse ......................................................................................................................................... 200 
Table B.24 Model 7 Self-Efficacy(W) with Intrinsic Rewards(M)  Intention(Y) Often and 
Dose Misuse ................................................................................................................................ 202 
Table B.25 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M)  Attitude(Y) 
Withdrawal and Feel Good Misuse............................................................................................. 204 
Table B.26 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M)  Intention(Y) 
Withdrawal and Feel Good Misuse............................................................................................. 206 
Table B.27 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M1) and Attitude(M2)  
Intention(Y) All Type Misuse ..................................................................................................... 208 
Table B.28 Model 7 Risk of Addiction(W) Full Model Attitude(Y) All Misuse Types ............ 210 





List of Figures 
 
Figure 2.1 Protection Motivation Theory12 ................................................................................... 12 
Figure 2.2 Theory of Planned Behavior22 ..................................................................................... 16 
Figure 2.3 Conditional Indirect Effects Model ............................................................................. 23 
Figure 2.4 Full Proposed Behavioral Model ................................................................................. 29 
Figure 2.5 Conditional Indirect Effect Model: Intention .............................................................. 29 
Figure 3.1 Intention Questions ...................................................................................................... 44 
Figure 3.2 Vignette 1: Control Scenario ....................................................................................... 45 
Figure 3.3 Vignette 2: Test Scenario ............................................................................................ 45 
Figure 3.4 National Institute of Drug Abuse: Modified Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST) - Lifetime: ...................................................................... 47 
Figure 3.5 National Institute of Drug Abuse: Modified Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST) – Six-month: .................................................................. 48 
Figure 3.6 Perceived Vulnerability Questions .............................................................................. 49 
Figure 3.7 Intrinsic Rewards Questions ........................................................................................ 49 
Figure 3.8 Extrinsic Rewards Questions ....................................................................................... 50 
Figure 3.9 Subjective Norms Questions ....................................................................................... 50 
Figure 3.10 Attitude Question: Often ........................................................................................... 51 
Figure 3.11 Attitude Question: Dose ............................................................................................ 51 
Figure 3.12 Attitude Question: Withdrawal .................................................................................. 52 
Figure 3.13 Attitude Question: Feel Good .................................................................................... 52 
Figure 3.14 Perceived Severity Questions .................................................................................... 53 
Figure 3.15 Risk of Addiction ...................................................................................................... 54 
Figure 3.16 Self-Efficacy .............................................................................................................. 55 
Figure 4.1 Study Recruitment ....................................................................................................... 58 
Figure 4.2 Process Model 4 and Key ............................................................................................ 76 
Figure 4.3 Process Model 7 and Abbreviated Key ....................................................................... 80 
Figure B.1 Process Model 4 and Key ......................................................................................... 160 
Figure B.2 Process Model 6 and Key ......................................................................................... 170 






List of Appendices 
 
 
Appendix A: Documents........................................................................................................... 117 







Background: Over 6 million people misuse prescription opioids yearly in the U.S. resulting in 
adverse events and deaths. Little is known about why people turn to opioid misuse.  
Objectives: This study objective was to examine the influence of moderators (when) and 
mediators (how) on pain level, drug seeking, and misuse (misuse scenario) to predict intention to 
misuse prescription opioids. Two theoretical models: Protection Motivation Theory (PMT) and 
the Theory of Planned Behavior (TPB) were integrated serving as the study framework. Risk of 
addiction and self-efficacy were the moderators, while attitude, perceived severity, perceived 
vulnerability, intrinsic rewards, extrinsic rewards, and subjective norms were the mediators.  
Methods: The web-administered instrument included PMT and TPB items.  It underwent pretest 
(5 subjects) and qualitative testing (13 subjects) to assess readability/sensibility and face validity. 
An additional 160 patients participated in the survey. Subjects were patients of the University of 
Michigan Health System Spine Clinic, age 18 years or older, diagnosed with chronic pain, taking 
an opioid for over a month, outpatient only, and without cancer-related pain. Subjects were 
randomized into one of two controlled vignettes created to standardize experimental misuse 
scenario conditions.  
Analysis: Qualitative responses were grouped by question and response similarity. Moderator 
and mediator association with intention to misuse prescription opioids was assessed using chi-
square, t-tests, and regression analysis. 
Results:  The interviews revealed that the vignettes, survey questions, and response options were 
understandable. Changes were suggested to perceived severity and extrinsic rewards questions to 
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enhance realism. Risk of addiction and self-efficacy were significant moderating variables. 
Attitude, perceived vulnerability, and intrinsic rewards were significant mediating variables.   
Discussion/Conclusion: Risk of addiction and self-efficacy predicted “when” perceived 
vulnerability, severity, intrinsic rewards, and attitude would describe “how” misuse scenario 
influenced intention to misuse prescription drugs. This theory-based study was among the first 
examining the effects of moderators and mediators on intention to misuse opioids. The perceived 
behavioral control factors and full model need to be tested. This study is a first step towards the 
development of instruments and interventions to measure individual predictors of opioid misuse 






Chapter 1  
Introduction, Objectives and Significance 
Introduction 
 Over 6 million people in the U.S. are non-medical users of prescription-type drugs with 
over 4.5 million specifically misusing prescription pain relievers.1 Estimates of societal costs 
related to opioid misuse and misuse show yearly costs over $55 billion in work place, health 
care, and criminal justice.2 Related to these costs, hospital emergency departments (ED) have 
experienced significantly more admissions for unintentional overdose involving misuse and 
misuse of prescription opioids. Specifically, ED visits increased 175%, from 144,644 in 2004 to 
397,160 in 2009.3 Overdose deaths from prescription opioids have reached nearly 17,000 deaths 
annually since 2012.4 The increasing yearly number of prescriptions for opioids has been a 
primary driver for these statistics. Specifically, prescriptions for opioid painkillers more than 
doubled between 1991 with 76 million prescribed and 2013 with 207 million prescribed.5  
Use of prescription opioids may lead to physical dependence when taking them on a 
regular schedule, especially with the strong doses that chronic pain patients may be prescribed, 
even when following the doctor’s directions exactly.6 Physical dependence on the opioid does 
not constitute misuse; however, it is a strong sign that a person may be developing a tolerance, 
need to use more medication to achieve the same effect, and/or be in danger of proceeding down 
the path of misuse and misuse. Prescription opioid misuse can be described as using the 
medication in any way other than prescribed. While misuse and addiction are commonly used 
terms they are not considered diagnostic. The Diagnostic and Statistical Manual of Mental 
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Disorders, Fifth Edition (DSM-V) uses the terms substance use disorder and opioid use disorder 
to describe when a person is misusing a substance(s) and/or experiencing deleterious behavior 
associated with the use of a substance(s). There are three levels of severity for opioid use 
disorder classified based upon number of diagnostic symptoms: mild (2-3), moderate (4-5), 
severe (6 or more). The following list details the DSM-V diagnostic criteria: 
1. Opioids are often taken in larger amounts or over a longer period than was intended.  
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
3. A great deal of time is spent in activities to obtain, use, or recover from opioid effects.  
4. Craving, or a strong desire or urge to use opioids.  
5. Opioid use resulting in failure to fulfill major role obligations at work, school, or home.  
6. Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids.  
7. Important interpersonal activities are given up or reduced because of opioid use.  
8. Recurrent opioid use in situations in which it is physically hazardous.  
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the substance.  
10. Tolerance, as defined by either of the following:  
a. A need for markedly increased amounts of opioids to achieve intoxication or 
desired effect.  
b. A markedly diminished effect with continued use of the same amount of an 
opioid. 




11. Withdrawal, as manifested by either of the following:  
a. The characteristic opioid withdrawal syndrome.  
b. Opioids (or related substance) are taken to relieve or avoid withdrawal symptoms.  
Note: Taking opioids solely under appropriate medical supervision discounts 
withdrawal. 
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition, (Copyright 2013). American Psychiatric Association. All Rights Reserved.  
While the DSM-V criteria are important for diagnosing opioid-related disorder, their use 
is seen after a person has already developed a problem. Likewise, the majority of the instruments 
that clinicians have for addressing potential and/or current substance use issues with their 
patients are more reactive than proactive. Many of these instruments require the prescriber to 
have more advanced knowledge of addiction-related behavior and/or access to information that is 
not always easy to find in the medical records, such as the D.I.R.E.7 Many of the other 
instruments rely on self-reports of specific substance use, misuse-related behavior and other 
psychosocially determinate indications of aberrant drug-related behaviors (ADRB).8 While some 
of these instruments are useful for determining likelihood that opioid misuse is occurring or will 
occur, the predictive power relies heavily on detecting ADRBs with very little, if any, focus on 
individualized thoughts, beliefs and attitudes that may help to predict a patient’s intention to 
misuse their prescription opioids. Intention, in this context, being the conscious plan, decision or 
self-instruction of a person to actually perform a particular behavior.9 
Qualitative assessment techniques often include focus groups and interviews and are an 
important part of helping to understand whether a survey or other instrument is accurately 
capturing the thoughts and opinions of the target population. Most often the qualitative pilot-
testing is performed before the instrument is used in a study. However, there are cases where 
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qualitative studies were conducted while the instrument was in the field in order to gain insight 
into future changes and developments for the instrument.10,11  
The survey developed for this research project was based on questions used in substance 
use based research, but with different subject populations. Likewise, vignettes, used as an 
experimental manipulation, have not been utilized when studying substance abuse before or for 
the purposes of determining factors predictive of a patient’s intention to misuse prescription 
drugs. A small pre-test of the survey was conducted to test and modify the instructions, 
questions, and response options within the survey for understandability and readability in an 
effort to maximize face validity and to reduce issues that may hinder the administration. The pre-
test was conducted with a small group of people of which only one was potentially from the 
target population.  
The qualitative findings from the pilot-test interviews were beneficial in explaining 
certain findings obtained in the second phase of the study, and will be beneficial in future 
research that will include assessment of the remaining perceived behavioral control-based (PBC) 
survey to complete the overall assessment of the behavioral.  
Many substance misuse treatment programs focus on individualized thoughts, beliefs and 
attitudes in an attempt to identify successful strategies to keep patients from continuing to misuse 
their substance of choice or relapse. Many treatment programs use cognitive behavioral therapy 
(CBT) often coupled with motivational interviewing (MI) in an attempt to identify different 
situations, thoughts, and other factors that may lead to substance use. Being able to identify key 
factors that help to identify when, how and why a person decides to misuse a substance is 
important in designing tools and interventions that will help to successfully prevent, detect and 
treat substance use disorders. 
 
5 
The long-term goal of this investigator is to discover significant theory-based predictors 
of when and how a patient will misuse their prescription drugs. He then intends to utilize those 
predictors to adapt and/or develop instruments and interventions to detect, prevent, and treat 
substance use disorders. 
Objectives 
 The overall objective of this study is to discover theory-based behavioral factors that are 
predictors of intention of chronic pain patients to misuse their controlled prescription drugs. The 
central hypothesis of the study is that conditional indirect effects models will reveal moderators 
(when) and mediators (how) that are predictive of intention of patients to misuse controlled 
prescription drugs. Testing the central hypothesis is dependent upon quantitative testing utilizing 
a theory-based survey to determine which predictive factors (mediators and moderators) exhibit 
the most influence on intentions of patients to misuse controlled prescription drugs. Two specific 
aims encompass the qualitative and quantitative research performed in this study: 
Aim 1: To assess the readability, sensibility, and face-validity of the study survey 
instrument using qualitative techniques.  The thoughts and opinions of a group of patients 
who have chronic pain were assessed using semi-structured interviews of individual 
patients. 
Aim 2: To determine which, if any, theory-based factors identified and operationalized 
from the combined study model utilizing the Protection Motivation Theory and Theory of 
Planned Behavior are predictive of intention to misuse controlled prescription drugs, 
utilizing a vignette manipulation of the conditions associated with pain level, drug 
seeking level, and misuse level (misuse scenario). 
With regard to these aims, the following study questions and hypotheses were examined: 
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1. Will the patients in the pilot-test qualitative study understand and identify with the 
vignettes and types of misuse examined thereby confirming the instrument has face-
validity? 
2. Will the pilot-test qualitative study patients identify survey questions that require revision 
and clarification on future survey instruments? 
3. The level of pain, drug seeking behavior, and drug misuse behavior (vignette) and a 
moderator (risk of addiction or self-efficacy) will interact to exert a conditional indirect 
effect on intention through a mediator (attitude, perceived severity, perceived 
vulnerability, intrinsic rewards, extrinsic rewards, and subjective norms) 
4. The moderators risk of addiction and self-efficacy, will be revealed as significant factors 
predicting when a particular mediator will influence intention to misuse controlled 
prescription drugs.  
a. Specifically, high risk of addiction should indicate that a mediator is likely to 
increase intention/likelihood to misuse and low risk of addiction should predict a 
decrease. 
b. High self-efficacy should indicate that a mediator is likely to decrease 
intention/likelihood to misuse and low self-efficacy should predict an increase. 
5. The mediators which include attitude, perceived severity, perceived vulnerability, 
intrinsic rewards, extrinsic rewards, and subjective norms, will be revealed as significant 
factors predicting how a particular moderator will interact with vignette to influence 
intention to misuse controlled prescription drugs. 
a. Perceived severity and perceived vulnerability are adaptive behaviors that if 
significant should function to reduce intention/likelihood to misuse. 
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b. Intrinsic rewards and extrinsic rewards are maladaptive behaviors that if 
significant should function to increase intention/likelihood to misuse. 
c. Attitude will be bi-directional. One of the other mediators will likely influence an 
increase/decrease in attitude which will influence increase/decrease in 
intention/likelihood to misuse. 
d. Subjective norms are expected to decrease intention/likelihood to misuse. 
Significance 
Deaths due to overdoses of controlled prescription drugs have eclipsed those of heroin 
and cocaine combined.12 In addition to the overdoses, adverse medical events, and draining law 
enforcement resources, diversion of controlled prescription drugs has contributed to an average 
yearly increase in illicit use of controlled prescription drugs of 1.9 million persons per year since 
2002.1  
Most of the efforts at curbing prescription drug abuse have been aimed at the illicit non-
medical use of opioids by adults and children. However, chronic pain patients are at greater risk 
for abusing prescription drugs and a primary source for diverting opioids for non-medical use. In 
order to design better interventions to prevent drug abuse it’s necessary to understand the many 
moderators and mediators that influence the intentions of prescription painkiller users.  
This contribution is significant because it is the first step in establishing a framework to 
understand how the various moderators and mediators in the behavioral model influence 
intention to misuse prescription drugs. This contribution is significant because it is a major step 
in developing tools and intervention strategies tailored to the perceptions, attitudes, beliefs and 
risk-taking for controlled prescription drug users. The major impact of this study will be 
contributions to the production of instruments and interventions designed to enable clinicians to 
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identify chronic pain patients who are susceptible to misuse of opioids.  By identifying subjects, 
interventions could be introduced that would encourage the responsible use of controlled 
prescription drugs that minimize the risk of misuse and diversion. These programs would then 
result in reductions of overdoses, adverse medical events, and significant medical and law 
enforcement cost savings. 
Innovation 
The proposed study is among the first to integrate Protection Motivation Theory with the 
Theory of Planned Behavior to determine the perceptions, attitudes and beliefs and the role of 
risk-taking and abuse potential in the use of controlled prescription drugs by patients. The 
protection motivation theory is useful for understanding the role of attitude and behavioral 
control on intention toward an observed behavior. The theory of planned behavior is useful for 
understanding perception, attitudes, beliefs and the contribution of modifiers like self-efficacy 
and risk-taking to the development of patient intentions and the consequent likelihood of those 
intentions leading to behavior. 
The proposed research is innovative in that, it will be among the first to examine the 
intentions of chronic pain patients and the importance of perceived severity, perceived 
vulnerability, intrinsic rewards, extrinsic rewards, subjective norms and whether self-efficacy 
and risk of abuse moderate these relationships in the abuse of controlled prescription drugs. 
Understanding how moderators and mediators affect changes in medication misuse intentions 
will provide researchers with information to develop instruments and interventions aimed at 
regulating and/or changing medication misuse behavior in order to prevent controlled 
prescription drug misuse.  
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The use of vignettes within this study is innovative because it is among the first theory-
based studies to use vignettes as randomizing manipulation examining the influence on patient’s 
intentions to misuse prescription opioids. Using the vignettes was useful for randomizing 
patients to different scenarios of pain level, drug seeking level, and misuse level. Drug abuse is a 
stigmatizing subject and asking patients to answer as a vignette patient further enhanced their 
anonymity by having the patient become the “paper patient” for answering the survey questions. 
By using the vignettes the study did not need to rely on finding patients who were actually 
actively misusing their prescription opioids and were then able to recruit significantly fewer 
patients in order to have enough in each group.  
This study will inform prescribers, pharmacists and other healthcare professionals about 
important behavioral factors of prescription drug misuse, such as risk of addiction and perceived 
vulnerability, to help develop personalized treatment programs that emphasize responsible 






Chapter 2  
Literature Review and Theoretical Models 
 This chapter discusses the behavioral theories utilized to construct a new behavioral 
model intended to detail the specific influences on intention to misuse controlled prescription 
drugs. Specifically, the new behavioral model combines the factors associated with the 
Protection Motivation Theory and the Theory of Planned Behavior. The study utilizes 
conditional indirect effects models and randomizing patients to one of two vignettes, addressing 
pain, drug seeking, and misuse, to determine which factors are serving as key moderators and 
mediators in predicting prescription misuse behavior. Each section of this chapter describes the 
operationalization and utilization of the factors within each theory. Additionally, each section 
details the use of each theory in substance use disorder research. Lastly, this chapter describes 
how the theories work together to form a new behavioral model for predicting prescription drug 
misuse. 
Protection Motivation Theory 
 Protection motivation theory (PMT) serves as a framework for understanding fear 
appeals and their impact. PMT focuses on how fear appeals may be used to influence attitudes 
and behavior. The theory has been useful in communication development and evaluation and 
predicting health behavior.13-16 Between the initial creation of PMT in 1975 and the subsequent 
revision in 1983 the focus of the theory changed from three components of a fear appeal: 1) 
magnitude of a particular event; 2) probability of event; and 3) protective response efficacy.13 
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The 1983 revision, which is the current incarnation of PMT, focuses upon the convergence of 
maladaptive responses comprising a threat appraisal and adaptive responses comprising a coping 
appraisal which together influence the intentions associated with protection motivation.14-16 The 
threat appraisal is composed of intrinsic rewards and extrinsic rewards which are counter-
balanced by perceived severity and perceived vulnerability. The coping appraisal is composed of 
response efficacy and self-efficacy which are counterbalanced by response costs.  
Intrinsic rewards increase the likelihood of a maladaptive response because they are 
perceived benefits associated with an otherwise unhealthy or harmful behavior. An example is 
misusing controlled prescription drugs to “feel good”. Extrinsic rewards increase the likelihood 
of a maladaptive response because a person witnesses friends, family or other important people 
receiving a perceived benefit from an otherwise unhealthy or harmful behavior. An example is 
growing up in a smoking household and a person taking up the habit because they perceive that 
their parent(s) enjoy smoking. Perceived severity and vulnerability to a given threat can serve to 
inhibit maladaptive responses. Perceived severity focuses on the consequences and their 
seriousness associated with a particular health threat. Thus the consequences and seriousness of a 
patient damaging their health due to the threat associated with prescription drug misuse may help 
to inhibit a maladaptive response. Perceived vulnerability looks at how susceptible an individual 
is to a particular health threat. Another way to look at a person’s perceived vulnerability would 
be to examine their willpower to avoid misusing their medication. The more vulnerable a person 
feels the lower their willpower to avoid misusing their medication and the more likely they will 
experience a negative outcome. In this way perceived vulnerability can be used to inhibit a 
maladaptive response by attaching outcomes which the person perceives as severe enough to 
stop the behavior. 
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Response efficacy is an adaptive response part of the PMT coping appraisal that focuses 
on the belief that a threat will be reduced by performing a recommended behavior. For example, 
a person may believe that stopping their misuse of prescription drugs will make it less likely 
they’ll have liver problems and be more likely to live longer. Self-efficacy is also an adaptive 
response that is the belief that a person can perform or avoid performing a specific behavior. 
Related to the previous example, a person with stronger self-efficacy should have an increased 
ability to perform behaviors beneficial to avoiding prescription drug misuse. Response costs are 
the adaptive responses that may serve to counterbalance response efficacy and self-efficacy in 
the PMT coping appraisal. Specifically, a person may believe (or know) that they will suffer 
withdrawal symptoms if they stop misusing their prescription drugs. In this way, the response 
costs may serve as barriers to performing an adaptive behavior or reinforce a maladaptive 
behavior. 
The threat and coping appraisals interact to comprise a person’s protection motivation.14-
16 The factors which comprise a person’s protection motivation ultimately function to increase or 
decrease their attitude towards the target behavior which, in turn, influences their intention to 
perform or avoid performing a particular behavior.13  




Protection Motivation Theory and Substance Use Disorders 
  Over the last 30 years, protection motivation theory has been used as a back bone to 
design a few different types of informative communication protocols and interventions aimed at 
alcohol and other substance use disorders.10,17-20 In 1993, Runge, Prentice-Dunn and Scogin 
developed an Alcohol Attitude Survey using protection motivation theory to examine which 
factors are involved with alcohol misuse problems in an elderly population.17 In this hypothesis 
generating study they found that increased vulnerability was associated with increased 
maladaptive behavior. Likewise, the factors that could potentially help prevent alcohol misuse 
were response efficacy, self-efficacy, response costs, and vulnerability.17  
Wallerstein and Sanchez-Merki developed a program for New Mexico youth in 
communities at high risk of alcohol and substance misuse.10 They incorporated factors from the 
protection motivation theory into a Freirian praxis model of health education. The Freirian 
practice model of behavior change, through education, focuses upon ‘triggering’ words and 
images of people’s problems that are emotionally and socially relevant.21 The study incorporated 
the threat and coping appraisals from PMT into a Freirian listening-dialogue-action model. 
Increased vulnerability, severity, and self-efficacy were found to be related to a person’s ability 
to engage in dialog about a problem.10 In addition to the qualitative research, there were three 
follow-up questionnaires given pre, post, and at 8 months after intervention exposure. However, 
results of the qualitative research indicated that the experimental design of the questionnaires 
needed to be modified by the inclusion of additional PMT variables self-efficacy, response 
efficacy, other-protective efficacy and empathy.10 The research discussion indicated four primary 
findings: 1) the three-stage model can help create a sense of empowerment; 2) emotions play an 
important role in the change process; 3) social change should be fully integrated into each stage 
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of a program; and in order to build trust and the support structures necessary for programs to 
have a lasting impact, health educators need to make long-term commitments to communities.10  
Ben-Ahron, White, and Phillips developed a PMT-based questionnaire in order to 
understand and potentially moderate high-risk drinking behavior.18 They compared the responses 
of higher and lower risk drinkers in order to reveal differences in coping and cognition. The 
questionnaire addressed PMT factors related to binge drinking. Particularly covered were 
perceived severity and vulnerability to binge drinking, self-efficacy to drink at safe limits, 
response efficacy to drink at advocated safe limits, intrinsic and extrinsic rewards associated with 
binge drinking, and response costs associated with safe drinking.18 Also addressed on the 
questionnaire were demographic variables, behavioral intentions toward safe drinking, and 
adaptive and non-adaptive binge drinking associated strategies: rational problem solving, 
avoidance, religious faith, wishful thinking, and fatalism.18 There were six variables that 
predicted intention towards future binge drinking accounting for 42% of the variance in 
intention. Specifically, people reported higher adaptive intentions (ability to drink safely) when 
1) rational problem solving was higher; 2) avoidance was lower; 3) perceived protection 
religious faith was lower; 4) vulnerability was lower; 5) intrinsic rewards were lower; and 6) 
females reported higher adaptive intentions than males.18 The researchers further conducted a 
path analysis that points to a mediating role for perceived vulnerability, intrinsic rewards, 
rational problem solving, avoidance, and religious faith. This study was among the first to utilize 
PMT as a framework for examining binge drinking. 
Preventing alcohol consumption by women who are pregnant or attempting to become 
pregnant is an important subject of several health communication campaigns that have used 
various parts of protection motivation theory. Cismaru et al reviewed 20 different social 
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marketing campaigns from around the world aimed at preventing fetal alcohol spectrum 
disorders (FASD).20 The goal of the review was to show how PMT can be used to create effect 
and persuasive communication-based interventions. The review revealed five PMT variables that 
were most utilized in the existing communications: severity and vulnerability in 95% of 
campaigns, response efficacy in 70%, self-efficacy in 55%, and costs in 45%.20 The evidence for 
this review is primarily anecdotal based on all of the prevention campaigns examined. The 
review concludes that perceived vulnerability and severity should be the primary focus of future 
campaigns while also providing low cost advice that emphasizes high levels of self-efficacy.20 
Likewise, programs should concentrate on helping pregnant women find and create alcohol-free 
environments. The logical follow-on to this review would be to conduct some quantitative 
research to attempt to discover which aspects of PMT and the existing communications are most 
successful in preventing FASD. More effective and targeted theory-based communications and 
interventions can then be developed. 
Some of the features of the protection motivation theory share features with the next 
behavioral intention theory, the theory of planned behavior (TPB). Particularly, the threat 
appraisals from PMT; perceived severity and vulnerability and intrinsic rewards directly relate to 
TPB attitude, and extrinsic rewards relates to TPB subjective norms. The coping appraisals from 
PMT; self-efficacy, response efficacy, and response costs relate to TPB perceived behavioral 
control. Lastly, both theories ultimately serve to predict intention towards a specific behavior. 
Theory of Planned Behavior 
 In 1975, Fishbein and Ajzen proposed the Theory of Reasoned Action (TRA) which 
focused on attitudes and subjective norms as the predictors of behavioral intention.9 The TRA 
was later extended by the addition of perceived behavioral control to become the Theory of 
 
16 
Planned Behavior (TPB).22-24 To better understand the structure of the TPB, please refer to 
Figure 2.2. Attitude is defined as ‘a learned disposition to respond in a consistently favorable or 
unfavorable manner with respect to a given object.’9 Perceived consequences and other attributes 
account for the behavioral beliefs that help form a person’s attitudes. A person’s beliefs about 
whether friends, family or other important people approve or disapprove of a particular behavior 
make up their subjective norms. These normative beliefs are governed by the extent to which a 
person is willing to conform to the perceived expectations of others. Perceived behavioral control 
helps to extend the theory beyond the limitations discovered when focusing solely upon attitude 
and subjective norms. Perceived behavioral control consists of beliefs that a person can actually 
perform or avoid performing a particular behavior because they have access to the necessary 
resources that may be required for success.22-24 The factors responsible for a person’s perception 
of control may be external (barriers, options, reliance on others) or internal (knowledge, 
competence, feelings, skills). The more positive factors at a person’s disposal relative to road-
blocks the higher the perceived behavioral control they are likely to report. 
Figure 2.2 Theory of Planned Behavior22 
 
Theory of Planned Behavior and Substance Use Disorders 
The theory of planned behavior has been used for at least the last 20 years to examine 
alcohol use disorder, mostly through predicting binge drinking and related risky drinking 
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behavior through understanding people’s intentions.25-29 Within the last 10 years the TPB has 
seen use in predicting substance use behavior for a variety of substance use disorder types 
ranging from tobacco and marijuana to prescription stimulants, steroids, and other illicit 
prescription drug use.27,30-35 The alcohol-based studies all sought to extend the TPB by enhancing 
the predictive power through the addition of factors that either build upon or extend the three 
core factors in TPB: attitudes, subjective norms, and perceived behavioral control. Particularly, 
these studies focused on outcome expectancies which related to attitudes and perceived 
behavioral control and extended norms that related to subjective norms. One of the earlier studies 
in 1998 examining alcohol outcome expectancies and attitudes toward drinking found that 
adding gender-specific alcohol outcome expectancies improved the predictive power of the 
model. Specific outcome expectancies that predicted excessive consumption were based on 
women’s perceived enhanced sociability and assertiveness and male’s expectancies for sexual 
functioning.25 Thinking back to the important factors in PMT we can ascertain that these 
outcome expectancies may fulfill the threat appraisal role of intrinsic rewards in increasing the 
likelihood of maladaptive behavior.  
In 2007, a study examined the effect of anticipated regret and descriptive norms within 
the TPB to predict binge drinking.26 Descriptive norms differ from subjective norms in that 
subjective norms represent what a person’s significant other think they ought to do versus 
descriptive norms where a person observes what their significant other are actually doing. This is 
an interesting potential linkage between extrinsic rewards in PMT and subjective norms in TPB. 
Anticipated regret was defined as “perceiving that one will feel regret at not performing a 
behavior.”26 This factor could also be reasonably linked to PMT as either a threat or coping 
appraisal depending upon how it was approached. In the case of this study it would function in 
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the perceived vulnerability and severity category as it focused on the belief that binge-drinking 
sessions would often lead to negative health consequences. They found that both attitudes and 
anticipated regret predicted intention and further that intentions and previous binge-drinking 
behavior were predictors of current drinking behavior.  
Continuing the trend of examining norms in relation to alcohol use, Kam et al looked to 
apply the TPB to predicting alcohol, tobacco, and marijuana among ethnically Mexican youth.27 
The researchers hypothesized that the norms would be multidimensional consisting of subjective 
norms (parental and peer injunctive), descriptive and personal substance use norms. Their second 
hypothesis suggested that the TPB variables attitude, personal norms, and perceived behavioral 
control would mediate the relationship between the multidimensional norms and intention. 
Lastly, they thought the model might work differently dependent upon the country of origin for 
each participant. Addressing their results in reverse order, they found that country of origin had 
no effect in the mediation model. In testing their second hypothesis, they found that positive 
attitudes towards alcohol, tobacco and other drugs, personal norms, and perceived behavioral 
control fully mediated parental and peer injunctive norms, while only partially mediating 
descriptive norms. Lastly, supporting the first hypothesis, they found that norms functioned in a 
multidimensional capacity.27 The significance of norms as a predictor within the TRA and TPB 
has been a matter of speculation for the last 20 years. These studies that are finding the norms to 
be fully or at least partially predictive may be doing so because of more specifically worded 
questioned designed to detect nuances in the norm that more generally worded questions in other 
studies could potentially be missing. 
This next study showed mixed results when subjective norm was one of the suspected 
predictors of intention to engage in risky drinking within a TPB framework.28 The study 
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examined the theory of planned behavior as a predictor of growth in risky college drinking. This 
study also used self-efficacy as a predictor in addition to standard perceived behavioral control 
questions. Intention was examined at baseline, peak drinking (# drink consumed during peak 
drinking occasion during last month) and for future episodic drinking. Self-efficacy, attitudes, 
and subjective norms were found predictive of both baseline and future episodic drinking. 
However, subjective norms were not predictive of peak drinking, whereas self-efficacy and 
attitudes were. Their results showed that intention mediated the relationship between self-
efficacy and attitudes on growth in risky drinking. Lastly, the researchers suggest that feedback 
on self-efficacy, attitudes, and intentions to engage in risky drinking may be useful for the 
development of interventions aimed at college populations.28 Once again a specific factor from 
PMT, self-efficacy, had been incorporated into a TPB framework in order to enhance the 
predictive power. 
One of the more recent alcohol-focused studies in 2012 examined salient beliefs of 
college students about binge drinking (defined as 7 or more units of alcohol in an evening) in 
order to better understand how those beliefs relate to the TPB and provide guidance for the 
development of future interventions aimed at reducing binge drinking.29 Higher intention to 
binge drink was associated with a person’s belief that their friends approved, getting “drunk” 
was an advantage/what they liked about binge drinking, their sports team would approve, and a 
celebratory environment and the associated drinking patterns made it easier to binge drink.29 
Conversely, inability to pay for drinks made binge drinking more difficult. This research showed 




The rest of the papers discussed in this section focus upon non-alcohol substance use and 
the use of the theory of planned behavior to understand and predict related behavior. The first 
paper examines smoking onset among 12 to 16 year olds with and without asthma.30 In addition 
to showing that attitude, subjective norm and perceived behavioral control were more predictive 
of intention towards onset of smoking in asthmatic adolescents this paper provided the 
questionnaire design in the appendix which proved helpful in the development of future 
questionnaires. There was an interesting cognitive dissonance that occurred when a previously 
non-smoking asthmatic would become a smoker. Previous to starting smoking, they would have 
negative attitudes, lower intention to smoke and higher perceived behavioral control (PBC). 
However, after they began smoking their cognition switched to pro-smoking.30 The study found 
that PBC was the strongest predictor of intention to smoke in asthmatic adolescents. Likewise, 
the subjective norms associated with their parents were stronger than non-asthmatics. The 
researchers concluded that smoking among adolescents with asthma was more planned and that 
focus on PBC and parent-based programs to reduce smoking initiation are important goals for 
future interventions.30 This study serves to illustrate the importance of preventing the initiation of 
substance use in the first place before important cognitive changes may be implemented through 
substance use. 
The next paper examined illicit use of prescription stimulants among college students, but 
rather than looking to use the theory of planned behavior to predict misuse this study was more 
deterministic in wanting to define attitudes, beliefs, knowledge and practices that related to 
prescription stimulant use.31 They found that the primary reasons for illicit stimulant use were 
primarily related to academic performance on campus; improved alertness and concentration, 
instead of recreational use. Versus non-illicit users, illicit users had lower scores on health 
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concerns with use, ethics, and perceived control. Likewise, they had higher perceived positive 
subjective norms. This study did not directly measure intention. They conclude that the TPB is a 
reasonable framework for understanding illicit stimulant use and further suggest that leveraging 
awareness of actual adverse health effects could be used to reduce illicit use by influencing 
attitudes to be less positive towards illicit use.31 This is another example of relating PMT-related 
threat appraisals of perceived vulnerability and severity to a potentially TPB-framed 
intervention. 
A cross-sectional study of 650 male high school students in Iran in 2011used the theory 
of planned behavior to predict drug misuse related behaviors.34 This study examined intention 
“not to use drugs” as determined by attitudes, subjective norms, and perceived behavioral 
control. Attitude and subjective norms were found to be the strongest predictors, specifically 
related to having drug misuse and/or smoking experience, being the child of drug users, and 
having drug-user friends. Determining and targeting key influential factors that may play 
significant roles in leading a person towards substance misuse is important for designing 
personalized interventions to prevent substance use and help people realize when they may need 
help and how to avoid future issues. 
The next study also took place in Iran, but among gym users examining vulnerability and 
intention to use anabolic steroids to improve athletic performance.32 Two hundred fifty three 
male body-builders were asked about their intentions to used anabolic-androgenic steroids. Not 
only were they asked about the TPB components of attitude, subjective norms, perceived 
behavioral control, and behavioral intentions, but they were also asked about specific steroid use, 
self-efficacy to resist use, perceived seriousness of use, and knowledge of side effects of steroid 
use. Positive attitudes towards steroid use aligned with positive subjective norms and served to 
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increase intention. Perceived behavioral control, self-efficacy to resist steroid use, and perceived 
seriousness of side effects were inversely related to attitude and subjective norms and served to 
decrease intention to use steroids. Self-efficacy and PBC were significantly related indicating a 
possible combination effect to reduce intention. The researchers also found the threat of 
perceived severity of a side effect to be an important predictor of reduced intention to use 
steroids if a person believed they were susceptible to the side effects.32  
The last paper in this section addressed the potential roles of the theory of planned 
behavior, protection motivation theory and eight other theories of behavior change in informing 
interventions for addictive behaviors.19 The researchers reported that the impetus for their review 
was based upon the fact that an important book detailing major theories used in the field of 
addiction, West RJ. “Theory of Addiction”, did not include many of the behavior change theories 
from within social and health psychology.36 The researchers also note that most interventions 
within the area of addictions do not usually report what, if any, theoretical framework is used to 
inform the intervention. This point and the paper’s overall suggestion for the use of theories of 
behavior change is the reason for inclusion of this paper in the review. While many interventions 
report that they are “theory-based”, there is very often little evidence of how theory influenced 
the development of the intervention. Michie and Prestwich developed a coding system to rate the 
use of theory within an intervention.37 The coding system uses five categories to classify the 
extent to which an intervention has discussed/explained the theoretical framework: 1) Is the 
theory mentioned? 2) Are the theoretical constructs targeted? 3) Are the constructs measured? 4) 
Are mediation effects tested? 5) Is theory refined? Utilizing this system of intervention 
framework reporting should lead to greater transparency linking the interventions efficacy to the 
theoretical base and constructs. Likewise, it should guide designers in the different ways that 
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theory can be used in intervention development. Lastly, the reviewers suggest that the theories of 
behavior changes can inform the development of interventions in two important ways 1) 
identifying targets and/or 2) devising methods to influence behavior change.19   
Moderation, Mediation, and Conditional Indirect Effects 
 Moderation, mediation and conditional indirect effects can be used to help explain the 
relationship between the independent variable (X) and dependent variable (Y) as explained by 
the variables within a given behavioral model.38,39 A mediator may be responsible for a causal 
effect between independent (X) and dependent (Y) variables. This indirect effect may also be 
called mediation. The effect of a moderator is to give a sense of “when” the mediator is having a 
causal effect between X and Y. Specifically, when a moderator interacts with the independent 
variable to influence the mediator, and also the mediator is found to influence the dependent 
variable, then the overall relationship is called a conditional indirect effect.38,39 The possible 
levels of moderator are low, moderate, high and may influence the direction, positive or 
negative, in which the dependent variable functions for that specific behavioral model. In other 
circles, conditional indirect effects may be called moderated mediation. A conditional indirect 
effect model is useful for testing the relationships among variables in several types of behavioral 
models. For an example diagram of a conditional indirect effect model see Figure 2.3. 




The Use of Vignettes 
Substance use and addiction are stigmatizing subjects in the U.S. and around the world. 
Because of potentially illegal behaviors within and around substance use disorders people are 
often not willing to provide information about their specific behavior or otherwise participate in 
research for personal reasons and more often the fear of possible legal problems.40 Likewise, 
people may be less inclined to share their thoughts and opinions openly on controversial topics 
for fear of judgement and/or societal marginalization.  The development and use of vignettes, 
which may be considered de facto scenarios, has been a means to study examine decision-
making in both target and general populations. A vignette may be thought of as specific 
situation, viewpoint, or an artificial patient that may be put into specific situations that a 
researcher would like to compare and contrast. People will then be asked to take on the 
viewpoint of the vignette instead of their own and then answer questions about or around that 
specific viewpoint. 
Through the creation of two or more vignettes an effective manipulation may be created 
where study volunteers may be randomized to different vignettes each representing a particular 
viewpoint and/or set of circumstances. Xie, Bagozzi, and Grønhaug conducted a randomized 
controlled experiment where they examined corporate environmental responsibility utilizing a 
three group vignette manipulation.41 They found that participants were able to assume the roles 
assigned to them within the vignette and then respond to survey questions examining corporate 
environmental irresponsible and responsible actions. 
Utilizing vignettes within the field of substance use disorder research helps to explore 
many of the sensitive issues that surround substance use.42 Likewise, substance use vignettes 
have been used with a general population of non-substance users to examine internal and 
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external responsibility attributions for addiction problems.43 The use of vignettes was found to be 
useful for getting participants involved, especially when extra measures were taken to ensure that 
confidentiality was maintained. Researchers found it easier to discuss drug use and related topics 
especially when stigmatizing language was avoided.40,42,43  
Theory-based Instruments to Prevent/Treat Prescription Substance Abuse  
 There are over 15 instruments that have been developed over the last twenty years to help 
detect and potentially prevent prescription and other substance abuse.7,8,44-54 However, none of 
the instruments developed, to date, have a theory-based framework. The current instruments 
primarily focus on aberrant drug-related behaviors (ADRB), psychosocial mediators and norms, 
such as family history of substance abuse and/or physical abuse, and psychiatric 
comorbidities.8,53,54 The inclusion of these predictors of current and/or development of a 
substance use disorder are based upon the observations of professionals and the results from 
many cross-sectional trials.55 The extent to which these instruments may be used to facilitate 
treatment begins with identifying that there may be a problem. Depending upon the stage at 
which a patient is within the cycle of a substance use disorder along with the honesty of a 
patient, some instruments will function better than others at detecting problems. Some 
instruments are self-completed, others are physician or therapist completed. The current 
instruments are usually focused on detecting or predicting ADRBs. A few of the instruments, 
such as the SOAPP-R and Opioid Risk Tool try to predict whether a patient is at risk of 
developing a substance use disorder in the future.48,49,51 Currently, a prescriber must decide 
whether or not to take a risk on prescribing an opioid for a potential future substance user. 
However, if there were an underlying theoretical framework that could identify individual risk 
factors for the patient, then the prescriber could help their patient understand the specific risks 
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they face taking the drug and refer them to educational literature and/or a theory-based 
educational program that can help the patient avoid future misuse by targeting their specific risk 
attributes. 
Theory-based Interventions to Prevent/Treat Prescription Substance Abuse 
 There is a lack of a comprehensive theoretical foundation for drug use prevention 
research. Part of this is due to the majority of the currently used predictors of drug use deriving 
from cross-sectional studies without any theoretical framework.55 The other primary reason for 
no comprehensive theoretical foundation is due to the fact that the issues that lead to or may 
otherwise help prevent substance use are more comprehensive than any single or integrated 
model has been able to encompass.55 In reviewing 39 substance use focused interventional 
studies, 18 used no discernable theory, and 21interventions utilized single or integrated (2 or 
more) theories from 20 different theories.55-64 Unfortunately, very few of these were specifically 
oriented towards prescription substance use disorders. 
 Of the theories that have been utilized for prescription substance use interventions the 
ones that see the most use within the current landscape of substance use treatment programs are 
cognitive-behavioral therapy (CBT), contingency management (CM) (also called motivational 
incentives), and 12-step facilitation therapy.65 Cognitive-behavioral therapy is an evidence-based 
psychosocial intervention that targets thoughts, beliefs, attitudes, behaviors and emotional 
regulation in order to address problematic patterns and help patients develop coping strategies.66 
Though CBT has roots some 30 years ago in several different theories (mostly related to operant 
conditioning), a “theory-practice gap” has developed where the current operationalization of 
CBT relies more on evolving technological utility in practice, than on underlying theoretical 
robustness.67 Contingency management derives from operant conditioning theories utilizing a 
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reward and discipline dynamic to reinforce desired behaviors and discourage undesirable 
behaviors.65 Lastly, 12-step programs such as Alcoholics Anonymous and Narcotics Anonymous 
specifically don’t have an underlying theoretical framework. Instead the 12 steps focus on three 
key ideas: 1) acceptance that a person has no control over the power of the substance over their 
life; 2) surrender to a higher power; and 3) active involvement with 12-step meetings and 
activities.65 The 12-step Narcotics Anonymous program has not proven to be quite as effective at 
preventing relapse and maintaining abstinence among members as compared to Alcoholics 
Anonymous when used as a single therapeutic option. Often NA and AA membership is 
encouraged in tandem with CBT and CM. The principles of CBT and CM are malleable enough 
to be able to apply changes in the underlying behavioral theory framework intended to both 
expand the important predictive factors of prescription substance abuse and deepen the ability of 
therapists to identify the behavioral factors that are most important to treating a patient’s specific 
substance use disorder issues.  
Literature Review Discussion 
 This review examined protection motivation theory, the theory of planned behavior, and 
the use of conditional indirect effects in order to determine significant independent, dependent, 
mediating, and moderating behavioral factors that could predict when and how a patient might 
misuse their prescription painkillers. Qualitative interviews and a quantitative survey were the 
tools used to help reveal these relationships. Understanding which factors are most important for 
predicting prescription drug misuse will help in the development of instruments and 
interventions aimed at detecting, preventing and treating substance use disorders. 
 Specifically, several papers within both the PMT and TPB review sections were already 
deepening their analysis of factors that predict substance use intention by adding in factors from 
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the other theory. Combining the PMT and TPB to effectively for a protection motivation theory 
of planned behavior (PM-TPB) would be a logical continuation of the direction in which these 
research projects are headed. Likewise, one of the most logical extensions of the theories is into 
the realm of prescription opioid misuse, particularly with chronic pain populations which receive 
the highest exposure to risk of opioid addiction. Testing the relationships between the PMT and 
TPB within the PM-TPB will likely take some time as together they account for particularly 
large theory to predict illicit prescription drug use. 
 The use of conditional indirect effects to these theories would be a both an extension and 
deepening of both PMT and TPB that has never been examined. Specifically, the discovery of 
significant moderator(s) will broaden the picture of intention prediction to include the conditions 
“when” substance use is more or less likely to occur. The development of instruments and 
interventions that help clinicians understand how a patient specifically relates to the PM-TPB 
moderators and mediators will help them to direct patients to appropriate services intended to 
prevent the development of a substance use disorder or develop a personalized treatment plan to 
help a patient recover from a substance use disorder. 
Proposing a New Behavioral Model – Protection Motivation – Theory of Planned Behavior 
This study utilizes the constructs and frameworks of protection motivation theory and the 
theory of planned behavior to connect the attitudes, beliefs and perspectives of opioid-using 
chronic pain patients and their intention to misuse controlled prescription drugs.9,13,15,16,22-24  A 
working model of the conceptual framework is shown in Figure 2.4. For this study, a conditional 
indirect effects model is utilized to examine the effects of moderators and mediators on the 
relationship between misuse scenario and intention to misuse prescription drugs as shown in 
Figure 2.5.38,39 Specifically, a smaller part of the PM-TPB model is examined in order to have a 
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better understanding of the factors that influence prescription drug misuse decision making 
through intention. 
Figure 2.4 Full Proposed Behavioral Model 
 




Protection Motivation Theory Contribution 
 Protection motivation theory (PMT) contributed the four threat-related appraisals: 
intrinsic rewards, extrinsic rewards, perceived severity, and perceived vulnerability; and the three 
coping-related appraisals: response efficacy, self-efficacy, and response costs to the new 
behavioral model. Though the PMT, when examined alone, is useful for predicting behavioral 
intention, Rogers and several other researchers have talked about attitude as a potential 
intermediate and attenuating factor between the threat appraisals and intention. Likewise, the 
PMT contributes extrinsic rewards as a norm-based measure of intention. As discussed in the 
introduction, researchers examining substance abuse have extended the PMT beyond extrinsic 
rewards using other behavioral norms including subjective norms as having an extended 
influence upon a patient’s intention to misuse their substance of choice. Lastly, the coping 
appraisals represent more specific measures for perceived behavioral control allowing for more 
specific determination of how PBC may affect intention to misuse prescription opioids.  
Theory of Planned Behavior Contribution 
 The theory of planned behavior (TPB) contributed the factors of attitude, subjective 
norms, and perceived behavioral control to the new behavioral model. Pairing the TPB with the 
PMT provided natural extension and deepening to both models. Attitude in the combined model 
serves to attenuate the effect of the threat appraisals: intrinsic rewards, extrinsic rewards, 
perceived severity, and perceived vulnerability; upon intention. Specifically, a patient may feel 
that each threat appeal was more bad/good; harmful/beneficial; and unfavorable/favorable. 
Therefore, depending upon the attitude, the magnitude of the effect of the threat on intention 
would change. Subjective norms logically extended the PMT’s norm-based factors beyond 
extrinsic rewards. Extrinsic rewards focused on whether perceived benefit associated with people 
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important to the patient misusing their opioids influenced a patient’s intention to misuse. 
Understanding a patient’s subjective norms concerning how family, friends, and strangers around 
them feel about opioid misuse should help to understand whether extrinsic rewards will result in 
increased or decreased intention to misuse opioids. Lastly, the coping appraisals: response 
efficacy, self-efficacy, and response costs; provided more specific factors to measure a patient’s 
perceived behavioral control and their influence upon intention. All of the factors from the 
combined PMT and TPB model help to identify specific strengths, weaknesses, and opportunities 
of an individual patient when examining their likelihood of misusing prescription opioids. 
Moderation, Mediation, and Conditional Indirect Effects Contribution 
 Moderation, mediation, and conditional indirect effects help explain the relationship 
between a patient’s pain level, drug seeking level, and misuse level (independent variable) and 
their intention to misuse prescription opioids (dependent variable). Adding moderation to the 
PM-TPB behavioral model deepens the understanding of intention to misuse opioids by 
providing a framework to understand “when” a patient will be more likely to misuse their 
opioids. The mediators provide an understanding of “how” a patient’s decides to misuse their 
opioids. For example, when a patient’s perceived risk of addiction (moderator) is moderate and 
high, then perceived vulnerability (mediator) accounts for the relationship between the current 
pain, drug seeking, and misuse levels of a patient and their behavioral intention, resulting in an 
increase in that patient’s intention to misuse their prescription opioids. 
Anticipated contribution of this model to instrument and intervention development 
 Using this behavioral model, researchers, therapists, and the patient can understand the 
behavioral factors that are most important in influencing intention to misuse prescription drugs.  
Once this behavioral model has been fully developed and tested the intention is to design several 
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instruments and interventions that could be used in tandem to detect, prevent, and/or treat 
prescription-based substance use disorders. Eventually, the instruments and interventions may be 
adapted for alcohol, illicit drugs, and other substance use disorders. 
One of the first instruments likely to be developed using the PM-TPB behavioral model 
would be intended for use by general practitioner and pain physicians as a screening tool at 
patient intake. Patients would be asked to self-complete the screening tool while waiting on their 
appointment with their physician. Based upon the behavioral model the screening tool would 
measure, before they have been prescribed a painkiller, what the patient’s risk of addiction was, 
what intrinsic rewards might motivate the patient, and where the patient stands concerning their 
attitudes, norms and behavioral control. Measuring these factors will give a baseline of the 
patient’s potential strengths and weaknesses associated with taking a painkiller. If a patient is 
deemed to be significantly at risk of developing a prescription opioid use disorder the physician 
and patient could then be more vigilant about prevention.  
The first intervention likely to be developed using the PM-TPB behavioral model would 
be an educational intervention that works off of the strengths and weaknesses revealed from the 
screening tool. The educational intervention is intended to be used for primary prevention of a 
patient escalating to prescription opioid misuse, abuse, and addiction. Whether this intervention 
is active through use of therapists to work with the patient or passive through providing the 
patient with informational literature and/or videos remains to be determined. 
The second instrument based on the PM-TPB will be developed to be administered to 
patients who are actively taking prescribed opioids for pain. The primary focus would be to 
measure the theory-based factors in order to understand the patient’s current profile. Where the 
second instrument would differ from the first is that it would also need to be able to detect when 
 
33 
a patient is misusing or abusing their opioids. The instrument could act in two ways: it could 
serve as the baseline measurement for new patients to a service who are already prescribed 
opioids; the instrument could also serve to update and document any changes from baseline, 
whether measured by instrument one or instrument two. By providing a quick means of 
comparing the newest instrument results to previous and/or baseline, the physician and patient 
can identify any new areas of concern, but also reinforce good continuing behaviors. If an opioid 
use disorder is detected, then a patient could be referred to therapy which could involve a 
proposed second intervention.  
The second intervention utilizing the PM-TPB would likely be a cognitive behavioral 
therapy type intervention that relies on the participation of the patient with a team of physicians 
and therapists. The development of this intervention is probably at least 5 years or more in the 
future. However, this intervention is likely to be coupled with a third version of the PM-TPB-
based instrument designed to very specifically target key behavioral factors that trigger and/or 
prevent misuse individualized to each patient. 
These instruments and interventions would be the culmination of years of research 
demonstrating that the PM-TPB behavioral model is useful for measuring, preventing, detecting 
and treating prescription opioid-related behavior, misuse, abuse, and addiction. This dissertation 
is intended as the first leg of that long journey establishing that the combined and moderated 
PM-TPB behavioral model contains a diverse group of behavioral factors capable of helping to 











To assess the readability, sensibility, and face-validity of the study survey instrument 
using qualitative techniques.  The thoughts and opinions of a group of patients who have chronic 
pain were assessed using semi-structured interviews of individual patients. 
Aim 1 Research Questions 
1. Will patients in the pilot-test qualitative study understand and identify with the vignettes 
and types of misuse examined thereby confirming the instrument has face-validity? 
2. Will the pilot-test qualitative study patients identify survey questions that require revision 
and clarification on future survey instruments? 
Aim 2 
To determine which, if any, theory-based factors identified and operationalized from the 
combined study model utilizing the Protection Motivation Theory and Theory of Planned 
Behavior are predictive of intention to misuse controlled prescription drugs, utilizing a vignette 
manipulation of the conditions associated with misuse scenario. 
Aim 2 Hypotheses 
1. The level of pain, drug seeking behavior, and drug misuse behavior and a moderator (risk 
of addiction or self-efficacy) will interact to exert a conditional indirect effect on 
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intention through a mediator (attitude, perceived severity, perceived vulnerability, 
intrinsic rewards, extrinsic rewards, and subjective norms) 
2. The moderators, risk of addiction and self-efficacy, will be revealed as significant factors 
predicting when a particular mediator will influence intention to misuse controlled 
prescription drugs.  
a. Specifically, high risk of addiction should indicate that a mediator is likely to 
increase intention/likelihood to misuse and low risk of addiction should predict a 
decrease. 
b. High self-efficacy should indicate that a mediator is likely to decrease 
intention/likelihood to misuse and low self-efficacy should predict an increase. 
3. The mediators which include: attitude, perceived severity, perceived vulnerability, 
intrinsic rewards, extrinsic rewards, and subjective norms, will be revealed as significant 
factors predicting how a particular moderator will interact with vignette to influence 
intention to misuse controlled prescription drugs. 
a. Perceived severity and perceived vulnerability are adaptive behaviors that if 
significant should function to reduce intention/likelihood to misuse. 
b. Intrinsic rewards and extrinsic rewards are maladaptive behaviors that if 
significant should function to increase intention/likelihood to misuse. 
c. Attitude will be bi-directional. One of the other mediators will likely influence an 
increase/decrease in attitude which will influence increase/decrease in 
intention/likelihood to misuse. 




Prior to the qualitative interviews (pilot-test) and the quantitative survey a small pre-test 
survey of four volunteers from around the University of Michigan College of Pharmacy was 
conducted to detect and address any potential issues of readability, understandability, or any 
other identified issues prior to final on-line release of the survey to the study population. Each 
pre-test survey taker was asked to sit down at a computer and log in to the survey with the study 
P.I. watching. Their interactions with the computer and survey were noted by the P.I. and each 
survey taker was encouraged to talk out their thoughts and actions as they proceeded through the 
survey. The pre-test survey taker’s responses were digitally recorded then later transcribed. Each 
volunteer was paid a $10 incentive to thank them for taking the time to help. The primary 
contributions from the pre-test survey were the addition of vignette reminders for every question 
on the survey and troubleshooting some login and password related issues that were discovered. 
The pre-test survey subjects found it difficult to remember what the details were of the vignette 
that they were assigned at the beginning of the survey. This lead to the creation of vignette 
reminders added to the top of each question on the on-line survey. With the reminders the 
qualitative interview patients later found it much easier to maintain their role as the vignette 
patient and were able to answer as the patient with confidence. 
Subject Sample/Patient Screening 
Patients were screened using the UMHS electronic medical record MiChart (chart 
review) and DataDirect (UMHS patient data warehouse) to identify qualified patients. 
Inclusion criteria: The study population was composed of 18 years or older outpatients 
diagnosed with chronic non-cancer pain (ICD-9 338.2)68 or the clinical equivalent of chronic 
non-cancer pain as determined by presence in a chart review of a combination of pain diagnosis 
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and pharmacological treatment for pain. Subjects were also taking at least one CR/ER (slow long 
acting) opioid and/or one IR (fast short acting) opioid pain medication for at least a minimum of 
one month prior to study enrollment. Participants needed to understand written English. 
Substance use related diagnoses (ICD-9: 304.**; 305.**; V61.42; V65.42)68 were used to 
identify Group 2 patients for recruitment. 
Exclusion criteria: Participants were excluded from the study if they were under 18 years 
old, had a current diagnosis of neoplasm-related (cancer) pain (ICD-9: 338.3)68, had not been 
taking at least one CR/ER (slow long acting) opioid and/or one IR (fast short acting) opioid pain 
medication for at least a month, were a hospital inpatient at the time of interview/survey 
administration and/or were unable to complete the interview/survey questionnaire.  
Patients for the Aim 1 individual interviews were screened for upcoming appointments at 
the UMHS Spine Clinic and those who completed interviews were flagged as ineligible to take 
the Aim 2 survey. Likewise, patient who had taken the Aim 2 survey were flagged as ineligible 
to be recruited for the Aim 1 individual interviews. 
The approval of the University of Michigan Institutional Review Board was obtained 
before beginning the study and informed consent was obtained from all participating subjects.  
Qualitative Study Design  
Interview Recruitment 
The medical director of The University of Michigan Physical Medicine & Rehabilitation 
Clinic granted permission to work with clinic staff to recruit patients for the study. Electronic 
medical records (MIChart) were examined to verify that the Spine Clinic population met the 
inclusion/exclusion criteria for this study. MIChart was used to identify potential subjects who 
visited physicians at the UMHS Physical Medicine & Rehabilitation Clinic. A preliminary letter 
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was sent to each patient explaining that we would like to recruit them into our study and 
interview them after their upcoming Physical Medicine & Rehabilitation appointment. (See 
Appendix A.1) Patients then received a follow-up phone call one week before their appointment 
to confirm that they wished to participate in the interview. Patients had several opportunities to 
opt-out of the interview before the appointment. The clinic staff helped to remind patients that 
they had agreed to individual interviews and guided them to the room set up with the interviewer 
after the patient had completed their appointment. Each interview lasted no longer than 90 
minutes, with the majority taking 45 minutes or less. Each participant received a check for $20 as 
an incentive. 
Interview Design 
Individual interviews were conducted with two groups of chronic pain patients from the 
UMHS Spine Clinic. Each individual interview group included at least 5 patients that met the 
inclusion/ exclusion criteria. Group 1 included patients that had no history of substance use. 
Group 2 included patients that had a past history of substance use (ICD-9: 304.**; 305.**; 
V61.42; V65.42).68 Qualitative interviews were conducted concurrently with the web 
administration of the survey. 
An interviewer reviewed a 60-question theory-based survey questionnaire with each 
patient. (See Appendix A.9) Each interview consisted of a short introduction describing the 
dissertation research project and its purpose. The patient was then asked to review a study 
consent form and sign if they agreed to participate in the research project. (See Appendix A.3) 
During the individual interviews the interviewer reviewed a 13-question script with the patient. 
(See Appendix A.4) The interviews were designed to determine how well each question and how 
well each question matched their personal experiences and whether the wording and situations of 
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the scenarios and questions were understandable, applicable and well-worded. An interview 
room was reserved at the Spine Clinics for same day recruitment and interviews. The patient’s 
response to each set of questions was digitally voice recorded. The digital recordings were later 
transcribed verbatim into Microsoft Word documents with only the patient’s study identifier and 
no other names or other personally identifiable information. The transcriptions were reviewed by 
two different reviewers who coded the responses by each individual and then met to discuss the 
findings and come to a consensus. 
 Reviewers one and two met to come to a general consensus about the statements 
on which they differed, and to determine the statements that determined a consensus among and 
between group members. Each statement’s theme was considered within the context of the 
question that the patient answered. Isolated statements by an individual group member and not 
similar in theme to a member of the other group were not considered to be significant. If at least 
two patients within a group made statements that shared a similar theme that theme was 
considered significant. If at least one patient from each group made a statement that shared a 
similar theme, then that theme was also considered significant. 
Quantitative Study Design  
Survey Recruitment 
A mail and e-mail-based recruitment method was used. DataDirect, a UMHS data 
warehouse query tool, was used to identify potential participants that met the inclusion and 
exclusion criteria of the study. Patients were first invited to participate in the Qualtrics-based 
internet survey through a mailed letter. (See Appendix A.5) Total recruitment needed to be at 
least 140 participants in order to have a sample size that was large enough to allow for regression 
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analysis and structural equation or path analysis depending upon whether any latent variables are 
identified. At least 70 patients needed to be recruited for each possible survey vignette.  
The initial mailing contained 300 letters each with a unique web-link, username, and 
password to the web-based survey. After two weeks an email was sent to those patients for 
whom we had an email address, but had not yet responded, inviting their participation. (See 
Appendix A.6) At four weeks after the initial mailing a final mailing was sent to any patients 
who had not yet responded. (See Appendix A.7) After four weeks, if recruitment quotas were not 
being met another round of mailings would be started.69 At four weeks, 200 new letters were 
sent. At six weeks, recruitment rates were averaging around 10%, therefore another 500 new 
letters were sent. At eight weeks, based upon the ongoing response rate of around 10% a final 
round of 500 new letters was sent.  
Patients used the unique username and password that they received in their letter to log in 
to a web-based Qualtrics survey. Before a patient can take the survey they needed to answer a set 
of questions based on the five inclusion/exclusion criteria to verify that they were qualified to 
take the survey. Patients who qualified were then asked to read through and electronically sign 
the consent form. (See Appendix A.8) At this point, a patient was randomized to the control or 
test vignette and then presented with the 60-question survey questionnaire. (See Appendix A.9) 
Completion of the questionnaire was expected to take around 30 minutes. Once the survey was 
completed and submitted, the survey patients were offered a check for $10 incentive. 
Survey Procedure Design 
This study utilized vignettes in order to randomize patients to different misuse scenarios. 
Drug abuse is a stigmatizing subject and asking patients to answer as a vignette patient further 
enhanced their anonymity by having the patient become the “paper patient” for answering the 
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survey questions. By using the vignettes the study did not need to rely on finding patients who 
were actually actively misusing their prescription opioids and were then able to recruit 
significantly fewer patients in order to have enough in each group. Subjects were randomized to 
one of the two vignettes (See Appendix A.9): 
Control: controlled pain, no drug seeking, no drug misuse (70 or more patients) 
Test: poorly-controlled pain, drug seeking, drug misuse (70 or more patients) 
A vignette may be thought of as specific situation, viewpoint, or an artificial patient that may be 
put into specific situations that a researcher would like to compare and contrast. People were 
then asked to take on the viewpoint of the vignette instead of their own and then answer 
questions about or around that specific viewpoint. Vignettes were utilized in order to encourage 
patients to be as truthful as possible in their responses because they should be more at ease not 
revealing what they would consider personal information about how they use or potentially 
misuse their own prescription drugs. Some of the potential downsides to using vignettes occur 
when people do not agree with, or otherwise are not able to identify with the vignette enough to 
answer questions from a perspective that is not their own.  
Measures and Analysis 
Measures: Qualitative 
Patients were asked to read through a paper version of the quantitative survey that was 
used in Aim 2. (See Appendix A.9) The interviewer was given a script to guide their questions 
and interaction with the patient. (See Appendix A.4) The interviewer would ask the patient to 
review the survey feature or question and answers and then ask the patient to comment on 
similarities and differences to how the patient might have experienced that behavioral factor. 
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There were 13 question sections on the interview questionnaire. The following were the general 
topics and question roots that each patient was asked: 
1. Describe the four types of misuse related to intention to misuse controlled 
prescription drugs: Frequency, Dose, Withdrawal, and Feeling Good. Ask 
individual patients for thoughts and opinions about the types of misuse. 
2. Describe the two vignettes and ask the patient to comment on similarities and 
differences between the scenarios and their actual experiences. 
3. Review self-efficacy questions and ask patient how they experience self-efficacy. 
4. Review risk of addiction questions and ask patient how they feel their risk of 
addiction influences their likelihood of abusing prescription drugs. 
5. Review perceived vulnerability questions and ask patient how they experience 
perceived vulnerability. 
6. Review perceived severity questions and ask patient how they experience 
perceived severity. 
7. Review intrinsic rewards questions and ask patient how they experience intrinsic 
rewards. 
8. Review extrinsic rewards questions and ask patient how they experience extrinsic 
rewards. 
9. Review subjective norms questions and ask patient how they experience 
subjective norms. 
10. Review attitude questions and ask patient to relate their attitudes towards the four 
types of prescription misuse. 
11. Review intention questions and ask patient to relate their attitudes towards the 
four types of prescription misuse. 
12. Review the demographic questions with the patient. 
13. Review the NIDA Risk Screening questionnaire with the patient. 
 
Analysis: Qualitative 
The interview response transcripts were analyzed in a group-by-question grid where the 
responses were grouped under each question asked by similar discussion topics.70 Data were 
coded in three ways (1) all mentions of a given code, (2) whether each individual mentioned a 
given code, or (3) whether the multiple interviews contained a given code.70 This method of 
grouping the responses allowed for cross-group comparisons between the two different interview 
groups. The coding and identification of significant discussion topics in each interview was 
carried out by two different reviewers. Both reviewers were licensed pharmacists and Ph.D. 
students in Social and Administrative Sciences at the University of Michigan. The reviewers read 
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through each patient’s interview transcript and coded responses according to the guide. At the 
conclusion of coding, the reviewers met to resolve any differences. The data were analyzed as a 
simple summation of the occurrences or each patient statement/theme. 
Measures: Quantitative 
The questionnaire shown in Appendix A.9 was developed based upon the PM-TPB 
adaptation of theoretical models to determine the association between the moderators and 
mediators and the dependent variables. The following subsections describe the dependent, 
independent, mediator and moderator variables of interest measured using the questionnaire. 
Particularly, the questions focus on four particular modes of prescription drug misuse: frequency 
– taking prescription painkillers more often than prescribed; dose – taking higher doses (more 
pills) of prescription painkillers than prescribed; withdrawal – taking prescription painkillers to 
avoid withdrawal symptoms (example: restlessness, agitation, and muscle aches); feeling good – 
taking prescription painkillers to “feel good” (example: a euphoric feeling of comfort and 
contentment). 
Dependent Variables 
The dependent variable of interest for this study was the intentions of patients to misuse 
prescription opioids. The questions are presented in Appendix A.9. The intention concept was 
assessed using two question roots with four 5-point bipolar Likert scales based upon the four 
types of misuse.26,28,30,71 The intention questions were located as the last theory-based questions 




Figure 3.1 Intention Questions 
 
Independent Variables 
Pain Level, Drug Seeking, and Drug Misuse Behavior 
The primary independent variables (X) in the model were defined by the two vignettes (1. 
control, 2. test) as a constant level of pain, drug seeking level, and drug misuse level. Pain was 
operationalized as 1) well-controlled or 2) poorly controlled. Drug seeking was listed as 1) 
absent or 2) present. Likewise, drug misuse behavior was also classified as 1) absent or 2) 
present. Pain was used as an independent variable because it is the primary reason that patients 
are started on opioid painkillers. Drug seeking behavior was used as an independent variable 
because it is a hallmark indicator that a person’s pain may be poorly controlled and/or that 
patient may be possibly misusing their medication or diverting their medication for use by 
another person. Misuse was used as an independent variable because it is also an indicator that a 




Patients were randomized to one of these two vignettes and asked to imagine themselves 
in the position of the vignette patient before answering the theory-based survey questions. 
The control and test vignettes are shown in the following figures: 
Figure 3.2 Vignette 1: Control Scenario 
(Pain Well-controlled/No Drug Seeking/No Misuse) 
 
 
Figure 3.3 Vignette 2: Test Scenario 
 (Pain Poorly Controlled/Drug Seeking/Misuse) 
 
 
Accompanying each question on the on-line survey there was a reminder for the patient 
of the pain, drug seeking and misuse features of the vignette that they were randomly assigned. 
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Several of the example questions shown in the questionnaire in Appendix A.9 retain these 
reminders. 
Demographic Variables 
At the end of the survey questionnaire patients were asked for the following demographic 
characteristics: gender, marital status, race, ethnic origin, employment, income, and education. 
(See Appendix A.9)  
Gender was measured as female or male.  
Marital status was measured as single, married/cohabitating, divorced, or widowed. Race 
was measured as white/Caucasian, black/African American, American Indian, Asian or 
Pacific Islander, or other.  
Ethnic origin was measured as Hispanic/Latino yes/no.  
Employment status was measured as full time, self-employed, part time, or not employed. 
Income was measured from less than $10,000 to greater than $100,000 in approximate 
$10,000 increments.  
Education was measured as less than high school, high school or GED, some college to 
bachelor’s, professional degree, or graduate degree.  
These variables are important potential modifiers, but also necessary to help understand the 
generalizability of the patient population to the larger public and the similarity of characteristics 
between the two test groups. 
History of Substance Misuse Screening Variables  
A patient’s own past substance misuse history was addressed with the NIDA-Modified 
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). This data was used to 
determine whether patients randomly assigned to the control or test vignette were similar in their 
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ASSIST score distributions. The ASSIST uses questions to determine substance misuse history 
and specific use within the last six months in order to establish a more objective measure of the 
patient’s risk of misuse.47,50,72 A shortened version of the NIDA-modified ASSIST was used. 
Specifically, a series of 12 Yes/No questions was asked about a person’s lifetime use of the 
following substances: tobacco, alcohol, cannabis, cocaine, prescription stimulants, 
methamphetamine, inhalants, prescription sedatives/sleeping pills, hallucinogens, street opioids, 
prescription opioids, and other possible substances. Then for each of the substance use categories 
specific level of substance use was asked within the past 6 months: never, one or twice, monthly, 
weekly, daily or almost daily. 
Figure 3.4 National Institute of Drug Abuse: Modified Alcohol, Smoking and Substance 







Figure 3.5 National Institute of Drug Abuse: Modified Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST) – Six-month: 
 
A future use for the ASSIST data will be to examine the patients who tested with a high 
actual risk of having a current or future substance use disorder and then examine their risk of 
addiction and intention scores on the survey to determine whether their responses differed from 
patients with low ASSIST scores, both dependent and independent of which vignette they were 
assigned. 
Mediator Variables 
The mediator variables addressed in the survey were perceived vulnerability, perceived 
severity, intrinsic rewards, extrinsic rewards, subjective norms and attitudes. Each mediator was 
assessed by a question set that addressed the specific mediator in relation to the four types of 
misuse. Five-point bipolar Likert scales were used for perceived vulnerability, intrinsic rewards, 
extrinsic rewards, and subjective norms. Five-point unipolar Likert scales were used for 
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perceived severity. The attitude concept was determined from four attitude questions which 
consisted of a question root based on one of the four types of misuse. Three 7-point bipolar 
Likert scales addressed the responses to each attitude. 









Figure 3.8 Extrinsic Rewards Questions 
 





Figure 3.10 Attitude Question: Often 
 






Figure 3.12 Attitude Question: Withdrawal 
 
 




Figure 3.14 Perceived Severity Questions 
 
The question roots for perceived vulnerability, perceived severity, intrinsic rewards, 
extrinsic rewards, and subjective norms were based on study instrument from previous studies 
conducted by Norman, Cox, Helmes, and Wu within the last 15 years on PMT-based surveys. 
16,73-75 The perceived vulnerability asked about a patient’s vulnerability to taking their 
prescription painkillers more often or in higher doses. A second question set asked about 
willpower to avoid taking the prescription painkillers more often or in higher doses. A third 
perceived vulnerability question set asked the patient to rate the likelihood that they would take 
their prescription painkiller in any of the four misuse types given their assigned vignette. Two 
perceived severity question sets asked about the severity and seriousness of prescription misuse. 
The first question set asked about how severe the physical consequences (drowsiness, dizziness, 
nausea) were perceived to be for each misuse type. The second question set asked how serious 
the situation would be associated with each misuse type. Both intrinsic rewards and extrinsic 
rewards consisted of one question set each addressing the four misuse types. The intrinsic 
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rewards questions focused on relief of problems (anxiety, personal, relationship) by taking 
painkillers more often or in higher doses, to avoid withdrawal, or to “feel good”. Extrinsic 
rewards asked if people who are important to the patient misused prescription painkillers. Lastly, 
subjective norms consisted of three question sets based on the perceived disapproval/approval of 
family, friends, or strangers. These questions omitted the withdrawal avoidance type of misuse 
because that type of misuse does not have a particular societal norm component. 
Moderator variables 
 The moderators were risk of addiction and self-efficacy. There were two questions about 
risk of addiction. The first question used a 5-point Likert scale that asked the patient to rate their 
likelihood of becoming addicted to their prescription painkillers given their assigned vignette. 
The second risk of addiction question asked the patient to select their probability of becoming 
addicted on a scale from 0% to 100%. There was one question set for self-efficacy that asked the 
patient to express their confidence in resisting the four types of misuse on a 5-point unipolar 
Likert scale ranging from not at all to extremely confident. 






Figure 3.16 Self-Efficacy 
 
Analysis: Quantitative 
Descriptive statistics were used to present demographic variables, inclusion/exclusion 
variables, PMT and TPB variables, and modified ASSIST variables.  A nonresponse bias was 
performed between the 160 patients that responded and 1,390 non-respondents to determine if 
the study population was representative of the overall target study population. Variables used for 
the nonresponse bias assessment included: gender, age, marital status, and race.  
Comparison of the two groups of subjects based on assignment to vignette group was 
conducted using independent samples Student’s t-test and Chi square tests. Comparisons 
between vignette groups were made for each study variable and type of misuse to determine 
which variables and misuse type were most influenced by the vignette manipulation. Comparing 
each vignette was important for determining the strength of the manipulation and the accuracy of 
the operationalization of the variable.  
Lastly, ordinary least regression using Hayes’ Process models 4 and 739 was used to 
examine the relationships between the variables that predict behavioral intention. The Hayes’ 
Process models are a series of structural models that examine the influence of mediators on the 
relationship between a given set of independent and dependent variables, which are further 
capable of including covariates, additional mediators, and moderators. Each model represents a 
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different configuration for the relationships which may reveal more information about how the 
independent variable ultimately influences the dependent within a behavioral model.  
The Process model 4 was selected because it demonstrates the effect of the mediators, 
attitude, subjective norms, perceived vulnerability, perceived severity, intrinsic and extrinsic 
rewards, on the relationship between the independent variables pain level, drug seeking, and 
misuse level and the dependent variable of intention to misuse prescription opioids.  The Process 
model 7 was selected because it demonstrates the conditional effect that can occur between the 
independent misuse scenarios and the dependent intention to misuse prescription opioids as 
determined by the moderators, risk of addiction and self-efficacy and the mediators, attitude, 
subjective norms, perceived vulnerability, perceived severity, intrinsic and extrinsic rewards.  
Specifically, the mean-centered products option was selected and bootstrapping was set 
to 10,000 iterations. The bootstrapping specifically examined the indirect effect(s) within the 
model. The bootstrapping within the OLS regression models served as both a secondary 
confirmation that there was a significant relationship between the independent misuse scenarios 
and the dependent intention towards misuse. For the model 7 regressions the bootstrapping 
values indicate the levels of the moderator (low, moderate, high) at which there was a significant 
conditional indirect effect. Intention towards misuse may increase or decrease depending upon 
how the moderator and mediator interact with pain, drug seeking, and misuse. 
The following variables and sets of equations described the relationship between the 
dependent variable, BI = behavioral intention, and the primary independent variables: A = 
attitudes, SN = subjective norms, PBC = perceived behavioral control and w = regression 
weights. 
BI = w1A + w2SN + w3PBC 
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Within the behavioral model for this study A, SN and PBC are further described by their related 
protection motivation variables: PV = perceived vulnerability, PS = perceived severity, IR = 
intrinsic rewards, ER = extrinsic rewards, SE = self-efficacy and RA = risk of addiction. 
A = w4PV + w5PS + w6IR + w7ERpartial SN = w2SN + w7ERpartial PBC = w8SE + w9RA  
International Business Machine’s SPSS® versions 23 and 24 were used to conduct the 









Six patients were successfully recruited to Group 1 and seven patients were recruited to 
Group 2. The recruitment rate for the individual interviews was 30% with 13 patients completing 
the interview out of a total of 43 patients contacted. 





 The demographic characteristics did not differ between the Group 1 non-users and Group 
2 past substance-users. Gender, marital status, race/ethnicity, and age did not differ between 
groups. The female/male distribution averaged 50:50. The marital status was nearly different 
between groups (p=0.053) with 6 of the 7 substance users being unmarried versus only 2 of 6 
non-users. Likewise, race/ethnicity was nearly different between groups (p=0.067) with all 6 
non-users reporting as Caucasian and only 4 of the 7 substance users reporting as Caucasian. The 
average age of the substance users interviewed was 45 years old, which with a standard deviation 
of 6 was closer to the average actual age. The average age of the non-users interviewed was 57 
years old; however, the standard deviation was 16 because 3 of the 6 non-users were between 61 
and 87 years old. 
Table 4.1 Qualitative Study Subject Characteristics 
 
Sub user (n=7) Non-user (n=6) 
Chi-square 
Frequency (%) 
or Mean (s.d.) 
Frequency (%) or 
Mean (s.d.) 
Gender 
Female 3 (42.9) 3 (50.0) 0.066 
p=0.797 Male 4 (57.1) 3 (50.0) 
Marital Status 
Unmarried 6 (85.7) 2 (33.3) 3.745 
p=0.053 Married 1 (14.3) 4 (66.7) 
Race/Ethnicity 
Non-caucasian 3 (42.9) 0 (0.0) 3.343 
p=0.067 Caucasian 4 (57.1) 6 (100.0) 
Age – (years)  45 (±6) 57 (±16) T-test 
31 – 40 2 (28.6) 1 (16.7) F=8.781 
p=0.099 41 – 50 4 (57.1) 2 (33.3) 
51 – 60 1 (14.3) 0 (0.0) 





 An Interview Coding Worksheet (See Appendix A.4-2) was completed for each interview 
patient by each of the two reviewers while examining each respective interview transcript. The 
raw results from the coding worksheets may be reviewed in Appendix Tables B.1 and B.2. The 
statements from each patient interview that the reviewers believed to be significant are listed in 
Table 4.2 and Table 4.3. Differences between the coding of reviewer one and reviewer two are 
indicated by bolded and shadowed boxes for each response or statement. Out of 533 coding 
choices, the reviewers differed on 25, a difference of less than 5%, indicating 95% initial 
agreement. These coding differences were discussed by the reviewers and found to be related to 
parts of a patient’s interview that one reviewer thought significant and the other reviewer did not 
during their appraisal. Table 4.2 lists the patient statements that reviewer one believed to be 
significant. Table 4.3 lists the patient statements that reviewer two believed to be significant. 
Reviewer one identified 70 significant patient statements with reviewer two identifying all but 7 
of those same statements as significant indicating 90% initial agreement. Reviewer two 
identified 76 significant patient statements with reviewer one identifying all but 4 of those same 
statements as significant indicating 94% initial agreement. 
 Reviewers one and two met to come to a general consensus about the statements on 
which they differed, and to determine the statements that determined a consensus among and 
between group members. Each statement’s theme was considered within the context of the 
question that the patient answered. Isolated statements by an individual group member and not 
similar in theme to a member of the other group were not considered to be significant. If at least 
two patients within a group made statements that shared a similar theme that theme was 
considered significant. If at least one patient from each group made a statement that shared a 
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similar theme, then that theme was also considered significant. Based upon criteria, the reviewers 
agreed that the 4 differing statements from reviewer two’s coding and one differing statement 
from reviewer one’s coding had no impact on the results. The reviewers examined the remaining 
6 differing statements from reviewer one’s appraisals and after reviewing the respective 
interviews, then reviewer two agreed to the inclusion of those statements. 
Table 4.2 Reviewer One: Patient Responses 




A01: Add third scenario in middle between 
where they are taking painkillers only because 
pain is not being well-controlled, but without 
drug seeking. 
A06: Suggests adding some information to 
scenarios about lifestyle 
A11: Suggests a possible scenario where 
patient has untreated pain 
 N13: Suggests a 3rd scenario where patient has 
no pain, but is abusing drug 
N23: Suggests asking if person has a caregiver 
and whether they are doing a good job at 





A01: Suggests being specific about age of 







A01: patients may misinterpret “feel good” 
especially with higher pain levels 
A06: thinks questions may be repetitive 
 N18: Suggests adding a question in addition to 
abuse asking if taking the drug resolves the 
patient’s pain 
N23: Suggests using different terminology 
other than vulnerability, because people might 
be embarrassed to be vulnerable and/or have 
weak willpower 
N26: Suggests using susceptible instead of 
vulnerable, because people might not want to 





A06: Thinks questions appear repetitive and 
people are not likely to admit weak willpower 
A11: Thinks people might not be very good at 
judging their own abilities for 
vulnerability/willpower 
 N26: Thinks both questions sound similar 
N27: Didn’t suggest changing terminology, but 
thought people might have a hard time 





A01: Suggests using stronger consequences, 
more severe 
A02: Would use more severe consequences 
like organ damage 
A06: Suggests adding more consequences 
A07: Might add more severe consequences of 
getting in trouble with law or damaging body 
A11: Suggests using more severe 
consequences like death etc 
 N18: Suggests more severe consequences – 
brain and organ damage etc 
N19: Suggests adding more severe 
consequences like losing life or going to jail 
N23: Suggest listing some more severe 
consequences than used 
N26: List more consequences like causing a 
car accident, etc 
N27: Suggest listing more ‘severe’ 
consequences beyond physical, to include 







A01: Suggests providing example of 
seriousness. Ex. Law enforcement or organ 
damage 
A06: Suggests asking responses to specific 
consequences 
A11: Thinks a ‘hardcore abuser’ is not likely to 
care much about the physical consequences 
associated with abusing drugs 
 N13: Define severity and serious better 
N18: Suggests mentioning possibility for 
car accident etc under severity 
N19: Suggests defining ‘serious’ better 
N23: Suggests mention examples like car 
accidents etc for serious 
N26: Be specific that that serious results could 





A04: Suggests adding more potential problems 
that persons may relate to 
A06: Suggest asking people how drug abuse 
relieves their problems more specifically 
A11: Suggests letting patients select the 
problems that is solves and allow them to 
describe how 
 N18: Allow person to select specifically which 
problems the drug abuse appears to solve 
N19: Suggests making a list that people could 





A11: People know their bodies well, so can tell 






A01: Suggest providing an example of extrinsic 
reward (family/friends smoking/drinking) 





A01: Not related, but suggests looking at 






A09: Suggest possibly adding doctors as a 
group 
 N13: Ask two questions, one each for approve 
and disapprove 
N19: Suggested adding teachers/role models 
N23: Suggest adding categories for 
church/community and coworkers 





  N18: Suggests defining or providing examples 




A01: Need to explain that attitude questions 
have 3 parts 
A11: Thinks that attitude might vary by time of 





A01: Suggests offering a question about 
whether patient is concerned with controlling 
pain 
 N13: Ask two questions, one each for likely and 
unlikely 
N18: Suggests replacing unlikely/likely with a 





A09: Thinks patients might lie about their true 
intention 
 N19: Patients may not be honest because of 




A02: suggests people will be more honest if 
they think they are responding anonymously 
A11: Thinks lifetime use is too general, thinks 





A01: Suggests possibly adding Community 
group 




A04: Suggests adding retirement to 
employment options 
A06: Suggests adding disability to employment 
A09: Suggests adding retired and disabled to 
employment 
N18: Suggests adding disabled to employment 
status 
N19: Suggests adding domestic partner etc to 
marital status. Also suggests adding retired and 
disabled to employment 
N23: Suggests adding retired and possibly 
disabled to employment 




A02: Suggesting asking in demographics about 
family history of abuse 
 N18: Suggests adding question about 





A01: Reminder about making a 3rd scenario 
with mild misuse issues 
 N23: Keep the survey questions simple and 
direct 
*Bold and Highlighted indicates difference from Reviewer Two 
 
Table 4.3 Reviewer Two: Patient responses 




A01: Suggests adding a case (scenario) with 
mild addiction issues. 
A06: Provide context for test group 
A11: Possibility of another scenario where 
patient is procuring medications to treat 
undiagnosed/untreated pain 
 N13: A third scenario where person has no 
pain but still takes medication to prevent 
withdrawal 
N23: Inquire if the responder has a family 
member/care giver who monitors/assists with 





A11: Providing a scenario instead of a direct 






A01: Believes that length of use of pain 
medication may influence patient’s 
response 
 N26: Responders may remain in denial and 




A04: Participants may have difficulty in 






A01: Suggests that responders with high pain 
levels may misinterpret “feel good”. Due to their 
pain they may not understand that it signifies 
euphoria. 
A06: the two questions may be repetitive 
 N18: Suggested asking if drug resolved 
responders pain 
N23: Participants may be embarrassed in 
accepting their vulnerability.  Instead of a direct 
question, use an alternate method 
N26: Use an alternate word for vulnerable as 






A06: Responders may not admit having weak 
willpower 
A11: Responders may not be able to judge and 
report their vulnerabilities accurately 
 N13: Questions and choices can’t be 
framed in any better way 
N27: Responders may have difficulty in 







A01: Add more serious consequences 
A02: Suggested using/adding more severe 
consequences to the question 
A06: Add dire physical and legal consequences 
A07: Add severe consequences like damage to 
the body and legal issues 
A11: Provide examples of drastic 
consequences 
 N18: Add additional severe consequences 
N19: Add additional severe consequences of 
drug abuse 
N26: Provide examples of dire consequences 
instead of just side effects like drowsiness 
N27: Add social and psychological 





A01: Add examples of serious consequences 
A06: Inquire about responses to each 
consequences 
A11: Assess responder’s knowledge of the side 
effects of the abused drugs 
 N13: Interviewee had a hard time 
distinguishing between “severe and serious”. 
Suggested explaining the two in a better way. 
N19: Explain serious situation better through 
specific consequences 






A04: More examples of the “physical problems” 
should be provided 
A06: Provide detailed examples of problems so 
responders can relate better 
A11: Provide more examples of other potential 
problems drugs may be relieving 
 N18: Provide more examples of rewards and 
let responder provide a categorical (yes/no) 
answer 
N19: Provide a list of problems so that 






A11: People know their bodies well, so can tell 






A01: Define/provide an example of extrinsic 






A09: Add doctor’s approval/disapproval also  N13: A binary choice (Approve/Disapprove) 
would be better. 
N19: Add teachers/role models category 
N23: Add community members (church 
members/coworkers) 




  N18: Responders may have difficulty in 
discerning between multiple choices. Specific/ 





A01: The question will be better understood if it 
explained that it has 3 parts— 'bad', 'harmful', or 
'favorable/unfavorable.' 
A11: Attitude may change over time. Inquiring 
about the responder’s attitude from  their friends 





A01: “offer another question that asks if 
someone is more concerned about controlling 
pain.” 
 N13: “Unlikely/Likely” in one question is 
confusing. Suggested using separate questions 
instead. 













A02: Interviewee suggested that participants 
will tend to be honest (in the self-report) if they 
are allowed to remain anonymous. 
A11: Use during the past six months may be 





A01: Inquire about family and community 
support 
A04: add “retired” option to question regarding 
employment status  
A06: Add “disability” option to the employment 
question 
A09: Add disabled to employment status 
 N13: Suggested adding transgender and 
retired options to the questions 
N18: Add “disabled” option 
N19: add “significant other/domestic partner” 
and “retired/ disabled” options to appropriate 
questions 
N23: Add retired/disabled option 




A02: The interviewee suggested that the 
demographics section should also include a 
question about family history of abuse 
 N18: Annual income may not reflect number of 





A01: Suggests adding a second test group 
(scenario) – one with mild abuse issues 
 N23: Keep the survey questions simple and 
direct 
*Bold and Highlighted indicates difference from Reviewer One 
 
Interview Summary Findings 
The following list describes the primary summary finding(s) of the qualitative analysis of each 
interview question: 
Question 1: Types of Misuse: Both groups agree on definitions of misuse and no 
comments. 
Question 2: Scenarios: Both groups agree scenarios are relatable and understandable. 
Two past substance users and one non-user suggested adding a third scenario. One past 
substance user suggested adding more lifestyle information. One non-user suggested 
looking at people with caregivers. 
Question 3: Risk of Addiction: Both groups no problems or opinions 
Question 4: Self-efficacy: Both groups no problems or opinions 
Question 5: Perceived Vulnerability: Both groups thought that people might be 
uncomfortable talking about vulnerability and admitting to weak willpower. Two non-
users suggested using different terminology than vulnerability. One patient from each 
group thought questions were a bit repetitive initially. 
Question 6: Perceived Severity: Both groups suggested using more and stronger 
consequences of drug misuse under severity. Examples: going to jail, causing car 
accident, death/injury. Both groups also suggested defining what serious is supposed to 
mean in the framework of the question. 
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Question 7: Intrinsic Rewards: Both groups suggested letting people check box which 
problems they believe the drug misuse is solving. Ex. Checkbox list and open text box 
where they can describe how problems are solved. 
Question 8: Extrinsic Rewards: Most patients understood and supported the question. 
One individual from each group suggested providing a more detailed example of how 
extrinsic reward works. 
Question 9: Subjective Norm: Both groups believe that Family, Friends and Strangers are 
appropriate. One past substance user suggested adding doctors, two non-users suggested 
specifying coworkers and church/community, and one non-user suggested adding role-
models/teachers to subjective norms. 
Question 10: Attitude: Both groups understood and supported questions. 
Question 11: Intention: Both groups understood and supported questions. One individual 
from each group thought that patients might not be honest about their intentions, 
especially if they are actively abusing. 
Question 12: ASSIST: Both groups understood and supported use of ASSIST. Everyone 
believed that most people could honestly answer, especially if they were assured that 
responses were anonymous. 
Question 13: Demographics: 9 of all 13 people: 4 past substance users and 5 non-users 
suggested adding retired and/or disabled to the employment question. In the target 
population, chronic pain patients, a significant proportion of the examined population 
likely reported as unemployed because they had no other valid choice. No other issues 
with the other demographic questions. 
Feedback: No significant thoughts or changes suggested overall. 
 
Interview Significant Themes 
The following significant themes were identified from the statements made by the interview 
patients: 
1. Scenarios – three patients suggested adding a third scenario where pain was poorly 
controlled, but drug seeking and misuse were controlled (2 sub users, 1 non-user) 
2. Perceived Vulnerability – two patients believed that the questions for PV were 
repetitive coming after questions about risk of addiction and self-efficacy (1 sub user, 
1 non-user) 
3. Perceived Vulnerability – five patients believed that patients may have a hard time 
admitting to being vulnerable and that another word should be substituted for 
vulnerable (2 sub users, 5 non-users) 
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4. Perceived Severity – eleven patients suggested using more severe consequences with 
more serious outcomes (5 sub users, 6 non-users) 
5. Intrinsic Rewards – five patients suggested allowing patients to specifically select 
intrinsic rewards and leave the question open-ended for them to add more (3 sub 
users, 2 non-users) 
6. Extrinsic Rewards – two patients suggested providing a better definition with specific 
examples (1 sub user, 1 non-user) 
7. Subjective Norms – two patients suggested adding coworkers/acquaintances/church 
associates as another group (2 non-users) 
8. Intention – two patients suggested asking separate questions for likely and unlikely (2 
non-users) 
9. Intention – two patients suggested that people who are addicted might not be honest 
about their intentions (1 sub user, 1 non-user) 
10. Demographics – five patients suggested adding disabled as an employment option (2 
sub users, 3 non-users) 
11. Demographics – five patients suggested adding retired as an employment option (2 
sub users, 3 non-users) 
Results: Quantitative 
Recruitment 
80 patients were successfully recruited to both the control and test vignettes surveys. Two 
of the control patients did not fully complete their questionnaires, dropping the effective number 
of valid control patients to 78. The target recruitment numbers of 70 or more per group were met; 
however, the recruitment rate was poor. The recruitment rate for the survey was 10.3% with 160 
patients completing the survey out of a total of 1551 patients contacted. (See Figure 4.1) 
Demographics 
 The demographic characteristics did not differ between the control vignette group and 
test vignette group of chronic pain patients. Specifically, gender, age, marital status, 
race/ethnicity, employment, income and education did not differ between groups. Likewise, the 
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control and test groups did not differ on their ASSIST score distribution with an average score of 
5 to 6 (moderate risk) with an equal distribution between low and moderate risk. 
Table 4.4 Descriptive Data 
 
Control (n=78) Test (n=80)  
Chi-square Frequency (%) 
or Mean (s.d.) 
Frequency (%) 
or Mean (s.d.) 
Gender 
Female 50 (64.9) 49 (61.3) 0.229 
p=0.632 Male 27 (35.1) 31 (38.8) 
Marital Status 
Single 10 (13.0) 12 (15.2) 3.206 
p=0.361 Married/Cohabiting 58 (75.3) 51 (64.6) 
Divorced 8 (10.4) 12 (15.2) 
Widowed 1 (1.3) 4 (5.1) 
Race/Ethnicity 
Non-caucasian 4 (5.2) 2 (2.5) 1.281 
p=0.527 Caucasian 73 (94.8) 77 (97.5) 
Employment    
Full Time 10 (13.0) 17 (21.5) 3.008 
p=0.390 Self Employed 6 (7.8) 4 (5.1) 
Part Time 7 (9.1) 4 (5.1) 
Not Employed 54 (70.1) 54 (68.4) 
Income    
<$10k - $29,999 31 (39.7) 32 (40.0) 12.878 
p=0.075 $30k - $69,999 18 (23.1) 22 (27.5) 
$70k - $99,999 16 (20.5) 16 (20.0) 
>$100,000 13 (16.7) 10 (12.5) 
Education 
≤ High School 5 (6.5) 13 (16.3) 4.912 
p=0.178 ≤ Bachelor’s 41 (53.2) 36 (45.0) 
Professional 10 (13.0) 14 (17.5) 
Graduate 21 (27.3) 17 (21.3) 
 Frequency (%) Frequency (%) T-test 
Age – (years) 57 (±14) 57 (±15)  
< 30 3 (3.8) 6 (7.5) F=0.029 
p=0.858 31 – 40 8 (10.3) 6 (7.5) 
41 – 50 13 (16.7) 6 (7.5) 
51 – 60 17 (21.8) 23 (28.7) 
61 – 87 37 (47.4) 39 (48.7) 
ASSIST Score 6 (±7) 5 (±6)  
Lower Risk (0 to 4) 41 (52.6) 35 (46.1) 0.801 
p=0.224 Moderate Risk (5 to  24) 36 (46.2) 42 (53.8) 





  Because the response rate to the survey was around 10% and also because the 
measurement helps to understand some study limitations, a nonresponse bias analysis was 
conducted. Gender and age did not significantly differ between respondents and non-
respondents; however, significantly more survey-takers were Caucasian (92.5%) and possibly 
also married (66.3%), than those who did not take the survey. Because of these differences 
between the survey population and the non-respondent population the ability to generalize these 
findings to a larger population may be affected. 
Table 4.5 Non-response Bias Data 
 




Frequency (%) or 
Mean (s.d.) 
Frequency (%) or 
Mean (s.d.) 
Gender 
Female 109 (68.1) 893 (64.2) 0.967 
p=0.325 Male 51 (31.9) 498 (35.8) 
Marital Status 
Unmarried 54 (33.8) 616 (44.3) 6.490 
p=0.011 Married 106 (66.3) 775 (55.7) 
Race/Ethnicity 
Non-caucasian 12 (7.5) 216 (15.5) 7.376 
p=0.007 
Caucasian 148 (92.5) 1175 (84.5) 
Age – (years) 57 (±14) 58 (±16) T-test 
< 30 9 (5.6) 72 (5.2) F=4.017 
p=0.799 31 – 40 14 (8.8) 134 (9.6) 
41 – 50 19 (11.9) 245 (17.6) 
51 – 60 42 (26.3) 329 (23.7) 
61 – 87 76 (47.5) 611 (43.9) 
 
Control vs Test Groups: Vignette manipulation 
 For each of the theory-based variables a chi-square analysis was conducted to determine 
whether the control and test vignette groups were significantly different in response. The chi-
square results can be viewed in Tables 4.6 through 4.14. If the responses by each group were 
significantly different, then the vignette manipulation was assumed to be significant for that 
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variable. Each table represents up to four chi-square analyses, one for each of the misuse types: 
often, dose, withdrawal, and feel good. The hypothesis posited that the control and test groups 
would differ on all of the model variables. With the exceptions of perceived severity, part of 
extrinsic rewards, and part of subjective norms the hypothesis was supported.  
Perceived severity: Perceived severity did not significantly differ between the control and test 
groups for each of the four types of misuse. 
Perceived vulnerability: Perceived vulnerability showed significant differences between the 
control and test vignette groups 
Intrinsic rewards: Intrinsic rewards showed significant differences between the control and test 
vignette groups.  
Extrinsic rewards: Extrinsic rewards also showed mixed results concerning differences between 
the control and test vignette groups. The control and test groups significantly differed on often 
and dose misuse, but not on withdrawal and feel good.  
Subjective norms: Subjective norms showed mixed results concerning differences between the 
control and test vignette groups. The control and test groups significantly differed regarding dose 
and feel good misuse, but not on often misuse.  
Attitude: Attitude showed significant differences between the control and test vignette groups.   
Intention: Intention showed significant differences between the control and test vignette groups.  
Risk of addiction: Risk of Addiction showed significant differences between the control and test 
vignette groups.  





Table 4.6 Chi-square: Perceived Severity 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Perceived Severity – Often (scale) 
Not at all 13(17.1) 9(11.5) 
1.029 
p=0.905 
Somewhat 16(21.1) 18(23.1) 
Moderately 19(25.0) 20(25.6) 
Very 16(21.1) 17(21.8) 
Extremely 12(15.8) 14(17.9) 
Perceived Severity – Dose (scale) 
Not at all 14(18.4) 10(12.7) 
1.601 
p=0.809 
Somewhat 11(14.5) 14(17.7) 
Moderately 18(23.7) 21(26.6) 
Very 19(25.0) 17(21.5) 
Extremely 14(18.4) 17(21.5) 
Perceived Severity – Withdrawal (scale) 
Not at all 15(19.5) 7(8.9) 
3.765 
p=0.429 
Somewhat 17(22.1) 19(24.1) 
Moderately 13(16.9) 17(21.5) 
Very 17(22.1) 19(24.1) 
Extremely 15(19.5) 17(21.5) 
Perceived Severity – Feel Good (scale) 
Not at all 16(20.8) 12(15.2) 
1.377 
p=0.848 
Somewhat 13(16.9) 18(22.8) 
Moderately 14(18.2) 14(17.7) 
Very 14(18.2) 14(17.7) 
Extremely 20(26.0) 21(26.6) 
 
Table 4.7 Chi-square: Perceived Vulnerability 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Perceived Vulnerability – Often (scale) 
Not at all 3(3.8) 1(1.3) 
42.456 
p<0.001 
Somewhat 72(92.3) 38(48.7) 
Moderately 3(3.8) 35(44.9) 
Very 0(0.0) 4(2.6) 
Perceived Vulnerability – Dose (scale) 
Not at all 2(2.6) 1(1.3) 
41.243 
p<0.001 
Somewhat 74(94.9) 41(51.9) 
Moderately 2(2.6) 34(43.0) 
Very 0(0.0) 3(1.9) 
Perceived Vulnerability - Withdrawal 
Very 53(67.9) 31(38.8) 
20.006 
p<0.001 
Unlikely 12(15.4) 15(18.8) 
Neither 9(11.5) 11(13.8) 
Likely 3(3.8) 12(15.0) 
Very 1(1.3) 11(13.8) 
Perceived Vulnerability – Feel Good 
Very 63(80.3) 38(47.5) 
24.667 
p<0.001 
Unlikely 9(11.5) 11(13.8) 
Neither 3(3.8) 6(7.5) 
Likely 2(2.6) 18(22.5) 





Table 4.8 Chi-square: Intrinsic Rewards  
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Intrinsic Rewards – Often 
Strongly 47(60.3) 22(27.5) 
20.191 
p<0.001 
Disagree 17(21.8) 24(30.0) 
Neither 7(9.0) 12(15.0) 
Agree 6(7.7) 14(17.5) 
Strongly 1(1.3) 8(10.0) 
Intrinsic Rewards – Dose 
Strongly 49(62.8) 19(23.8) 
27.103 
p<0.001 
Disagree 16(20.5) 24(30.0) 
Neither 5(6.4) 11(13.8) 
Agree 7(9.0) 19(23.8) 
Strongly 1(1.3) 7(8.8) 
Intrinsic Rewards – Withdrawal 
Strongly 41(52.6) 25(31.3) 
11.795 
p=0.019 
Disagree 11(14.1) 21(26.3) 
Neither 13(16.7) 9(11.3) 
Agree 10(12.8) 17(21.3) 
Strongly 3(3.8) 8(10.0) 
Intrinsic Rewards – Feel Good 
Strongly 49(62.8) 28(35.0) 
17.160 
p=0.002 
Disagree 7(9.0) 17(21.3) 
Neither 13(16.7) 11(13.8) 
Agree 7(9.0) 16(20.0) 
Strongly 2(2.6) 8(10.0) 
 
Table 4.9 Chi-square: Extrinsic Rewards 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Extrinsic Rewards – Often 
Strongly 41(52.6) 24(30.4) 
10.228 
p=0.037 
Disagree 11(14.1) 13(16.5) 
Neither 16(20.5) 19(24.1) 
Agree 6(7.7) 16(20.3) 
Strongly 4(5.1) 7(8.9) 
Extrinsic Rewards – Dose 
Strongly 42(53.8) 25(31.6) 
9.557 
p=0.049 
Disagree 11(14.1) 16(20.3) 
Neither 14(17.9) 16(20.3) 
Agree 6(7.7) 15(19.0) 
Strongly 5(6.4) 7(8.9) 
Extrinsic Rewards – Withdrawal 
Strongly 42(53.8) 28(35.0) 
5.945 
p=0.203 
Disagree 9(11.5) 15(18.8) 
Neither 16(20.5) 22(27.5) 
Agree 8(10.3) 10(12.5) 
Strongly 3(3.8) 5(6.3) 
Extrinsic Rewards – Feel Good 
Strongly 42(54.5) 28(35.0) 
6.250 
p=0.181 
Disagree 9(11.7) 12(15.0) 
Neither 16(20.8) 24(30.0) 
Agree 5(6.5) 9(11.3) 




Table 4.10 Chi-square: Subjective Norms 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Subjective Norm – Often (scale) 
Strongly 45(57.7) 33(41.8) 
5.824 
p=0.104 
Disagree 25(32.1) 36(45.6) 
Neither 8(10.3) 8(10.1) 
Agree 0(0.0) 2(2.5) 
Strongly 0(0.0) 0(0.0) 
Subjective Norm – Dose (scale) 
Strongly 50(64.1) 35(45.5) 
10.045 
p=0.011 
Disagree 20(25.6) 37(48.1) 
Neither 8(10.3) 4(5.2) 
Agree 0(0.0) 1(1.3) 
Strongly 0(0.0) 0(0.0) 
Subjective Norm – Feel Good (scale) 
Strongly 55(71.4) 36(46.8) 
14.432 
p=0.002 
Disagree 15(19.5) 36(46.8) 
Neither 7(9.1) 4(5.2) 
Agree 0(0.0) 1(1.3) 
Strongly 0(0.0) 0(0.0) 
Table 4.11 Chi-square: Attitude 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Attitude – Often (scale) 
Very 53(69.7) 38(50.0) 
12.327 
p=0.025 
Bad,H,Unfav 11(14.5) 21(27.6) 
Somewhat 7(9.2) 4(5.3) 
Neither 4(5.3) 5(6.6) 
Somewhat 1(1.3) 4(5.3) 
Good,Ben,Fav 0(0.0) 4(5.3) 
Very 0(0.0) 0(0.0) 
Attitude – Dose (scale) 
Very 52(70.3) 32(42.1) 
15.881 
p=0.006 
Bad,H,Unfav 12(16.2) 23(30.3) 
Somewhat 4(5.4) 6(7.9) 
Neither 6(8.1) 8(10.5) 
Somewhat 0(0.0) 4(5.3) 
Good,Ben,Fav 0(0.0) 2(2.6) 
Very 0(0.0) 1(1.3) 
Attitude – Withdrawal (scale) 
Very 44(57.9) 27(34.6 
13.323 
p=0.028 
Bad,H,Unfav 14(18.4) 22(28.2) 
Somewhat 4(5.3) 13(16.7) 
Neither 11(14.5) 9(11.5) 
Somewhat 2(2.6) 3(3.8) 
Good,Ben,Fav 1(1.3) 2(2.6) 
Very 0(0.0) 2(2.6) 
Attitude – Feel Good (scale) 
Very 60(80.0) 37(48.1) 
22.870 
p=0.001 
Bad,H,Unfav 8(10.7) 21(27.3) 
Somewhat 1(1.3) 8(10.4) 
Neither 5(6.7) 3(3.9) 
Somewhat 1(1.3) 5(6.5) 
Good,Ben,Fav 0(0.0) 2(2.6) 
Very 0(0.0) 1(1.3) 
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Table 4.12 Chi-square: Intention 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Intention – Often (scale) 
Strongly 64(83.1) 40(50.6) 
22.029 
p<0.001 
Disagree 8(10.4) 18(22.8) 
Neither 5(6.5) 10(12.7) 
Agree 0(0.0) 8(10.1) 
Strongly 0(0.0) 3(3.8) 
Intention – Dose (scale) 
Strongly 64(84.2) 40(51.3) 
22.468 
p<0.001 
Disagree 7(9.2) 20(25.6) 
Neither 5(6.6) 8(10.3) 
Agree 0(0.0) 7(9.0) 
Strongly 0(0.0) 3(3.8) 
Intention – Withdrawal (scale) 
Strongly 60(82.2) 42(53.8) 
15.482 
p=0.004 
Disagree 5(6.8) 16(20.5) 
Neither 5(6.8) 8(10.3) 
Agree 3(4.1) 9(11.5) 
Strongly 0(0.0) 3(3.8) 
Intention – Feel Good (scale) 
Strongly 65(84.4) 44(56.4) 
15.440 
p=0.004 
Disagree 5(6.5) 13(16.7) 
Neither 4(5.2) 10(12.8) 
Agree 3(3.9) 8(10.3) 
Strongly 0(0.0) 3(3.8) 
 
Table 4.13 Chi-square: Risk of Addiction 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Risk of Addiction (scale) 
Very unlikely  21(27.6) 7(8.9) 
41.012 
p<0.001 
 23(30.3) 10(12.7) 
 16(21.1) 8(10.1) 
 4(5.3) 7(8.9) 
 4(5.3) 6(7.6) 
 5(6.6) 12(15.2) 
 2(2.6) 6(7.6) 





Table 4.14 Chi-square: Self-Efficacy 
 Control (n=78) Test (n=80) Chi-square 
Frequency (%) Frequency (%) 
Self-Efficacy – Often (confidence) 
Not at all 0(0.0) 19(23.8) 
44.714 
p<0.001 
Somewhat 2(2.6) 13(16.3) 
Moderately 3(3.9) 12(15.0) 
Very 24(31.2) 14(17.5) 
Extremely 48(62.3) 22(27.5) 
Self-Efficacy – Dose 
Not at all 0(0.0) 15(19.0) 
36.312 
p<0.001 
Somewhat 4(5.4) 15(19.0) 
Moderately 3(4.1) 12(15.2) 
Very 17(23.0) 13(16.5) 
Extremely 50(67.6) 24(30.4) 
Self-Efficacy – Withdrawal 
Not at all 1(1.4) 17(21.5) 
33.887 
p<0.001 
Somewhat 2(2.8) 8(10.1) 
Moderately 3(4.2) 15(19.0) 
Very 21(29.2) 17(21.5) 
Extremely 45(62.5) 22(27.8) 
Self-Efficacy – Feel Good 
Not at all 3(4.0) 10(12.7) 
28.649 
p<0.001 
Somewhat 2(2.7) 12(15.2) 
Moderately 1(1.3) 10(12.7) 
Very 13(17.3) 19(24.1) 
Extremely 56(74.7) 28(35.4) 
 
Hayes’ Regression Model 4 – What are the basic mediation relationships? 
 Exploring the basic mediation that may be occurring in the behavioral model is important 
before showing the final regression results that show the influence of risk of addiction and self-
efficacy on the relationships. Hayes Process model 4 was used within SPSS to run ordinary least 
squares regression.39 The Process model 4 represents basic mediation (M) where the 
relationship between the independent variables, pain level, drug seeking, and misuse, 
(vignette=X) and the dependent variable, intention to misuse prescription opioids, (intentions=Y) 
are described by one or more mediators, perceived vulnerability and severity, intrinsic and 
extrinsic rewards, attitudes, and subjective norms. There may also be a direct relationship (Direct 
XY) between the misuse scenarios and intention to misuse prescription opioids. Several 
covariates (gender, age, race, employment, income, and education) were run in the model. Figure 
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4.2 is a graphical representation of this model and a key to understanding the following 
abbreviated Model 4 results tables. 






X (vignette) = Pain, drug seeking, misuse influences Mediator (Mi), if significant. 
Mi = Mediator (Mi) influences Dependent (Y), if significant. 
Direct XY = Vignette (X) directly influences Dependent (Y), if significant. 
 
Abbreviated regression tables and prescription misuse types 
To ease interpretation, the tables are presented in a more abbreviated form that excludes 
the covariates. Whenever possible, significant regressions with the highest combination of 
mediators (up to four or six) and the most combined misuse types (up to all four), are presented. 
Please refer to Table 4.15 for guidance on the misuse types and possible combinations. The full 
table for each regression is available within Appendix B. 
 
Table 4.15 Prescription Misuse Types and Combinations 
Types of misuse:  
• Taking prescription more OFTEN than prescribed.  
• Taking prescription in higher DOSE than prescribed.  
• Taking prescription to avoid WITHDRAWAL symptoms.  
• Taking prescription to “FEEL GOOD.” 
Combined misuse cases 
• ALL TYPE MISUSE combines results for all four misuse types 
• OFTEN and DOSE combines results for those two medication-related types of misuse. 
• WITHDRAWAL and FEEL GOOD combines results for those two symptom/feeling-
based types of misuse 
 
 




Model 4 – Intention(Y) 
Table 4.16 and Table 4.17 show model 4 where intention was the dependent variable for 
combined misuse types often & dose and withdrawal & feel good. There was no direct effect in 
either model. In the Table 4.16 often & dose model, perceived vulnerability, intrinsic rewards, 
and attitude showed relationships with the vignette; however only perceived vulnerability and 
attitude were full mediators.  
Table 4.16 Model 4 Intention Full Model - Often & Dose – Abbreviated* 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .09 .12 .77 .66 .09 6.95*** 
  R2=.13   R2=.34  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. t b s.e. t 
X (Vignette) .46 .10 4.60*** .24 .13 1.85 
  R2=.21   R2=.08  
 Subjective Norm (M5) Attitude (M6) 
Model b s.e. t b s.e. t 
X (Vignette) .08 .06 1.35 .26 .11 2.39* 
  R2=.20   R2=.14  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Severity) .03 .05 .50    
M2 (Perceived Vuln) .55 .07 7.85***    
M3 (Intrinsic Rewards) -.01 .08 -.19  
M4 (Extrinsic Rewards) .08 .05 1.57  
M5 (Subjective Norm) -.14 .12 -1.24 
M6 (Attitude) .26 .07 3.84*** 
X (Vignette) -.09 .07 -1.29    
 Effect 95% CI     
Direct effect XY -.09 (-.23, .05)     
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
In the Table 4.17 withdrawal & feel good model, perceived vulnerability, intrinsic 
rewards, extrinsic rewards, subjective norms, and attitude showed relationships with the vignette; 
however only perceived vulnerability, intrinsic rewards, and attitude were full mediators. 
 
78 
Table 4.17 Model 4 Intention Full Model - Withdrawal & Feel Good – Abbreviated* 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .10 .12 .88 .57 .10 5.76*** 
  R2=.12   R2=.24  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. t b s.e. t 
X (Vignette) .39 .10 3.70*** .22 .11 2.03* 
  R2=.18   R2=.10  
 Subjective Norm (M5) Attitude (M6) 
Model b s.e. t b s.e. t 
X (Vignette) .16 .06 3.00** .38 .11 3.58*** 
  R2=.13   R2=.13  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Severity) -.01 .05 -.12    
M2 (Perceived Vuln) .21 .09 2.41*    
M3 (Intrinsic Rewards) .27 .09 3.08**  
M4 (Extrinsic Rewards) .08 .05 1.46  
M5 (Subjective Norm) -.06 .11 -.58 
M6 (Attitude) .25 .07 3.88*** 
X (Vignette) .04 .07 .61    
    R2=.61     
 Effect 95% CI     
Direct effect XY -.04 (-.10, .19)     
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Model 4 – Theory of Reasoned Action 
Table 4.18 shows subjective norm and attitude mediating intention as would be expected 
in the theory of reasoned action. Both subjective norm and attitude showed relationships with the 
vignette; however, only attitude showed a relationship with intention looking all the combination 
of all misuse types. There was a direct relationship detected between vignette and intention in 





Table 4.18 Model 4 Theory of Reasoned Action All Misuse Types – Abbreviated* 
Mediator variable models 
 Subjective Norm (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .11 .05 2.07* .33 .10 3.40*** 
  R2=.11   R2=.15  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Subjective Norm) .01 .13 .11    
M2 (Attitude) .39 .07 5.46***    
X (Vignette) .18 .07 2.52*    
    R2=.36     
 Effect 95% CI     
Direct effect XY .18* (.04, .33)     
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Hayes’ Regression Model 7 – Demonstrating conditional indirect effects 
 The Process Model 7 represents a conditional indirect effect that could also be called 
moderated mediation with one moderator (W) that may interact (X*W) with the independent 
variable (vignette=X) to influence one or more mediators (Mi). Each mediator (Mi) may also 
have a relationship with the dependent variable. Only when the interaction (X*W) and mediator 
to dependent variable (Mi) relationships are both significant does a conditional indirect occur. 
There may also be a direct relationship (Direct XY) between the independent and dependent 
variables. When there is a significant conditional indirect effect the confidence intervals listed at 
the bottom of the tables represent bootstrapping performed upon the original results for each 
mediator in the model. They represent the conditions of when the moderator generates the 
conditional indirect effect. The possible levels of moderator are low, moderate, high and may 
influence the direction, positive or negative, in which the dependent variable functions for that 
specific behavioral model. More specifically, at the mean value for the moderator the level is 
moderate, at minus one standard deviation the moderation level is low, and conversely at plus 
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one standard deviation the moderation level is high. Several covariates (gender, age, race, 
employment, income, and education) were run in the model. In the case of these specific model 7 
analyses each of the protection motivation variables: perceived severity, perceived vulnerability, 
intrinsic rewards, and extrinsic rewards were run as the mediator with attitude or intention as the 
dependent variable. In a few cases, perceived vulnerability and intrinsic rewards, attitude was run 
as an additional mediator with intention as the dependent variable. Figure 4.3 is a graphical 
representation of this model and a key to understanding the following abbreviated model 7 
results tables. 
 






X*W = Moderator (W) interacts with Vignette (X) to influence Mediator (Mi), if significant. 
Mi = Mediator (Mi) influences Dependent (Y), if significant. 
Direct XY = Vignette (X) directly influences Dependent (Y), if significant. 
W = -1SD = When perceived Moderator (W) is at a LOW level it influences the conditional 
indirect effect of Vignette (X) on Dependent (Y) as mediated by Mediator (Mi), if significant. 
W = 0 = When perceived Moderator (W) is at a MODERATE level it influences the conditional 
indirect effect of Vignette (X) on Dependent (Y) as mediated by Mediator (Mi), if significant. 
W = 1SD =  When perceived Moderator (W) is at a HIGH level it influences the conditional 
indirect effect of Vignette (X) on Dependent (Y) as mediated by Mediator (Mi), if significant. 
 
Model 7 – Perceived vulnerability 
Table 4.19, Table 4.20, and Table 4.21 represent models where perceived vulnerability 
was the mediator variable, risk of addiction was the moderating variable, and intention was the 
Vignette (X) Dependent (Y) 
Mediator (Mi) Moderator (W) 
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dependent variable in Table 4.19 and Table 4.20. In Table 4.21 attitude was an added mediator 
variable. Table 4.19 was an often & dose model, whereas Table 4.20 and Table 4.21 were 
withdrawal & feel good models. There was no direct effect in any of the models. All three 
models demonstrated significant conditional indirect effects.  
 
Model 7 – Perceived vulnerability – Intention with often & dose misuse and risk of addiction 
For Table 4.19, when risk of addiction was perceived to be moderate and high, then 
perceived vulnerability to taking prescription drugs more often and in higher doses than 
prescribed mediated the conditional indirect effect  between vignette (pain, drug seeking, and 
misuse) and intention to misuse. At perceived moderate and high risk of addiction perceived 
vulnerability increased intention towards often and dose misuse increasing the likelihood of often 
and dose misuse.  
 
Table 4.19 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Often & Dose Misuse – Abbreviated* 
Mediator variable models 
 Perceived Vulnerability (M1)  
Model b s.e. t    
X*W .18 .04 4.98***    
  R2=.63     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .53 .06 8.27***    
  R2=.50     
Direct  Effect 95% CI     
Direct XY -.01 (-.16, .15)     
Conditional Indirect Perceived Vulnerability   
W = -1SD(-2.47) -.04 (-.15, .04)    
W = 0 .19 (.10, .31)    
W = 1SD(2.47) .43 (.24, .65)    




Model 7 – Perceived vulnerability – Intention with withdrawal and feel good misuse and risk of 
addiction 
For Table 4.20, when risk of addiction was perceived to be moderate and high, then 
perceived vulnerability to taking prescription drugs to avoid withdrawal and to feel good 
mediated the conditional indirect effect  between vignette (pain, drug seeking, and misuse) and 
intention to misuse. At perceived moderate and high risk of addiction perceived vulnerability 
increased intention towards withdrawal and feel good misuse increasing the likelihood of 
withdrawal and feel good misuse. 
 
Table 4.20 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Withdrawal & Feel Good – Abbreviated* 
Mediator variable models 
 Perceived Vulnerability (M1)  
Model b s.e. t    
X*W .15 .04 3.67***    
  R2=.51     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .54 .06 8.84***    
  R2=.45     
Direct  Effect 95% CI     
Direct XY .02 (-.13, .18)     
Conditional Indirect Perceived Vulnerability   
W = -1SD(-2.47) -.06 (-.17, .02)    
W = 0 .14 (.03, .25)    
W = 1SD(2.47) .34 (.12, .55)    
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Model 7 – Perceived vulnerability and Attitude –Intention with withdrawal and feel good misuse 
and risk of addiction 
For Table 4.21, when risk of addiction was perceived to be moderate and high, then 
perceived vulnerability and attitude toward taking prescription drugs to avoid withdrawal and to 
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feel good mediated the conditional indirect effect between vignette (pain, drug seeking, and 
misuse) and intention to misuse. At perceived moderate and high risk of addiction perceived 
vulnerability and attitude increased intention towards withdrawal and feel good misuse 
increasing the likelihood of withdrawal and feel good misuse. 
 
Table 4.21 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M1) and 
Attitude(M2)  Intention(Y) Withdrawal & Feel Good – Abbreviated* 
Mediator variable models 
 Perceived Vulnerability (M1) Attitude(M2) 
Model b s.e. t b s.e. t 
X*W .18 .04 4.62*** .14 .05 2.65** 
  R2=.56   R2=.21  
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .40 .06 6.57***    
M2 (Attitude) .33 .06 5.74***    
  R2=.56     
Direct  Effect 95% CI     
Direct XY -.01 (-.15, .13)     
Conditional Indirect Perceived Vulnerability  Attitude 
W = -1SD(-2.45) -.06 (-.16, .0) W = -1SD(-2.45) -.01 (-.10, .07) 
W = 0 .12 (.06, .22) W = 0 .10 (.04, .20) 
W = 1SD(2.45) .30 (.15, .49) W = 1SD(2.45) .21 (.10, .38) 
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Model 7 – Perceived severity – Intention with withdrawal misuse and self-efficacy 
For Table 4.22, when self-efficacy was perceived to be low and moderate, then perceived 
severity to taking prescription drugs to avoid withdrawal partially mediated the conditional 
indirect effect between vignette (pain, drug seeking, and misuse) and intention to misuse. At 
perceived low and moderate self-efficacy a negative perceived severity partially increased 
intention towards withdrawal misuse increasing the likelihood of withdrawal misuse.   
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Table 4.22 Model 7 Self-Efficacy(W) with Perceived Severity(M)  Intention(Y) 
Withdrawal Misuse – Abbreviated* 
Mediator variable models 
 Perceived Severity (M1)  
Model b s.e. t    
X*W -.25 .12 -2.01*    
  R2=.12     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Severity) -.14 .07 -2.00*    
  R2=.16     
Direct  Effect 95% CI     
Direct XY .35 (.17, .53)     
Conditional Indirect Perceived Severity   
W = -1SD(-1.41) -.09 (-.24, -.01)    
W = 0 -.05 (-.13, -.00)    
W = 1SD(1.19) -.00 (-.07, .04)    
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Model 7 – Intrinsic rewards – Intention with often and dose misuse and self-efficacy 
For Table 4.23, when self-efficacy was perceived to be high, then intrinsic rewards 
related to taking prescription drugs more often and in higher doses than prescribed partially 
mediated the conditional indirect effect between vignette (pain, drug seeking, and misuse) and 
intention to misuse. At perceived high self-efficacy intrinsic rewards was partially responsible 













Table 4.23 Model 7 Self-Efficacy(W) with Intrinsic Rewards(M)  Intention(Y) Often and 
Dose Misuse – Abbreviated* 
Mediator variable models 
 Intrinsic Rewards (M1)  
Model b s.e. t    
X*W .27 .11 2.55*    
  R2=.27     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic Rewards) .33 .06 5.09***    
  R2=.33     
Direct  Effect 95% CI     
Direct XY .23 (.07, .38)     
Conditional Indirect Intrinsic Rewards   
W = -1SD(-1.36) -.06 (-.29, .10)    
W = 0 .06 (-.02, .17)    
W = 1SD(1.15) .16 (.07, .31)    
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Model 7 – Intrinsic rewards – Intention with withdrawal and feel good misuse and risk of 
addiction 
For Table 4.24, risk of addiction did not indicate a particular directionality in the 
bootstrapping section. The intrinsic rewards related to avoiding withdrawal and feeling good 
mediated the conditional indirect effect between vignette (pain, drug seeking, and misuse) and 











Table 4.24 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M)  Intention(Y) 
Withdrawal and Feel Good Misuse – Abbreviated* 
Mediator variable models 
 Intrinsic Rewards (M1)  
Model b s.e. t    
X*W .10 .05 2.12*    
  R2=.35     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic Rewards) .58 .05 10.55***    
  R2=.53     
Direct  Effect 95% CI     
Direct XY .10 (-.03, .24)     
Conditional Indirect Intrinsic Rewards   
W = -1SD(-2.42) -.09 (-.22, .03)    
W = 0 .05 (-.07, .17)    
W = 1SD(2.42) .19 (-.03, .41)    
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Model 7 – Intrinsic rewards and Attitude – Intention with all type misuse and risk of addiction 
For Table 4.25 when risk of addiction was perceived to be moderate and high, then 
intrinsic rewards and attitude toward all type misuse mediated the conditional indirect effect 
between vignette (pain, drug seeking, and misuse) and intention to misuse. At perceived 
moderate and high risk of addiction intrinsic rewards and attitude increased intention towards all 














Table 4.25 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M1) and Attitude(M2)  
Intention(Y) All Type Misuse – Abbreviated* 
Mediator variable models 
 Intrinsic Rewards (M1) Attitude(M2) 
Model b s.e. t b s.e. t 
X*W .09 .04 2.21* .11 .05 2.20* 
  R2=.34   R2=.20  
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic Rewards) .41 .07 6.06***    
M2 (Attitude) .22 .06 3.44***    
  R2=.51     
Direct  Effect 95% CI     
Direct XY .06 (-.07, .19)     
Conditional Indirect Intrinsic Rewards  Attitude 
W = -1SD(-2.47) -.00 (-.09, .08) W = -1SD(-2.47) -.00 (-.07, .06) 
W = 0 .09 (.02, .21) W = 0 .06 (.01, .15) 
W = 1SD(2.47) .19 (.07, .39) W = 1SD(2.47) .12 (.01, .28) 
* p<.05, ** p<.01, *** p<.001 *Abbreviated = covariates excluded from table 
 
Model 7 – Full mediation – Intention with all type misuse 
For Table 4.26, intrinsic rewards and attitude were the only mediators which were 
influenced by an interaction between risk of addiction and vignette. Perceived vulnerability, 
intrinsic rewards, and attitudes all showed relationships with intention, but without a significant 
influencing interaction (X*W) perceived vulnerability was not responsible for mediating a 
conditional indirect effect.  The bootstrapping also confirmed that perceived vulnerability was 
not a significant factor in this model. 
When risk of addiction was perceived to be moderate and high, then intrinsic rewards and 
attitudes toward all type misuse mediated the conditional indirect effect between vignette (pain, 
drug seeking, and misuse) and intention to misuse. At perceived moderate and high risk of 
addiction intrinsic rewards and attitudes increased intention towards all type misuse increasing 
the likelihood of all type misuse.  
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Table 4.26 Model 7 Risk of Addiction(W) with All Mediators and Intention(Y) All Misuse 
Types  - Abbreviated* 
Process Model 7 Regression findings for Full Model Intention (Y) x Perceived Severity (M1), 
Perceived Vulnerability (M2), Intrinsic Rewards (M3), Extrinsic Rewards (M4), Subjective Norm 
(M5), and Attitude (M6) x Risk of Addiction(W) all misuse types 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X*W -.08 .05 -1.55 -.02 .03 -.60 
  R2=.13   R2=.25  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. t b s.e. t 
X*W .09 .04 2.38* -.03 .06 -.50 
  R2=.36   R2=.10  
 Subjective Norm (M5) Attitude (M6) 
Model b s.e. t b s.e. t 
X*W -.04 .03 -1.30 .10 .04 2.60** 
  R2=.15   R2=.22  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Severity) -.37 .19 -1.94    
M2 (Perceived Vuln) .81 .33 2.42*    
M3 (Intrinsic Rewards) .26 .12 2.29*  
M4 (Extrinsic Rewards) .04 .05 .70  
M5 (Subjective Norm) -.07 .16 -.40 
M6 (Attitude) .28 .14 1.97* 
    R2=.60     
 Effect 95% CI     
Direct effect XY -.03 (-.14, .08)     
Conditional Indirect Perceived Severity  Perceived Vulnerability 
W = -1SD(-2.52) -.07 (-.30, .04) W = -1SD(-2.52) .09 (-.04, .32) 
W = 0 .01 (-.08, .15) W = 0 .06 (-.03, .22) 
W = 1SD(2.52) .09 (-.03, .33) W = 1SD(2.52) .02 (-.11, .22) 
Conditional Indirect Intrinsic Rewards  Extrinsic Rewards 
W = -1SD(-2.52) -.01 (-.07, .05) W = -1SD(-2.52) .01 (-.01, .07) 
W = 0 .05 (.01, .15) W = 0 .01 (-.01, .05) 
W = 1SD(2.52) .12 (.02, .28) W = 1SD(2.52) .00 (-.01, .05) 
Conditional Indirect Subjective Norm  Attitude 
W = -1SD(-2.52) -.01 (-.08, .02) W = -1SD(-2.52) .00 (-.08, .08) 
W = 0 -.00 (-.04, .01) W = 0 .08 (.01, .20) 
W = 1SD(2.52) .00 (-.02, .08) W = 1SD(2.52) .15 (.02, .36) 







Chapter 5  
Discussion 
Main Findings of Overall Study 
Neither the protection motivation theory nor the theory of planned behavior have been 
leveraged, to date, as theoretical frameworks for predicting prescription opioid misuse and 
misuse. Several of the substance use related papers that used a protection motivation theory 
framework to examine the threat and coping appraisals associated with predicting intention were 
beginning to extend into the areas of the attitudes, subjective norms, and perceived behavioral 
control aspects of the theory of planned behavior.18,20 Many of the papers that use the theory of 
planned behavior to examine substance use intention have also made extensions to incorporate 
PMT-based factors such as self-efficacy, perceived vulnerability, perceived severity and 
occasional use of intrinsic and extrinsic rewards.25-28,31,32 Some of these studies have examined 
mediation between their key study variables and intention, the mediation alone only accounted 
for a proximal cause for the behavior. In order to develop a fuller picture of the situations that are 
likely to lead to substance misuse and have a better understanding of the conditions that lead to 
substance use the addition of a moderator or moderators either from inside or outside the existing 
theoretical framework will help to explain when misuse is more likely to occur, or be avoided. 
Qualitative Theme Interpretations 
Scenarios 
 The survey questions were overall well understood and supported. Several suggestions 
made by the patients reflected decisions that had already been made during the survey creation 
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process. Though three patients suggested incorporating a third intermediate scenario, this 
possibility was discussed during the instrument development stage. At one point there were two 
intermediate scenarios, one where pain was poorly controlled and there was no drug seeking or 
misuse, as the patients had suggested, and another where pain was well-controlled, but there was 
also drug seeking and misuse. These other two scenarios would have required recruiting twice as 
many patients and might not have been significantly different from the control or test groups. 
Perceived Vulnerability 
 For several people, asking them to talk about their “vulnerability” made them feel uneasy 
as they felt admitting vulnerability was a topic of embarrassment and they may have a hard time 
admitting vulnerability and weak willpower. They had no issues with operationalizing 
vulnerability as will power, but suggested changing vulnerability to susceptibility or another 
term that they were less likely to find embarrassing. A few people thought the questions about 
perceived vulnerability were repetitive because they were placed after the questions on the 
instrument asking about risk of addiction and self-efficacy. Though the question roots and 
answers are different for each set of questions, it is understandable that they sound similar in 
nature. 
Perceived Severity 
 Nearly all of the patients stated that the situation for the perceived severity questions was 
not severe enough. The survey instrument asked them to consider the consequences associated 
with taking too many tablets or capsules of a painkiller, which were nausea, vomiting, dizziness, 
possible respiratory depression. The patients understood why the questionnaire designers used 
the physical symptoms associated with misusing prescription opioids; however, they felt that the 
consequences and severity were not significant enough to make a patient reconsidering misuse of 
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their medication. Eleven of the thirteen patients interviewed suggested that an example or 
examples of consequences associated with drug misuse needed to have more serious and severe 
consequences to affect a person’s perceived severity. Some of the more salient examples 
included causing an accident that kills themselves and/or others, that a person may ruin their 
health severely, especially ruining their liver, or the possibility of trouble with law enforcement.  
Intrinsic Rewards 
 Though most of the patients found the intrinsic rewards listed to be adequate, several 
patients from both groups suggested allowing survey respondents to be more specific about 
which intrinsic rewards applied to their situation. The patients suggested checkboxes for each of 
the possible intrinsic rewards and an additional ability to free-text any other perceived intrinsic 
rewards a patient believed to be important. Patients wanted to list intrinsic rewards that were not 
listed, but they still believed were important to predicting desire to misuse their prescription 
painkillers. 
Extrinsic Rewards 
 Defining extrinsic rewards with an easier to understand description and an example was 
mentioned by one patient from each group. A definition with a more understandable example 
may yield a different result with future instruments. A more specific example would be a person 
beginning smoking because they grew up in a household where smoking seemed to be 
acceptable. 
Subjective Norms 
Overall, patients found the subjective norms of family, friends, and strangers to be 
acceptable. However, five patients had expressed interest in seeing more subjective norms. 
Specifically, those of roles models, authority figures, or people that they feel may not be family, 
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friend, or stranger, such as co-workers or fellow church members. Coworkers/acquaintances/ 
church associates would effectively fall into an area that is in between strangers and friends. 
However, coworkers and church associates would both require a conditional situation that a 
person is working and/or going to church.  This may be appropriate for some specific 
populations, but not likely for a general population. The inclusion of subjective norms beyond 
the primary three is not supported in the literature. 
Intention 
 A few patients indicated that they might have problems being honest about their 
intentions to ultimately misuse their painkillers. Randomizing patients to vignettes and ensuring 
their complete anonymity of response were at least two different methods utilized in this 
instrument to encourage honest answers. Operationalizing unlikely and likely into two different 
questions would likely result in the same answer, just reverse coded. 
Demographics 
 Nearly every patient felt that the types of the employment within the demographics 
section should include retired and/or disabled. Patients who are suffering from chronic pain are 
largely made up of more people who are disabled and/or retired. The employment options on the 
instrument forces most of these patients to answer as unemployed. The income and education 
variables might be able to reveal that there is more to a patient than unemployment, but this may 
be a case were a specific population warrants some more specific measurements, especially if the 
employment covariate were found to have any significant impact. For future surveys targeting 
chronic pain patients including those two extra employment categories may help to clarify the 




Significance of the Vignette Manipulation 
Perceived Severity: Overall similarity between groups 
Perceived severity was the only mediator where the control and test groups did not 
significantly differ from each other for all four types of misuse. These results seem to confirm 
the qualitative interview findings that patients believed that the operationalization of perceived 
severity within the survey was not strong enough to elicit a fear-based response. 
Perceived Vulnerability: Significant differences between groups 
Perceived vulnerability showed differences between the control and test vignette groups. 
Often and dose misuse were similar in their response patterns. Withdrawal and feel good misuse 
types were also similar in response patterns.  The test vignette patients indicated that they felt 
more vulnerable and less willpower towards often and dose misuse. The test vignette patients 
were also more vulnerable to taking their prescription painkillers to avoid withdrawal and feel 
good. The similarity in responses between often and dose misuse and likewise withdrawal and 
feel good misuse may help to indicate that for future surveys and analyses often and dose misuse 
could be combined as dose-based misuse and withdrawal and feel good misuse could be 
combined as symptom-based misuse. These significant differences between groups also seemed 
to be indicative that perceived vulnerability might be a significant factor helping predict how 
misuse scenario influences intention to misuse prescription opioids for all misuse types. This 
prediction was proved to be accurate through the regression analysis in the next discussion 
section. 
Intrinsic Rewards: Significant differences between groups 
Intrinsic rewards showed significant differences between the control and test vignette 
groups. The intrinsic rewards results distribution did not demonstrate any differential patterns 
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between the dose-based and symptom-based misuse types. The significant differences between 
the control and test groups also seems to be indicative that intrinsic rewards might also be a 
significant factor helping predict how misuse scenario influences intention to misuse prescription 
opioids for all misuse types. This prediction was proved to be accurate through the regression 
analysis in the next discussion section. 
Extrinsic Rewards: Mixed results between groups 
The extrinsic rewards control and test groups significantly differed on often and dose 
misuse, but not on withdrawal and feel good misuse.  The extrinsic rewards results distribution 
also did not demonstrate any differential patterns between the dose-based and symptom-based 
misuse types. The significant differences between the dose-based misuse control and test groups 
seemed like it could be indicative that extrinsic rewards might also be a significant factor helping 
predict how misuse scenario influences intention to misuse prescription opioids for the dose-
based misuse types. This prediction was not proved to be accurate. There were no regressions 
where extrinsic rewards were responsible for a significant conditional indirect effect. 
Subjective Norms: Mixed results between groups 
The subjective norms control and test groups significantly differed regarding dose and 
feel good misuse, but not on often misuse. The subjective norms results distribution also did not 
demonstrate any differential patterns between the dose-based and symptom-based misuse types. 
Likewise, the fact that dose misuse was significantly different and often misuse was not seems to 
argue against including both in an overall dose-based misuse category. Withdrawal misuse was 
not examined for subjective norms due to practically issues of withdrawal not functioning to 




Attitude: Significant differences between groups 
Attitude showed significant differences between the control and test vignette groups. 
However, the attitude results distribution did not demonstrate any differential patterns between 
the dose-based and symptom-based misuse types. The significant differences between the control 
and test groups also seems to be indicative that attitude might also be a significant factor helping 
predict how misuse scenario influences intention to misuse prescription opioids for all misuse 
types. This prediction was proved to be accurate through the regression analysis in the next 
discussion section.  
Intention: Significant differences between groups 
Intention showed significant differences between the control and test vignette groups. 
The misuse types showed no apparent similarities within groups. Intention was the dependent 
variable in all of the regressions. Differences between the intention to misuse prescription 
opioids were expected between the two misuse scenarios. 
Risk of Addiction: Significant differences between groups 
 Risk of Addiction showed significant differences between the control and test vignette 
groups. However, the risk of addiction results distribution did not demonstrate any differential 
patterns between the dose-based and symptom-based misuse types. The significant differences 
between the control and test groups seems to be indicative that risk of addiction might be a 
significant factor helping predict when misuse scenario influences intention to misuse 
prescription opioids. 
Self-Efficacy: Significant differences between groups 
Self-efficacy showed significant differences between the control and test vignette groups. 
The misuse types showed no apparent similarities within groups. The significant differences 
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between the control and test groups seem to be indicative that self-efficacy might also be a 
significant factor helping predict when misuse scenario influences intention to misuse 
prescription opioids. 
Significance of Regression Findings 
Perceived Vulnerability and Risk of Addiction: 
 Two model 7 regressions showed significant conditional indirect effects between misuse 
scenarios and increasing intention toward both dose-based and symptom-based misuse of 
prescription opioids as predicted by moderate to high levels of risk of addiction and the influence 
of perceived vulnerability. 
1. At perceived moderate and high risk of addiction, perceived vulnerability increased 
intention towards often and dose misuse increasing the likelihood of often and dose 
misuse. 
2. At perceived moderate and high risk of addiction, perceived vulnerability increased 
intention towards withdrawal and feel good misuse increasing the likelihood of 
withdrawal and feel good misuse. 
The results of these regressions indicate that perceived vulnerability plays a significant 
role in whether a patient is likely to misuse their prescription opioids in the future. Specifically, 
perceived vulnerability interacts with perceived risk of addiction to indicate how intention to 
misuse prescription opioids is likely to be influenced. The regression models indicate that as 
perceived vulnerability increases, that is the person becomes more vulnerable, so does the 
likelihood of misuse. Likewise, moderate and high levels of perceived risk of addiction were also 
indicative of higher levels of perceived vulnerability. 
Perceived Vulnerability with Attitude and Risk of Addiction: 
 One model 7 regression showed significant conditional indirect effects between misuse 
scenarios and increasing intention towards symptom-based misuse of prescription opioids as 
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predicted by moderate to high levels of risk of addiction and the influence of perceived 
vulnerability and attitude. 
1. At perceived moderate and high risk of addiction, perceived vulnerability and attitude 
increased intention towards withdrawal and feel good misuse increasing the likelihood of 
withdrawal and feel good misuse. 
The results of this regression indicate that attitude, along with perceived vulnerability, 
plays a significant role in whether a patient is likely to misuse their prescription opioids in the 
future. Specifically, attitude interacts with perceived risk of addiction and provides an additional 
source of mediation along with perceived vulnerability to give an indication of how intention is 
likely to be influenced. The regression models indicate that as perceived vulnerability and 
attitude increases, the person becomes more vulnerable and attitude shifts towards favoring 
misuse, so does the likelihood of misuse. Likewise, moderate and high levels of perceived risk of 
addiction were also indicative of higher levels of perceived vulnerability and attitude. 
Perceived Severity and Self-Efficacy: 
 One model 7 regression showed significant conditional indirect effects between misuse 
scenarios and increasing intention towards withdrawal-only based misuse of prescription opioids 
as predicted by the level of self-efficacy and the influence of perceived severity. 
1. At perceived low and moderate self-efficacy a negative perceived severity partially 
increased intention towards withdrawal misuse increasing the likelihood of withdrawal 
misuse. 
The results of this regression indicate that perceived severity plays a significant role in 
whether a patient is likely to misuse their prescription opioids in the future. Specifically, 
perceived severity partially interacts with perceived risk of addiction to indicate how intention to 
avoid withdrawal is likely to be influenced. Because there is also a direct effect of the misuse 
scenario on intention toward withdrawal misuse, perceived severity can only exert a partial effect 
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within the model. The regression model indicates that as perceived severity decreases, the person 
perceives the consequences associated with withdrawal misuse as less of a threat, then the 
likelihood of misuse to avoid withdrawal increases. Likewise, low and moderate levels of 
perceived self-efficacy were also indicative of lower levels of perceived severity. Depending 
upon how avoid withdrawal is framed it may not be considered a form of misuse. The test misuse 
scenario sets up avoiding withdrawal as a form of misuse because the patient is misusing their 
opioids primarily for feel good misuse and secondarily for avoiding withdrawal. Likewise, 
because a patient could perceive avoiding withdrawal as a positive outcome and perceived 
severity was operationalized in the study in a way that did not evoke a fear response, then as 
perceived severity decreases the increase in intention to misuse opioids to avoid withdrawal 
makes sense. 
Intrinsic Rewards and Self-Efficacy: 
 One model 7 regression showed significant conditional indirect effects between misuse 
scenarios and increasing intention towards dose-based misuse of prescription opioids as 
predicted by the high level of self-efficacy and the influence of intrinsic rewards. 
1. At perceived high self-efficacy intrinsic rewards partially increased intention towards 
often and dose misuse increasing the likelihood of often and dose misuse.  
The results of this regression indicate that intrinsic rewards plays a significant role in 
whether a patient is likely to misuse their prescription opioids in the future. Specifically, intrinsic 
rewards partially interacts with perceived self-efficacy to indicate how intention to take 
prescription opioids in higher doses and more often is likely to be influenced. Because there is 
also a direct effect of the misuse scenario on intention toward dose-based misuse, intrinsic 
rewards can only exert a partial effect within this model. The regression model indicates that as 
the value of intrinsic rewards increases, the person perceives that their self-efficacy also 
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increases, then the likelihood of dose-based misuse increases. Likewise, high levels of perceived 
self-efficacy were also indicative of high levels of intrinsic rewards. 
According to theory, high self-efficacy should be associated with helping to avoid 
misuse. A person with high self-efficacy should have an increased ability to avoid performing a 
negative behavior. However, in this case there are two other possible explanations: the influence 
of the intrinsic rewards may be so strong as to overwhelm the expected effect of self-efficacy, 
and/or a person may associate their self-efficacy with better self-control over how they take their 
prescription opioids in which case they feel that the intrinsic rewards can provide them with a 
perceived good, but under their control. Likewise, because there was a significant direct effect of 
the misuse scenario on intention, then the influence of self-efficacy may have been affected as 
well. 
Intrinsic Rewards and Risk of Addiction: 
One model 7 regression showed significant conditional indirect effects between misuse 
scenarios and increasing intention towards symptom-based misuse of prescription opioids as 
predicted by risk of addiction and the influence of intrinsic rewards. Though risk of addiction 
and intrinsic rewards produced a conditional indirect effect the bootstrapping section of the 
regression did not indicate a particular level or levels of operation.  
1. Though level of risk of addiction is uncertain, intrinsic rewards increased intention 
towards withdrawal and feel good misuse increasing the likelihood of withdrawal and 
feel good misuse.  
The symptom-based misuse types of taking opioids avoiding withdrawal and to feel good 
could be considered intrinsic rewards by themselves. This relationship may account for why 
there is no specific level of risk of addiction that is responsible for helping to predict when 
intrinsic rewards influences an increase in prescription opioid misuse. The results for the next 
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model examined indicate that operating levels of risk of addiction are likely moderate and high 
when interacting with intrinsic rewards. 
Intrinsic Rewards with Attitude and Risk of Addiction: 
The last model 7 regression showed significant conditional indirect effects between 
misuse scenarios and increasing intention towards all four types of misuse of prescription opioids 
as predicted by risk of addiction and the influence of intrinsic rewards and attitude.  
1. At perceived moderate and high risk of addiction intrinsic rewards and attitude increased 
intention towards all type misuse increasing the likelihood of all type misuse. 
The results of this regression indicate that intrinsic rewards play a significant role in 
whether a patient is likely to misuse their prescription opioids in the future. Specifically, intrinsic 
rewards interact with perceived risk of addiction to indicate how intention toward both dose-
based and symptom-based misuse of prescription opioids is likely to be influenced. The 
regression models indicate that as intrinsic rewards and attitude increases, the influence of the 
potential positive outcomes associated with intrinsic rewards increases and attitude shifts 
towards favoring misuse, so does the likelihood of misuse. Likewise, moderate and high levels of 
perceived risk of addiction were also indicative of higher levels of perceived vulnerability and 
attitude. 
 
Test of the Theoretical Model 
The proposed study is among the first to integrate Protection Motivation Theory13,15 with 
the Theory of Planned Behavior9,22,23 to determine the perceptions, attitudes, beliefs, and the role 
of risk-taking and misuse potential in the use of controlled prescription drugs by patients.76  
The proposed research is innovative, because it will be among the first to examine the 
prescription opioid misuse intentions of chronic pain patients and the importance of perceived 
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severity, perceived vulnerability, intrinsic rewards, extrinsic rewards, subjective norms for 
describing “how” these relationships occur and whether self-efficacy and risk of addiction 
describe “when” these relationships occur.  
Hypotheses predictions 
Though the literature review did not find any PMT or TPB studies that specifically 
examined prescription opioid misuse, several studies were found where one of the mediating 
variables, perceived vulnerability, intrinsic rewards, perceived severity, extrinsic rewards, 
subjective norms, and attitudes, as well as the moderator self-efficacy served as one or more 
predictors of intention to misuse alcohol or illicit drugs. 
Perceived Vulnerability 
 The finding that perceived vulnerability was a significant predictor of substance use 
intention was consistent with several of the PMT and TPB.17,18,20,26,31,32 In particular, perceived 
vulnerability served as a predictor variable when examining binge drinking, other alcohol use 
disorders, and illicit drug use. Understanding which behavioral intentions were being examined 
was important to understand how perceived vulnerability functioned to influence intention. If the 
intention was towards increased maladaptive behavior such as binge drinking or increased illicit 
drug use, then perceived vulnerability increased.17,20,26,31,32  The findings in literature were 
consistent with the finding in this study that increasing perceived vulnerability leads to increased 
prescription opioid misuse. Another study found that when the intention was to avoid alcohol 
use, a protective behavior, then perceived vulnerability and intrinsic rewards associated with 
drug taking or alcohol use decreased.18 This finding is also consistent with the theory and the 
result that should be expected if the behavioral intention that was examined would be intention to 




Intrinsic rewards was a significant mediator in one of the PMT studies and an implied 
predictive factor in one TPB study both of which examined alcohol use intention.18,25 This study, 
in which intrinsic rewards was a significant mediator, showed the influence decreasing if the 
intention was towards an adaptive behavior such as avoiding alcohol use. However, in the TPB 
study intrinsic rewards, such as perceived enhanced sociability, assertiveness, and sexual 
function expectancy, served to increase the likelihood of maladaptive behavior, which was binge 
drinking.25  
Perceived Severity 
Perceived severity, though shown to be a significant predictor in one regression, was 
expected to play a larger role in this model than was observed based upon the role it played in 
several of the reviewed studies.18,20,26,31,32 Perceived severity increased and intention towards 
drinking or illicit drug use decreased. The PM-TPB model demonstrated the reverse relationship. 
When self-efficacy was low and moderate, then decreasing perceived severity was associated 
with increasing intention to misuse prescription opioid. This is likely due to the fact that the 
specific situation and/or consequences used in the survey did not generate strong feelings of 
being threatened among the survey takers. This is a hypothesized reason for these finding, but 
with a basis in the qualitative study findings that perceived severity, as operationalized within the 
survey by adverse effects associated with taking too many opioids, were found by the 
interviewed patients to be insufficient to evoke a fear response. Future iterations of the survey 
will incorporate the patient’s suggestions to make the consequences of drug misuse 
operationalized for perceived severity much more serious and severe, such as killing another 




Extrinsic rewards associated with binge drinking in one PMT and one TPB study. 
Specifically, when people observed people important to them, such as friends or significant 
others enjoying themselves due to binge drinking, that person’s intention to binge drink was also 
increased.18,26 Though the PM-TPB study did not show any significant regressions for extrinsic 
rewards the findings that a maladaptive response would occur in relation to increasing extrinsic 
rewards is consistent with the theory predictions. Extrinsic rewards are expected to be better 
defined and operationalized on future survey in an effort to determine if there could be a 
significant conditional indirect effect. Several patients in the qualitative analysis indicated that 
they would have preferred a better definition for extrinsic rewards along with an example. When 
included on future surveys extrinsic rewards will be better defined and an example that should be 
relatable to a chronic pain population will be used.  
Attitude 
 Attitude is a primary predictor of intention within the TPB and implied, but not often 
used within PMT studies. The literature review revealed a study where an “Alcohol Attitude 
Survey” was developed using PMT intended to discover factors associated with preventing 
alcohol misuse.17 Attitude served as a co-dependent variable within the study to describe how 
each factor influenced the patient’s perspective on drinking. Six of the TPB studies specifically 
utilized attitude to predict intention towards drinking, drug use, and smoking.26-28,30,31,34 Within 
the PM-TPB study results analyses attitude was found be associated with increases in to misuse 
prescription opioids. Specifically, when perceived risk of addiction was moderate and high, then 
both perceived vulnerability and intrinsic rewards functioned along with attitude to increase 
intention. Attitude is likely to play the role of modifying the effect of the other mediating 
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variable on intention. For example, if a patient has a positive attitude towards misuse believing it 
to be good, beneficial, and favorable, then the effect of another mediator such as intrinsic 
rewards could be magnified to increase the patient’s intention to misuse. Conversely, a patient 
may believe misuse to be bad, harmful, and unfavorable. This should serve to reduce their 
intention to misuse, yet if the value of their intrinsic rewards is very high, their perceived 
vulnerability is also high and the patient desperately wants to avoid withdrawal and/or feel good, 
they may still reluctantly misuse their prescription opioids. 
Subjective Norms 
 Though subjective norms are examined at an implied level through extrinsic rewards, 
none of the PMT-based studies examined for the literature review utilized subjective norms as a 
potential predictor of substance use intention. This was expected because subjective norms have 
never been a specific part of the PMT. On the other hand, subjective norms were a key predictor, 
if not the solitary predictor, in all of the substance use-related studies examined for the TPB.25-
32,34 There were no significant conditional indirect effects that included subjective norm as a 
variable within this research study. Though the chi-square showed that the control and test 
groups differed on their responses to two of the types of misuse, this difference did not translate 
to the regression analyses. This could be due to subjective norm not being effectively 
operationalized within the vignettes. Patients were left to determine their subjective norms based 
upon either what they thought they should be for each vignette or what they might actually be for 
the person answering the questions. Though, in several other studies of the TRA and TPB, 






Self-efficacy was a significant predictor of substance use intention in many PMT and 
TPB studies.10,17,18,20,28,32,34 Self-efficacy worked as a protective factor within these studies 
working to reduce intention to reduce substance use. Self-efficacy exhibited two different 
functions within the regressions, when used to describe when perceived severity would influence 
intention, self-efficacy operated as low and moderate levels with decreasing levels of perceived 
severity to increase intention to misuse. This would be consistent with self-efficacy working as a 
protective factor, but failing because it is not operating at a strong enough level to avoid 
performing a maladaptive behavior. For the other case, self-efficacy operated at a high level to 
increase intrinsic rewards resulting in increased intention to misuse. A possible explanation for 
this outcome would be patients that believe they have control over whether or not they succumb 
to intrinsic rewards. However, because the result is still increased intention to misuse, the high 
self-efficacy is likely overconfidence that the patient can regulate their own drug use. 
Understanding that self-efficacy has an influence on multiple aspects of the behavioral 
model makes it a potent target for behavior change. Also important, is understanding how self-
efficacy functions for a patient. Do they use their self-efficacy to work towards avoiding misuse? 
Or do they incorrectly believe that self-efficacy means they have power over the drug? When a 
clinician can understand a patient’s perception of self-efficacy and where it intersects with other 
parts of the behavioral model, then the clinician can devise personalize treatment plans to help a 
patient recognize their strengths, but also recognize and work on weaknesses. 
Risk of Addiction 
Based upon the regression results from the PM-TPB study, when perceived risk of 
addiction is moderate or high, then perceived vulnerability, intrinsic rewards, and/or attitude are 
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likely to result in an increasing intention to misuse prescription opioids. Risk of addiction was 
not a variable considered in any of the PMT or TPB studies, and had not previously been 
examined as a theory-based influence on intention to misuse prescription opioids. Many different 
instruments have been developed to measure a patient’s potential for developing a substance use 
disorder in the future. Operationalizing risk of addiction within a theoretical framework seemed 
like a logical next step towards developing a new behavioral model that more completely 
explained important personal factors that predict when and how a person might intend to misuse 
their prescription opioids.  
Understanding that perceived risk of addiction has an influence on multiple aspects of the 
behavioral model makes it a potent target for behavior change. Risk of addiction is likely to play 
a larger role in identifying new opioid patients that may require educational interventions to 
prevent them from misusing their prescription opioids in the future. Because risk of addiction 
influences perceived vulnerability, intrinsic rewards, and attitudes, the reasonable assumption is 
that changes the patient is able to make to those variables would in turn change their perceived 
risk of addiction. By helping a patient understand how they relate to their predictors of 
prescription drug misuse, then avoiding problems in the first place should become easier, as well 
as, helping patients to realize they may have a problem that need treatment. 
Health Policy and Clinical Implications 
This study will inform prescribers, pharmacists and other healthcare professionals about 
the role of risk of addiction, self-efficacy, perceived vulnerability, intrinsic rewards, and attitude 
in behavioral models of prescription drug misuse to help develop personalized treatment 
programs that emphasize responsible medication use and control of symptoms, while minimizing 
the potential for misuse. Though still in its nascent stages of testing, PM-TPB-based instruments 
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and interventions could very well serve an important role in becoming the next-generation of 
theory-based substance-use prevention and treatment. 
Policy Implications 
If the instruments and interventions to be developed in the future prove be adept at 
detecting, preventing, and treating not only prescription opioid misuse, but other forms of 
substance use and addiction, then their use could become an important part of policy for many 
different types of clinics and organizations. Depending upon which instruments and/or 
interventions prove to be most successful, that would drive which stakeholders would be looking 
to adopt them into their environment. The first steps would be to work with physician and 
psychologist groups that are looking for solid theory-based instruments and interventions that 
can be personalized to their patient population. Demonstrated success in frontline venues such as 
doctor’s offices, pain clinics, and substance treatment programs would begin to provide a base of 
support for the dissemination of the information to larger networks. 
Treatment policy would be the most impacted area. Theory-based instruments could be 
used for risk-assessment pre-treatment and concurrent with treatment to provide information to 
prescribers and therapists about a patient’s personal strengths, weaknesses, and risk factors. 
Knowledge of those factors can then be used to help determine whether a patient might be 
appropriate for treatment, need education to avoid problems, or identify how to treat current 
problems. 
At the highest policy levels, use of the instruments and interventions could be written into 
guideline for treatment and reimbursement by insurance companies and/or government health 
care agencies like Medicare and Medicaid. Likewise, national organization like NIDA and 
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NAIAA could advocate for the PM-TPB materials as a preferred means of helping to fight 
substance use disorders within the U.S. and potentially elsewhere. 
Clinical Implications 
Patients 
Patients are often afraid to take prescription opioids to treat their pain for a myriad of 
reason, but particularly because they are afraid of becoming addicted. Likewise, patients who 
may have developed a substance use disorder may not be able to recognize changes in 
themselves that are directly attributable to the disorder may not realize they need help. Through 
the development of instruments and interventions that work together patients can be receive 
personally tailored interventions to provide education about themselves and responsible 
medication use, prevention of the development of a substance use disorder, recognizing that they 
have a problem that needs to be addressed, and resolving their substance use disorder and 
maintaining sobriety. 
Prescribers/Clinicians 
Currently, a prescriber must decide whether or not to take a risk on prescribing an opioid 
for a potential future substance user. However, if there were an underlying theoretical framework 
that could identify individual risk factors for the patient, then the prescriber could help their 
patient understand the specific risks they face taking the drug and refer them to educational 
literature and/or a theory-based educational program that can help the patient avoid future misuse 
by targeting their specific risk attributes. 
Prescribers and clinicians will be offered instruments and interventions which work 
together through a shared theoretical framework. The instruments will be designed to seamlessly 
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to inform the implementation of the intervention using personalized information characterizing a 
patient’s relative strengths, weaknesses, opportunities, and threats. 
Study Limitations and Alternative Strategies 
Generalizability 
This study had some limitations. The primary limitation was the generalizability of the 
results from UMHS chronic pain patients to the general population of patients using controlled 
opioid medications across the United States in more diverse communities. This was likely 
exacerbated by the fact that the recruitment will be a convenience sample recruited from the 
Burlington Physical Medicine and Rehabilitation Spine Clinic. Within UMHS over 6000 patients 
that conformed to the inclusion/exclusion criteria. Out of 1550 patients contacted only 160 
patients responded as qualified for the survey, and only 158 completed the full questionnaire. 
Offering a check for $10 for each completed survey was only sufficient to produce a response 
rate of around 10%.  
Language and cultural barriers 
Instrument characteristics 
The instrument used in this study was written only in English and administered only 
through a web-based interface. Because of these two study features patients who did not read and 
write in English were likely unable to complete the questionnaire. People who do not have 
personal internet access, are unwilling to used public resources such as from a library, or who 
find web-administered instrument too technologically challenging were also likely missed. In 
different parts of the U.S. where reading and writing in Spanish and other languages account for 
a large portion of the population, different language versions of the instrument may be created. 
Likewise, a small study of preference to complete the instrument between electronic versus paper 
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may lead to allowing patients to indicate a choice to complete a questionnaire on paper instead of 
over the internet. 
Respondent characteristics 
Racial and cultural differences often lead to different attitudes, beliefs, and perceptions 
among people. These differences often influence how or whether people approach learning a new 
language, adopting a new technology, how they approach medical issue, how they interact with 
medical professionals, and think about issues surrounding substance use. Treatment 
Improvement Protocol #59 “Improving Cultural Competence” from the Center for Substance 
Abuse Treatment within the Substance Abuse and Mental Health Services Administration has 
been produced as a valuable to tool to help counselors and behavioral health organizations work 
towards cultural competence.80 Cultural competence is defined as “A set of congruent behaviors, 
attitudes, and policies that come together in a system, agency, or among professionals and enable 
the system, agency, or professionals to work effectively in cross-cultural situations.”80 Utilizing 
the recommendations of TIP #59 will guide the development of future iterations of this 
instrument and related interventions incorporating features within the formatting that maintain 
cultural sensitivity.  
Perceived behavioral control still to be tested 
This survey is the first part of a larger project aimed at developing instruments and 
interventions designed to detect, prevent, and treat prescription drug misuse and potentially other 
substance use disorders. Before that point is reached; though, the remaining perceived behavioral 
control portion of the behavioral model needs to be examined. Because this study examined only 
the attitude and subjective norm-related factors within the overall behavioral model it may not 
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have the complete picture of which factors provide the most predictive power of future opioid 
misuse.  
Substance of choice 
Instrument characteristics 
 Because this instrument is focused on prescription opioid misuse it may not be 
immediately useful for testing patient populations with other potential substance use disorders 
such as alcohol or heroin. Adapting the terminology of the instrument to address specific 
substances, then testing the instrument with “at risk” and recovering users of the substance of 
interest may give a sense of whether the PM-TPB model will be useful for substances other than 
opioids. 
Patient characteristics 
 Beliefs about and traditions involving substance use can vary significantly between 
cultural communities and ethnicities. For example, in African American communities alcohol 
and drug abuse may be a socially unacceptable sign of weakness, whereas in some Asian 
communities alcohol use is imbued with beneficial, ceremonial, and curative properties, yet 
illicit substance use is unacceptable and not easy to discuss.80 Understanding, that these 
differences occur within different cultural and ethnic communities are important for tailoring 
instruments and interventions to achieve maximum effectiveness. 
Recall bias and social desirability 
There may also be some recall bias and inherent social desirability bias because this study 
collected cross-sectional data using self-reported measures. Whether or not a person is going to 
misuse their prescription opioids is a volatile dependent variable. This was likely the primary 
reason for the study response rate being so low. There might also be issues of how comfortable a 
person was talking about their tendencies towards drug misuse and how well they understood 
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their own tendencies towards different aspects around that behavior. The study design attempted 
to control for a patient’s honesty regarding their specific drug use by randomizing them into a 
vignette and asking them to assume the role of that patient when answering the theory-based 
questions in the instrument. The data collected on the questionnaires was kept completely 
confidential and patients were informed that the information they shared would not be 
communicated to anyone or otherwise used outside of this study. This was another strategy to 
encourage patients to answer each question as truthfully as possible.  
Type I error 
 A large part of this study was a model building exercise. Because of the large number of 
models generated over the course of testing the relationships between variables within the 
behavioral model, there is a chance that several false positives could have been detected 
indicating a presence of Type I error. The study currently attempts to control for Type I error 
using basic Multiple Comparison Procedures (MCP). For this simple version of the MCP, the 
more models that demonstrate that a particular moderator and mediator are responsible for a 
conditional indirect effect the stronger the evidence that the null hypothesis is being correctly 
rejected for that model.  Another way to examine the Type I error potential, within this study, 
would be to examine the familywise error rate (FWER), using a sequential Bonferonni-type 
procedure which can control the false-discovery rate for the independent tests statistics 
increasing the power.81 Though the MCP is implied within the study, if deemed necessary, the 





Future changes to study instruments 
 On future instruments perceived vulnerability questions will likely be reworded so as to 
not embarrass or stigmatize the patient. Likewise, they will be moved at least one or two 
questions away from other look-alike sound-alike questions. Perceived severity will be 
operationalized with examples of outcomes related to misuse that have consequences which are 
very serious and very severe, such as the loss of life and limb. Intrinsic rewards will be addressed 
in a more open-ended manner allowing patients to be much more specific about what their 
specific rewards and triggers for misuse are within the intrinsic reward framework. Extrinsic 
rewards will be prefaced by a better definition with easily relatable examples. With intention 
being the primary dependent variable of interest on this instrument and future instrument, 
encouraging people to be as honest as possible about their answers whether they are answering 
as themselves or a paper patient is one of the most important goals. Questions should not 
stigmatize patients while allowing them to answer anonymously and honestly. Future 
instruments administered to chronic pain patient populations will likely include employment 
options for disabled and retired. 
Future research suggestions and directions 
 Prescription drug misuse is a contentious study subject. Planning for future subject 
recruitment might consider an increase in the incentive payment, use of an optional paper survey, 
expansion to include several potentially qualified chronic pain populations. Future versions of 
the survey and related extensions should be administered to several different patient populations 
around the U.S. in order to get a better idea of how generalizable the results are between 
different population centers. 
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The vignette manipulation was useful for randomizing patients into a specific 
independent variable set intended to inform their answers on the survey. When developing the 
questions for the coping appraisal and perceived behavioral control side of the overall behavioral 
model it will be important to make sure that the questions allow the vignette to inform the 
patient’s decision. Future versions of the survey might simplify the types of misuse to one or two 
types, likely medication taking related and symptom-related. A survey that covers all of the 
constructs in the behavioral model might be able to be administered instead of needing to break it 
into sections to prevent fatigue. A shorter survey may also be able to be given in a crossover 
format where patients are randomized to one vignette at the beginning, but then asked to assume 
the other vignette and complete the questionnaire again from the opposite perspective. With a 
patient as their own control it might be easier to determine the effect that patient’s own sense of 
self and experience with prescription drug misuse inform their decisions.  
 Finding compatible instruments and interventions aimed at detection, prevention, and 
treatment of substance use disorders should focus on perceived risk of addiction, self-efficacy, 
perceived vulnerability, perceived severity, intrinsic rewards, and attitudes as predictors of 
behavioral intention. Ideally, some of the PM-TPB variables are already in use on existing 
instruments and interventions. Hopefully, development of modified instruments and intervention 
would go faster. The current state of cognitive behavioral therapy (CBT) instruments and 
interventions may lend themselves to adaptation using the PM-TPB. Many experts in the field 
are lamenting the loss of cohesion that an underlying theoretical model could provide for CBT. 
Currently, a “theory-practice gap” has developed between the original theory of CBT and the 




Despite the limitations, this study was among the first to examine the effects of mediators 
and moderators on intention to misuse of controlled prescription opioids. Understanding whether 
the proposed behavioral model is accurate and what mediators and moderators are most 
predictive of intention to misuse prescription painkillers is an important first step towards 
developing interventions for chronic pain patients that target key good behaviors to support and 
bad behaviors to prevent misuse. This is especially important for chronic pain patients who have 
a consistent need for pain analgesia, thus a constant struggle to avoid misuse, yet maintain 
personal comfort and functional status. 
Misuse of controlled prescription opioids and the larger realm of substance use disorders 
have reached the epidemic level of disruption to nearly aspect of society in the United States. 
Development of a strong theory-based set of instruments and interventions designed to help 
detect, prevent, and treat prescription drug misuse is the long-term goal of this research and 
primary investigator. Finding strong results from a field study without removing any of the six 
covariates in all of the regressions is encouraging. This study which was hopefully the first of 
many to come not only expanded protection motivation theory and the theory of planned 
behavior into the prediction of prescription opioid misuse intention, but significantly deepened 
that field through the addition of conditional indirect effects to help explain the when, why, and 
how behind prescription drug use within a theory-based framework. Understanding whether the 
proposed behavioral model is accurate and what mediators and moderators are most predictive of 
intention to misuse prescription painkillers is an important first step towards developing 
interventions for chronic pain patients that target key good behaviors to support and bad 
behaviors to prevent misuse. This is especially important for chronic pain patients who have a 
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consistent need for pain analgesia, thus a constant struggle to avoid misuse, yet maintain 








Appendix A: Documents 
A.1 Interview Mailing 
First Name, Last Name        Date 
Address 
City, State Zip Code 
 
Dear First Name, Last Name: 
 
Hello, my name is David Malewski. I am a graduate student at the University of Michigan. You 
have been identified from your medical record as a patient at the University of Michigan Health 
System Physical Medicine & Rehabilitation clinic in the Burlington building qualified for a 
research study. According to the database you are at least 18 years old, have chronic non-cancer 
pain, and have been taking at least one long-acting and/or one short-acting painkiller for more 
than a month. This data may not be accurate, if so, or if you would otherwise want to opt-out of 
this study please see the information at the end of this letter. 
 
I am recruiting patients with chronic pain to participate in individual interviews. We are 
conducting research looking at the decisions that patients make about taking their prescription 
painkillers. We want to know how those decisions affect whether people will misuse prescription 
painkillers. 
  
Participation in this interview is completely voluntary and anonymous. Should you decide to 
participate in this study none of the information you share on the will be shared with anyone 
other than study personnel. Your name or any other personally identifying information will not 
be associated with any information from your interview. 
 
Should you decide that you would like to participate I would like to talk with you just after your 
next doctor’s appointment currently scheduled on [Appointment Date at Appointment 
Time] at The University of Michigan Physical Medicine & Rehabilitation clinic in the 
Burlington building. Your participant code will be: [Participant #] 
 
Interview participation will consist of reviewing a 60 question survey questionnaire. The 
interviewer will ask you 13 questions about how the survey questions compare to your 
experience and opinions about how you take your painkillers. The interview is expected to take 




As an incentive we offer you a $20 check for completion of the interview. Your name and 
address will only be collected for reimbursement purposes, but the university will not have a 
specific reason other than “study participation” because they require that information for their 
records. 
 
We hope that you will participate in our study.  
 
We will call you one week before your appointment to confirm that you want to do the interview 
after your doctor’s appointment. However, if you do not want to participate in this study or be 
contacted again please either send an e-mail to malewski@umich.edu with the subject “Decline 
Study Participation – [Participant #]” or call 314-482-5695 and leave a brief message. 
 









A.2 Interview In-Person Screening 
Hello, my name is Dave Malewski. I am a Graduate student at the University of Michigan. I 
previously sent you a letter explaining that I would like to recruit you to participate in an 
individual interview. We are conducting research looking at the decisions that patients make 
about taking their prescription painkillers. 
  
If you still wish to participate in our study I would like to ask you a few preliminary screening 
questions to make sure that you meet all of the qualifications to participate in the study: 
 
Participant ______ 
1. What is your current age? ____  (patient needs to be at least 18 years or older) 
2. Do you have a current diagnosis of chronic pain, or the equivalent diagnosis of chronic 
pain such as consistent low back pain treated over the course several months to years? 
______ 
3. Are you taking at least one long acting and/or one short acting painkiller for at least the 
last month? (ex. Oxycontin and Percocet) _______ 
4.  Do you have cancer-related pain? _______ 
5. *(Group 2 subjects only) Do you have a past history of substance misuse? _____  (Ex. 
Alcohol, illicit drugs, NOT tobacco) 
 
Participation in the interview will consist of a 90 minute session with an interviewer. There are 
TWO alternatives for the interviews: 
  
1. If you have time right now we will conduct the interview in a private office today.  
2. Otherwise, we will schedule to interview you at a time that is more convenient. You will 
meet with the interviewer at a location at or near the College of Pharmacy on the main 
University of Michigan campus where your privacy for the interview can be assured. You 
will receive a parking pass. In order to send you a reminder just before your interview 
appointment we would like your e-mail and/or phone number. 
 
You will be sent a $20 check as an incentive for participation after completion of the interview. 
Your name and address will only be collected for reimbursement purposes, but the university 
will not have a specific reason other than “study participation” because they require that 




A.3 Interview Consent Document 
UNIVERSITY OF MICHIGAN 
CONSENT TO BE PART OF A RESEARCH STUDY 
INFORMATION ABOUT THIS FORM 
You may take part in a research study.  This form tells you about the study.  It describes the 
study purpose, risks, and possible benefits.   
Please review this information carefully.  The study researchers will answer any questions you 
may have. You might also talk to your friends, family, or doctors about your participation in this 
study.    
If you decide to take part in the study, you will be asked to sign this form.   
Before you sign this form, be sure you understand what the study is about, including the risks 
and possible benefits to you. 
1.  GENERAL INFORMATION ABOUT THIS STUDY AND THE RESEARCHERS 
1.1 Study title:  
PDAIIS, Prescription drug misuse independent interview 
1.2 Company or agency sponsoring the study:  
The University of Michigan College of Pharmacy, Blue Cross Blue Shield of Michigan Foundation 
1.3 Names, degrees, and affiliations of the researchers conducting the study:  
David Malewski, M.S. Pharm.D., Ph.D. Candidate, the University of Michigan 
Steve Erickson, Pharm.D., Associate Professor of Pharmacy, the University of Michigan 
Karen Farris, Ph.D., Professor of Pharmacy, the University of Michigan 
Richard Bagozzi, Ph.D., Professor of Marketing, the University of Michigan 
Mark Ilgen, Ph.D., Associate Professor of Psychiatry, the University of Michigan 
Rajesh Balkrishnan, Ph.D., Professor of Public Health Services, the University of Virginia 
Peter Batra, M.S., Research Analyst, the University of Michigan 
2.  PURPOSE OF THIS STUDY 
2.1 Study purpose:  
We want to learn more about chronic pain patients’ attitudes regarding pain, drug seeking, and 
prescription drug misuse. During a recorded interview, study subjects will give their opinions 
about the questions on a study survey and how well the survey relates to their own experience. 
3.  INFORMATION ABOUT STUDY PARTICIPANTS (SUBJECTS) 
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You may STOP the interview at any time.  Taking part in this study is voluntary.  If you leave 
the study, there will be no penalty, and you will not lose any incentive.   
3.1 Who can take part in this study?  
You have been identified from your medical record for recruitment from The University of 
Michigan Health System Spine Center at the Burlington Building. 
You may be able to take part in this study if you 
• Are at least 18 years old 
• Have chronic pain that is not caused by cancer 
• Have been taking one long-acting and/or one short-acting painkiller for more than one 
month 
• Are receiving outpatient care (not staying overnight in the hospital) 
We’re looking for two groups of subject. Some subjects will have no history of substance 
misuse. Other subjects will have a history of substance misuse, not counting tobacco use. 
3.2 How many people (subjects) are expected to take part in this study?  
We are recruiting up to 20 people. 
4.  INFORMATION ABOUT STUDY PARTICIPATION  
4.1 What will happen to you in this study? 
1. Interviewer will identify self and describe the purpose of the interview. 
a. You will review a survey questionnaire. 
2. You will get a copy of the survey to read through. 
a. The scenario describes fictional scenarios and then asks the respondent to 
assume one of the scenarios and answer questions about prescription drug 
misuse. 
3. Audio recording will begin. 
4. Interviewer will ask you questions about the survey. 
a. We will review the survey with you section by section asking you to tell us your 
opinions about the questions and how they relate to your own experiences. 
5. Audio recording will end. 
4.2 Audio recording of interview 
The interview will be audio recorded on two digital voice recorders and later written down. We 
will not collect personal information from you. If you accidentally mention personal information 
during the interview we will delete it from the written record. The audio recording will be 
deleted after it has been written down. 
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4.3 How much of your time will be needed to take part in this study?   
Up to 90 minutes 
4.4 When will your participation in the study be over?  
Your study participation will be over at the completion of the interview.  
5. INFORMATION ABOUT RISKS AND BENEFITS 
5.1 What risks will you face by taking part in the study?  What will the researchers do to 
protect you against these risks? 
Some survey questions are about drug misuse and may cause stress. You may skip any question 
during the interview at any time.  
There is a very small risk that people other than the researchers may see your study data. To 
help prevent this from happening, the research records will be kept in password-protected 
computer files that only the study team has access to.  Also, we will keep any information that 
might identify you, such as your name and address, in a restricted computer file that is 
password-protected. When we transfer data from the University of Michigan Health System, we 
will use specialized computer transfer programs and servers that protect your confidential and 
health information.  
As with any research study, there may be additional risks that are unknown or unexpected.  
5.2 What happens if you get hurt, become sick, or have other problems as a result of this 
research? 
The researchers have taken steps to minimize the risks of this study. Please contact any of the 
researchers listed in Section 10 about any injuries, side effects, or other problems that you have 
during this study. You should also tell your regular doctors. 
5.3 If you take part in this study, can you also participate in other studies? 
Being in more than one research study at the same time may increase the risks to you. It may 
also affect the results of the studies. You should not take part in more than one study at a time 
without approval from the researchers involved in each study.   
Additionally, participating in the interview portion of this study disqualifies you from 
participating in the later survey portion of this overall study. 
5.4 How could you benefit if you take part in this study?  How could others benefit? 
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You might not receive any personal benefits from being in this study. You may learn something 
about different forms of prescription drug misuse. You may become more aware of your 
feelings about how you take your painkillers. This study will help us gain important information 
about how to help other patients manage their use of prescription painkillers. 
6. OTHER OPTIONS 
6.1 If you decide not to take part in this study, what other options do you have? 
It is up to you whether you choose to participate in this study. You are free to leave the study 
even after agreeing to participate.     
7. ENDING THE STUDY 
7.1 If you want to stop participating in the study, what should you do? 
You have the right to stop at any point. If you want to stop, or are unsure about continuing with 
the interview, please inform your interviewer. 
7.2 Could there be any harm to you if you decide to leave the study before it is finished? 
Leaving the study early should not result in any harm. 
7.3 Could the researchers take you out of the study even if you want to continue to 
participate? 
Yes. Some examples of reasons a researcher may end your participation are: 
 The researcher believes that it is not in your best interest to stay in the study. 
 You become ineligible to participate. 
 You do not follow instructions from the researchers. 
 The study is suspended or canceled. 
8. FINANCIAL INFORMATION 
8.1 Who will pay for the costs of the study? 
All study-related costs are paid by the study administrator. 
8.2 Will you be paid or given anything for taking part in this study? 
You will receive a check for $20 in the mail after you complete the interview. 
8.3 Who could profit or financially benefit from the study results? 
No one will profit or financially benefit from the study results. 
9. CONFIDENTIALITY OF SUBJECT RECORDS 
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The information below describes how your privacy and the confidentiality of your research 
records will be protected in this study. 
9.1 How will the researchers protect your privacy? 
Interview privacy 
1. Password protected computer file, program and servers to transfer data about you from 
the University of Michigan Health System. 
a. Identifying information will only be used to identify you for recruiting and 
incentive payments. 
2. No name or other identifying information on the audio recording or written record. 
3. We will keep your research record confidential, to the extent provided by federal, state, 
and local law.  
4. We will not allow anyone to see your record, other than people who have a right to see 
it.  
5. After the study is completed, all information that could link your identity to your survey 
information will be destroyed.  
Incentive payment privacy 
1. In a separate password-protected file your name and address will be entered. 
a. No other information will be collected. 
2. Once you have received your incentive payment for study participation your name and 
address will be deleted from our study records. 
9.2 What information about you could be seen by the researchers or by other people?  Why?  
Who might see it? 
Signing this form gives the researchers your permission to obtain, use, and share information 
about you for this study, and is required in order for you to take part in the study. Information 
about you may be obtained from University of Michigan Health System, including: 
• Hospital/doctor's office records (chronic pain diagnosis, substance misuse diagnosis, 
medication prescriptions) 
• Medication fill and refill records 
• Demographic information 
• Personal identifiers 
There are many reasons why information about you may be used or seen by the researchers or 
others during or after this study.  Examples include: 
• The researchers may need the information to make sure you can take part in the 
study.   
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• University, Food and Drug Administration (FDA), and/or other government officials 
may need the information to make sure that the study is done in a safe and proper 
manner.    
• Study sponsors or funders, or safety monitors or committees, may need the 
information to:  
o Make sure the study is done safely and properly 
o Learn more about side effects  
o Analyze the results of the study  
• If you receive any payments for taking part in this study, the University of Michigan 
accounting department may need your name and address for tax reporting 
purposes.  
• Federal or State law may require the study team to give information to government 
agencies. For example, to prevent harm to you or others, or for public health 
reasons. 
The results of this study could be published in an article, but would not include any information 
that would let others know who you are.  
9.3 What happens to information about you after the study is over or if you cancel your 
permission? 
Researchers will not continue to use information about you, but will keep it secure until it is 
destroyed. We will destroy it 7 years after the last report has been created. Sometimes, it may 
be necessary for information about you to continue to be used or disclosed, even after you 
have canceled your permission or the study is over.  Examples of reasons for this include: 
• To avoid losing study results that have already included your information  
• To help University and government officials make sure that the study was conducted 
properly 
9.4 When does your permission expire? 
Your permission expires at the end of the study, unless you cancel it sooner. You may cancel 
your permission at any time by contacting the researchers listed in Section 10 "Contact 
Information" (below).  
10. CONTACT INFORMATION 
10.1 Who can you contact about this study? 
Please contact the researcher listed below to: 
• Obtain more information about the study 
• Ask a question about the study procedures or equipment 
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• Talk about study-related costs to you or your health plan  
• Report an illness, injury, or other problem (you may also need to tell your regular doctor) 
• Leave the study before it is finished 
• Express a concern about the study 
Principal Investigator:        
David Malewski M.S., Pharm.D., Ph.D. Candidate  
University of Michigan College of Pharmacy   
428 Church Street, Ann Arbor, MI  48109  
Telephone:  314-482-5695     
e-mail:  malewski@umich.edu             
You may also express a concern about the study by contacting the Institutional Review Board 
listed below, or by calling the University of Michigan Compliance Help Line at 1-866-990-0111. 
 University of Michigan Medical School Institutional Review Board (IRBMED) 
2800 Plymouth Road 
Building 520, Room 3214 
Ann Arbor, MI 48109-2800 
Telephone: 734-763-4768 
Fax: 734-615-1622 
e-mail: irbmed@umich.edu  
If you are concerned about a possible violation of your privacy, contact the University of 
Michigan Health System Privacy Officer at 1-888-296-2481. 
When you call or write about a concern, please provide as much information as possible, 
including the name of the researcher, the IRBMED number (at the bottom of this form), and 
details about the problem.  This will help University officials to look into your concern.  When 
reporting a concern, you do not have to give your name unless you want to. 
11. RECORD OF INFORMATION PROVIDED 
11.1 What documents will be given to me? 
Your signature in the next section means that you have received copies of all of the following 
documents: 
  This "Consent to be Part of a Research Study" document.  (Note: In addition to the copy 
you receive, copies of this document will be stored in a separate confidential research file 










I understand the information printed on this form.  I have discussed this study, its risks and 
potential benefits, and my other choices with ____________________.  My questions so far 
have been answered.  I understand that if I have more questions or concerns about the study or 
my participation as a research subject, I may contact one of the people listed in Section 10 
(above).  I understand that I will receive a copy of this form at the time I sign it and later upon 
request.  I understand that if my ability to consent for myself changes, either I or my legal 
representative may be asked to re-consent prior to my continued participation in this study. 
 
Signature of Subject:     Date: _____ 
 
Name (Print legal name):     ______________________________________                   
 
Date of Birth:   
 
 
Principal Investigator (or Designee): 
I have given this research subject (or his/her legally authorized representative, if applicable) 
information about this study that I believe is accurate and complete.  The subject has indicated 
that he or she understands the nature of the study and the risks and benefits of participating. 
 
Name:   Title:   
 





A.4-1 Interview Questionnaire 
Qualitative Interview Questions: 
1. Describe the four types of misuse related to intention to misuse controlled prescription 
drugs: Frequency, Dose, Withdrawal, and Feeling Good.  
a. Script “We are looking at four different types of prescription drug misuse, 1. 
Taking them more often than prescribed, 2. Taking them in higher doses 
(more pills) than prescribed, 3. Taking them to avoid the symptoms of 
withdrawal (restlessness, agitation, muscle aches), 4. Taking them to “feel 
good.” 
b. Script “How are these definitions of prescription drug misuse similar or 
different from what you think?” 
c. Allow up to 2 minutes before next question. 
2. Describe the two vignettes and ask the patient to comment on similarities and differences 
between the scenarios and their actual experiences. (Page 1) 
a. Script “Instead of asking people to tell us directly about their use and/or 
potential misuse of prescription drugs, we are asking them to put themselves 
in the shoes of one of two made up patients. The first one possibility is 
Scenario 1. (Show scenario 1)” 
b. Script “The second possibility is Scenario 2. (Show scenario 2.)” 
c. Script “We are using these two different scenarios to get an idea of whether 
people’s pain, drug seeking and drug use are likely to affect their decision 
making.” 
d. Script “What are your thoughts and opinions about the use of these scenarios 
to examine decision making? What would you do similarly or differently?”  
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e. Allow up to 2 minutes before next question. 
3. Review risk of addiction questions and ask patient how they feel their risk of addiction 
influences their likelihood of abusing prescription drugs. (Page 2) 
a. Script “The risk of addiction questions ask the patient to consider their 
situation and then make a determination of how likely or unlikely it is that 
they would become addicted to their prescription painkillers.” 
b. Script “What are your thoughts and opinions about asking patients about 
their risk of addiction?” 
c. Allow up to 3 minutes before next question. 
4. Review self-efficacy questions and ask patient how they experience self-efficacy. (Page 
2) 
a. Script “The self-efficacy questions ask about the patient’s confidence in being 
able to resist each of four potential types of drug misuse.” 
b. Script “What are your thoughts and opinions about asking patients about 
their confidence in resisting abusing their prescription drugs?” 
c. Allow up to 3-4 minutes before next question 
5. Review perceived vulnerability questions and ask patient how they experience perceived 
vulnerability. (Page 3) 
a. Script “The perceived vulnerability questions ask about the patient’s 
vulnerability to abusing their painkillers. The less vulnerable they feel, the 
less likely they are to misuse their drugs.” 
b. Script “What are your thoughts and opinions about asking patients about 
their perceived vulnerability to prescription drug misuse?” 
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c. Allow up to 3-4 minutes before next question. 
6. Review perceived severity questions and ask patient how they experience perceived 
severity. (Page 4) 
a. Script “The perceived severity questions ask patients about how severe and 
serious the consequences would be of abusing drugs. The more serious and 
severe the less likely they are to misuse their drugs.” 
b. Script “What are your thoughts and opinions about asking patients about 
their perceived severity of prescription drug misuse?” 
c. Allow up to 3-4 minutes before next question. 
7. Review intrinsic rewards questions and ask patient how they experience intrinsic rewards. 
(Page 5) 
a. Script “The intrinsic rewards questions ask patients about some potentially 
positive aspects or avoidance of negative aspects associated with abusing 
drugs. With more positives and/or negatives avoided they are more likely to 
misuse their drugs.” 
b. Script “What are your thoughts and opinions about asking patients about the 
intrinsic rewards of prescription drug misuse?” 
c. Allow up to 3-4 minutes before next question. 
8. Review extrinsic rewards questions and ask patient how they experience extrinsic 
rewards. (Page 5) 
a. Script “The extrinsic rewards questions ask patients about social approval 
associated with abusing drugs. The more there are people around them who 
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are neutral or approve of their drug misuse the more likely they are to 
misuse their drugs.” 
b. Script “What are your thoughts and opinions about asking patients about the 
extrinsic rewards of prescription drug misuse?” 
c. Allow up to 3-4 minutes before next question. 
9. Review subjective norms questions and ask patient how they experience subjective 
norms. (Page 6) 
a. Script “The subjective norms questions ask patients about the 
approval/disapproval and potential influence of other people (family, friends, 
strangers) on abusing drugs. The approval/disapproval may 
increase/decrease the likelihood of drug misuse” 
b. Script “What are your thoughts and opinions about the influence of 
subjective norms on prescription drug misuse?” 
c. Allow up to 3-4 minutes before next question. 
10. Review attitude questions and ask patient to relate their attitudes towards the four types 
of prescription misuse. (Pages 7-8) 
a. Script “The attitude questions assess whether patients are thinking about 
prescription drug misuse in a more positive or negative manner. The more 
positive the more likely they are to misuse their drugs and vice versa.” 
b. Script “What are your thoughts and opinions about asking patients about 
their attitudes towards prescription drug misuse?” 
c. Allow up to 3-4 minutes before next question. 
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11. Review intention questions and ask patient to relate their attitudes towards the four types 
of prescription misuse. (Page 9) 
a. Script “The intention questions ask patients about the actual likelihood of 
abusing drugs. The stronger the patient’s intention the more likely they are 
to misuse their drugs.” 
b. Script “What are your thoughts and opinions about asking patients about 
their intention to misuse their prescription drugs?” 
c. Allow up to 3-4 minutes before next question. 
12. Review the NIDA Risk Screening questionnaire with the patient. (Page 10) 
a. Script “The NIDA-modified ASSIST (Alcohol, Smoking and Substance 
Involvement Screening Test) is included as a brief and minimally invasive 
way to ask patients about their past substance use. The more substances used 
and the more often they are used relate the future risk of addiction for a 
patient.” 
b. Script “What are your thoughts and opinions about using the NIDA-
ASSIST?” 
c. Allow up to 2 minutes before next question. 
13. Review the demographic questions with the patient. (Pages 11-12) 
a. Script “The demographic questions ask patients about their background in 
order to how many other people the findings of this study may apply to.” 
b. Script “What are your thoughts and opinions about the demographic 
questions we ask?” 
c. Allow up to 2 minutes. 
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14. Feedback and final comments 
a. Script “We are now done with the interview.” 
b. Script “Do you have any final questions or comments about the survey or 




A.4-2 Interview Coding Worksheet 
Interview ID: 
Question block 1: Types of Abuse 
1.1 Are definitions similar or different from patient experience? Similar / Different 
1.2 If different, what reason(s) for being different?   Yes / No 
 Comment:___________________________________________________________ 
1.3 Any other thoughts, suggestions or changes about types of abuse? Yes / No 
 Comment: ___________________________________________________________ 
Question block 2: Scenarios 
2.1 Are scenarios relatable?      Yes / No 
2.2 Are scenarios understandable?     Yes / No 
2.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 3: Risk of Addiction 
3.1 Thought and opinion about RA?     Yes / No 
3.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
3.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 4: Self-efficacy 
4.1 Thought and opinion about SE?     Yes / No 
4.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
4.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
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Question block 5: Perceived Vulnerability 
5.1 Thought and opinion about PV?     Yes / No 
5.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
5.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 6: Perceived Severity 
6.1 Thought and opinion about severity?     Yes / No 
6.2 Thought and opinion about serious?     Yes / No 
6.3  Suggested changes/modification to consequences?   Yes / No  
  
 Comment: ___________________________________________________________ 
6.4 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 7: Intrinsic Rewards 
7.1 Thought and opinion about IR?     Yes / No 
7.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
7.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 8: Extrinsic Rewards 
8.1 Thought and opinion about ER?     Yes / No 
8.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
8.3 Any other thoughts, suggestions or changes?    Yes / No 
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 Comment: ___________________________________________________________ 
Question block 9: Subjective Norms 
9.1 Thought and opinion about SN?     Yes / No 
9.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
9.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 10: Attitude 
10.1 Thought and opinion about Att?     Yes / No 
10.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
10.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 11: Intention 
11.1 Thought and opinion about Int?     Yes / No 
11.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
11.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 12: ASSIST 
12.1 Thought and opinion about ASSIST?     Yes / No 
12.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
12.3 Will people be able to fill out honestly?    Yes / No 
12.4 Any other thoughts, suggestions or changes?    Yes / No 
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 Comment: ___________________________________________________________ 
Question block 13: Demographics 
13.1 Thought and opinion about demographics?    Yes / No 
13.2 If changes suggested what are they?     Yes / No 
 Comment: ___________________________________________________________ 
13.3 Any other thoughts, suggestions or changes?    Yes / No 
 Comment: ___________________________________________________________ 
Question block 14: Feedback and Final Comments 
14.1 Any final suggestions?      Yes / No 





A.5 Survey Mailing 
First Name, Last Name        Date 
Address 
City, State Zip Code 
 
Dear First Name, Last Name: 
 
Hello, my name is David Malewski. I am a graduate student at the University of Michigan. You 
have been identified from a large database of University of Michigan Health System patients as 
qualified for my research study. According to the database you are at least 18 years old, have 
chronic non-cancer pain, and have been taking at least one long-acting and/or one short-acting 
painkiller for more than a month. This data may not be accurate, if so, or if you would otherwise 
want to opt-out of this study please see the information at the end of this letter. 
 
I am recruiting patients with chronic pain to participate in a survey. We are conducting research 
looking at the decisions that patients make about taking their prescription painkillers. We want to 
know how those decisions affect whether people will misuse prescription painkillers. 
 
Participation in this survey is completely voluntary and anonymous. Should you decide to 
participate in this study none of the information you share on the will be shared with anyone 
other than study personnel. Your name or any other personally identifying information will not 
be associated with any information from your survey questionnaire. 
 Participation will consist of a 60 question online survey and should take between 20 and 30 
minutes to complete.  
As an incentive we offer you a $10 check for completion of the survey. Your name and address 
will only be collected for reimbursement purposes. 
 
If you wish to participate in this research study please open up a web browser (such as Internet 
Explorer, Google Chrome, or Apple Safari) and enter the complete following web address in the 
address bar: 
 
http://tinyurl.com/pdaiis  Username: [Participant #] Password: [password] 
  
You will be prompted to answer a few preliminary questions to make sure that you meet the full 
requirements of the study. If you qualify, you will then be asked to consent to participate in the 
study, after which you will be presented the survey questions. All of these questions are 
answered anonymously with no personally identifiable information linked. 
 
After you complete the survey you will have the option of providing your name and an address 
to which will be sent a $10 check. This information is entered into a completely different system 
and will not be associated in any way with the study information. 
 
We hope that you will participate in our study. However, if you do not want to be contacted 
again about participation in this study please either send an e-mail to malewski@umich.edu with 
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the subject “Decline Study Participation – [Participant #]” or call 314-482-5695 and leave a brief 
message. 
 









A.6 Survey E-mail Reminder 
Hello, my name is David Malewski. I am a graduate student at the University of Michigan. You 
were identified as a qualified patient within The University of Michigan Health System to 
participate in our research survey. Two weeks ago I sent you a mailing. I wanted to send you a 
reminder about possible participation in my research study. 
 
I am recruiting patients with chronic pain to participate in a survey. We are conducting research 
looking at the decisions that patients make about taking their prescription painkillers. We want to 
know how those decisions affect whether people will misuse prescription painkillers. We would 
appreciate your participation in this study to contribute towards the future development of ways 
to help chronic pain patients avoid abusing their painkillers, while still responsibly managing 
their pain.  
 
Participation in this individual interview is completely voluntary and anonymous. Should you 
decide to participate in this study none of the information you share on the will be shared with 
anyone other than study personnel. Your name or any other personally identifying information 
will not be associated with any information from your survey questionnaire.  
Participation in the survey will consist of online completion of a 60 question survey 
questionnaire. The amount of time needed to complete the questionnaire is between 20 and 30 
minutes.  
 
As an incentive we offer you a $10 Visa Gift Card for completion of the survey. Your name and 
address will only be collected for reimbursement purposes, but the university will not have a 
specific reason other than “study participation” because they require that information for their 
records. 
 
If you wish to participate in this research study please open up a web browser (such as Internet 
Explorer, Google Chrome, or Apple Safari) and enter the complete following web address in the 




You will be prompted to answer a few preliminary questions to make sure that you meet the full 
requirements of the study. If you qualify, you will then be asked to consent to participate in the 
study, after which you will be presented the survey questions. All of these questions are 
answered anonymously with no personally identifiable information linked. 
 
After you complete the survey you will have the option of providing your name and an address 
to which will be sent a $10 Visa Gift Card. This information is entered into a completely 
different system and will not be associated in any way with the study information. 
 
We hope that you will participate in our study. 
Thank you for your consideration. 
Sincerely, 




A.7 Survey Mail Reminder 
Hello, my name is David Malewski. I am a graduate student at the University of Michigan. Four 
weeks ago I sent you a mailing. I wanted to send you a reminder about possible participation in 
my research study. You have been identified from a large database of University of Michigan 
Health System patients as qualified for my research study. According to the database you are at 
least 18 years old, have chronic non-cancer pain, and have been taking at least one long-acting 
and/or one short-acting painkiller for more than a month. This data may not be accurate, if so, or 
if you would otherwise want to opt-out of this study please see the information at the end of this 
e-mail. 
 
I am recruiting patients with chronic pain to participate in a survey. We are conducting research 
looking at the decisions that patients make about taking their prescription painkillers. We want to 
know how those decisions affect whether people will misuse prescription painkillers.  
 
Participation in this survey is completely voluntary and anonymous. Should you decide to 
participate in this study none of the information you share will be shared with anyone other than 
study personnel. Your name or any other personally identifying information will not be 
associated with any information from your survey questionnaire. 
  
Participation will consist of a 60 question online survey and should take between 20 and 30 
minutes to complete.  
 
As an incentive we offer you a $10 check for completion of the survey. Your name and address 
will only be collected for reimbursement purposes. 
 
If you wish to participate in this research study please open up a web browser (such as Internet 




  Username:    Password: 
 
You will be prompted to answer a few preliminary questions to make sure that you meet the full 
requirements of the study. If you qualify, you will then be asked to consent to participate in the 
study, after which you will be presented the survey questions. All of these questions are 
answered anonymously with no personally identifiable information linked. 
 
After you complete the survey you will have the option of providing your name and an address 
to which will be sent a $10 check. This information is entered into a completely different system 
and will not be associated in any way with the study information. 
 
We hope that you will participate in our study. However, if you do not want to be contacted 
again about participation in this study please either send an e-mail to Malewski@umich.edu with 
the subject “Decline Study Participation” or call 314-482-5695 and leave a brief message. 
 
We hope that you will participate in our study. 
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Thank you for your consideration. 
Sincerely, 




A.8 Survey Consent Document 
University of Michigan 
Consent To Be Part Of A Research Study 
 
NAME OF STUDY AND RESEARCHERS 
 
Title of Project: Attitude and intention to misuse controlled prescription drugs: a 
conditional indirect effects model 
 
Principal Investigator: David Malewski, MS PharmD 
Co-Investigators: Steven Erickson, PharmD; Karen Farris, PhD; Richard Bagozzi, 
PhD; Rajesh Balkrishnan, PhD; Mark Ilgen, PhD; Peter Batra, MS 
 
GENERAL INFORMATION 
We’re doing a study to learn more about prescription drug misuse. To get information 
we’d like at least 140 people to answer a survey. We expect it to take about 20 to 30 
minutes to complete the survey. 
 
You may STOP taking the survey at any point. Answering this survey is voluntary. 
You don’t have to answer it if you’d rather not. You can skip any questions that you 
don’t want to answer, whatever the reason, and you don’t have to tell us why. Choosing 
not to answer our survey won’t affect the medical care you might receive at the 
University of Michigan Health System. 
 
It’s possible that some of the questions may make you feel uncomfortable. If a question 
makes you uncomfortable, you can just skip it and go to the next question. 
 
To keep your information confidential, we will: 
 
Label your survey with a code, rather than your name or any other details that 
someone could use to identify you. Although we’ll keep a list of all the people 
who answered our survey, no one outside our study team will be able to figure 
out who answered the survey or which people gave which answers. We plan to 
publish what we learn from this study, but we won’t include any personal 
information that could reveal who answered the survey. 
 
Your survey responses will be completely anonymous. There will be no code key 
to match a survey code to a specific name. No one, including members of our 
study team, will know which subjects gave which answers. 
 
Answering our survey won’t benefit you directly. We hope what we learn will help other 
people in the future. 
 
We have prepared two different surveys for this study, although each subject will 
complete only one survey.  We will use a random method (like flipping a coin) to 
determine which survey you receive 
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• Survey 1 describes a scenario in which your pain is well-controlled and doesn’t 
require you to seek more prescription painkillers. 
• Survey 2 describes a scenario in which your pain is not well-controlled and you 
have reason to seek more prescription painkillers. 
 
You will answer the survey questions as if you are the individual in the scenario. 
 
At the end of the survey form, you’ll answer questions about your: 
• gender 
• marital status 
• race-ethnicity 
• employment status and income 
• education 
 
Finally, the survey form contains a two-question alcohol, smoking and substance use 
screening test 
 
To thank you for taking part in our study, we’ll send you a check for $10 after you take 
the survey. Recorded separate from your survey responses, the University of Michigan 
accounting department may need your name, address, Social Security number, 
payment amount, and related information for tax reporting purposes. 
 
The results of this study could be published in an article, but would not include any 
information that would let others know who you are.  
 
As a rule, the researchers will continue to use information about you until the study is 
over and will keep it secure until it is destroyed. Limited information about you may 
continue to be used after the study is over, for other research, education, or other 
activities. But use of this information would not reveal your identity. 
 
Principal Investigator:  
David Malewski M.S., Pharm.D.  
University of Michigan College of Pharmacy   
428 Church Street, Ann Arbor, MI  48109 
Telephone:  314-482-5695  
e-mail:  malewski@umich.edu          
 
You may also express a concern about the study by contacting the Institutional Review 
Board : 
 
University of Michigan Medical School Institutional Review Board (IRBMED) 
2800 Plymouth Road 
Building 520, Room 3214 
Ann Arbor, MI 48109-2800 
Telephone: 734-763-4768 




If you are concerned about a possible violation of your privacy or concerned about a 
study, you may contact the University of Michigan Health System Compliance Help Line 
at 1-866-990-0111. 
 
Do you wish to participate in this study? 
o Yes, I would like to take part 
o No, I don’t want to take part 
 





A.9 Survey Questionnaire 
Vignette 1 (Control – Pain Well-controlled/No Drug Seeking/No Misuse): 
 
 





































































Appendix B: Coding Grids and Process Models 
Table B.1 Reviewer One: Interview coding 
Question Substance User Non-User 
 A01 A02 A04 A06 A07 A09 A11 N13 N18 N19 N23 N26 N27 
1.1 S S S S S S S S S S S S S 
1.2 N N N N N N N N N N N N N 
1.3 N N N N N N N N N N N N N 
2.1 Y Y Y Y Y Y Y Y Y Y Y Y Y 
2.2 Y Y Y Y Y Y Y Y Y Y Y Y Y 
2.3 Y N N Y N N Y Y N N Y N N 
3.1 Y N N N N N N N N N N N N 
3.2 Y N N N N N N N N N N N N 
3.3 N N N N N N N N N N N N N 
4.1 N N N N N N N N N N N N N 
4.2 N N N N N N N N N N N N N 
4.3 N N N N N N N N N N N N N 
5.1 N N N N N N N N Y N Y Y N 
5.2 N N N N N N N N Y N Y Y N 
5.3 Y N N Y N N Y N N N N Y Y 
6.1 Y Y N Y Y N Y Y Y Y Y Y Y 
6.2 Y N N N N N Y Y Y Y Y Y Y 
6.3 Y Y N Y Y N Y N Y Y Y Y Y 
6.4 Y N N Y N N Y Y Y Y Y Y N 
7.1 N N Y Y N N Y N Y Y N N N 
7.2 N N Y Y N N Y N Y Y N N N 
7.3 N N N N N N Y N N N N N N 
8.1 Y N N N N N N N Y N N N N 
8.2 Y N N N N N N N Y N N N N 
8.3 Y N N N N N N N N N N N N 
9.1 N N N N N Y N Y N Y Y Y N 
9.2 N N N N N Y N N N Y Y Y N 
9.3 N N N N N N N Y N N N N N 
10.1 N N N N N N N N Y N N N N 
10.2 N N N N N N N N Y N N N N 
10.3 Y N N N N N Y N N N N N N 
11.1 Y N N N N N N Y Y N N N N 
11.2 Y N N N N N N Y Y N N N N 
11.3 N N N N N Y N N N Y N N N 
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12.1 N N N N N N N N N N N N N 
12.2 N N N N N N N N N N N N N 
12.3 Y Y Y Y Y Y Y Y Y Y Y Y Y 
12.4 N Y N N N N Y N N N N N N 
13.1 Y N Y Y N Y N Y Y Y Y Y N 
13.2 Y N Y Y N Y N Y Y Y Y Y N 
13.3 N N N N N N N N Y N N N N 
14.1 Y N N N N N N N N N Y N N 
 
Table B.2 Reviewer Two: Interview coding 
Question Substance User Non-User 
 A01 A02 A04 A06 A07 A09 A11 N13 N18 N19 N23 N26 N27 
1.1 S S S S S S S S S S S S S 
1.2 N N N N N N N N N N N N N 
1.3 N N N N N N N N N N N N N 
2.1 Y Y Y Y Y Y Y Y Y Y Y Y Y 
2.2 Y Y Y Y Y Y Y Y Y Y Y Y Y 
2.3 Y N N Y N N Y Y N N Y N N 
3.1 Y N N N N N Y N N N N N N 
3.2 N N N N N N Y N N N N N N 
3.3 Y N N N N N N N N N N Y N 
4.1 N N N N N N N N N N N N N 
4.2 N N N N N N N N N N N N N 
4.3 N N Y N N N N N N N N N N 
5.1 Y N N Y N N N N Y N Y Y N 
5.2 Y N N Y N N N N Y N Y Y N 
5.3 N N N Y N N Y Y N N N N Y 
6.1 Y N N Y Y N Y Y Y Y N Y Y 
6.2 Y N N Y N N Y Y Y Y N Y Y 
6.3 Y Y N Y Y N Y N Y Y N Y Y 
6.4 Y N N Y N N Y Y N Y N Y N 
7.1 N N Y Y N N Y N Y Y N N N 
7.2 N N Y Y N N Y N Y Y N N N 
7.3 N N N N N N Y N N N N N N 
8.1 Y N N N N N N N N N N N N 
8.2 Y N N N N N N N N N N N N 
8.3 N N N N N N N N N N N N N 
9.1 N N N N N Y N Y N Y Y Y N 
9.2 N N N N N Y N Y N Y Y Y N 
9.3 N N N N N N N N N N N N N 
10.1 N N N N N N N N Y N N N N 
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10.2 N N N N N N N N Y N N N N 
10.3 Y N N N N N Y N N N N N N 
11.1 Y N N N N N N Y Y N N N N 
11.2 Y N N N N N N Y Y N N N N 
11.3 N N N N N Y N N N N N N N 
12.1 N N N N N N N N N N N N N 
12.2 N N N N N N N N N N N N N 
12.3 Y Y Y Y Y Y Y Y Y Y Y Y Y 
12.4 N Y N N N N Y N N N N N N 
13.1 Y N Y Y N Y N Y Y Y Y Y N 
13.2 Y N Y Y N Y N Y Y Y Y Y N 
13.3 N Y N N N N N N Y N N N N 
14.1 Y N N N N N N N N N Y N N 
*Bold and Highlighted indicates difference from Reviewer One 
 






X (vignette) = Pain, drug seeking, misuse influences Mediator (Mi), if significant. 
Mi = Mediator (Mi) influences Dependent (Y), if significant. 
Direct XY = Vignette (X) directly influences Dependent (Y), if significant. 
Types of misuse:  
• Taking prescription more OFTEN than prescribed.  
• Taking prescription in higher DOSE than prescribed.  
• Taking prescription to avoid WITHDRAWAL symptoms.  
• Taking prescription to “FEEL GOOD.” 
Combined misuse cases 
• ALL TYPE MISUSE combines results for all four misuse types 
• OFTEN and DOSE combines results for those two medication-related types of misuse. 
• WITHDRAWAL and FEEL GOOD combines results for those two symptom/feeling-
based types of misuse 
 
  






Table B.3 Model 4 Attitude Full Model - Often & Dose 
Process Model 4 Regression findings for Full Model Attitude (Y) by Perceived Severity (M1), 
Perceived Vulnerability (M2), Intrinsic Rewards (M3), and Extrinsic Rewards (M4) OFTEN and 
DOSE misuse types 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .12 .12 1.03 .66 .09 7.10*** 
Age -.01 .01 -1.41 -.01 .01 -1.67 
Gender .29 .25 1.16 -.12 .20 -.61 
Marital -.23 .23 -.99 .19 .18 1.06 
Race -.90 .57 -1.57 -.33 .45 -.72 
Employ .08 .11 .77 .10 .09 1.13 
Income .01 .06 .23 .08 .05 1.72 
Education .37 .13 2.81** .08 .10 .80 
  R2=.14   R2=.34  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. T b s.e. t 
X (Vignette) .46 .10 4.65*** .25 .13 2.01* 
Age .00 .01 .57 -.00 .01 -.38 
Gender -.31 .21 -1.46 .15 .27 .58 
Marital -.05 .20 -.23 .18 .25 .74 
Race .08 .49 .15 -.64 .61 -1.05 
Employ -.09 .09 -.96 .06 .12 .51 
Income -.09 .05 -1.72 -.06 .06 -.87 
Education .03 .11 .30 -.09 .14 -.61 
  R2=.21   R2=.09  
Outcome variable model 
 Attitude (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) 
-.16 .08 -1.96    
M2 (Perceived Vuln) .07 .11 .68    
M3 (Intrinsic 
Rewards) 
.48 .11 4.49***  
M4 (Extrinsic 
Rewards) 
-.03 .07 -.49  
X (Vignette) .00 .11 .03    
Age .00 .01 .12    
Gender -.36 .20 -1.83    
Marital .28 .18 1.52    
Race -.03 .45 -.07    
Employ -.06 .09 -.64    
Income -.01 .05 -.14    
Education .09 .11 .88    
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    R2=.41     
 Effect 95% CI     
Direct effect XY .00 (-.22, .23)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influence mediators Perceived 
Vulnerability, Intrinsic Rewards, and Extrinsic Rewards. Intrinsic Rewards influences Attitude 
for OFTEN and DOSE misuse. There was no direct effect of vignette on Attitude. There was a 
significant conditional indirect effect of vignette on Attitude towards OFTEN and DOSE misuse 





Table B.4 Model 4 Attitude Full Model - Withdraw & Feel Good 
Process Model 4 Regression findings for Full Model Attitude (Y) by Perceived Severity (M1), 
Perceived Vulnerability (M2), Intrinsic Rewards (M3), and Extrinsic Rewards (M4) 
WITHDRAWAL and FEEL GOOD misuse types 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .11 .11 .98 .54 .10 5.59*** 
Age -.01 .01 -1.50 -.02 .01 -2.30* 
Gender .39 .24 1.61 -.23 .21 -1.10 
Marital -.24 .22 -1.12 .08 .19 .42 
Race -.71 .60 -1.18 .03 .52 .06 
Employ .07 .10 .67 .11 .09 1.17 
Income .06 .06 1.04 .02 .05 .44 
Education .33 .12 2.67** .19 .11 1.81 
  R2=.13   R2=.22  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. T b s.e. t 
X (Vignette) .37 .10 3.70*** .21 .10 2.06* 
Age -.01 .01 -1.63 -.01 .01 -1.10 
Gender -.23 .22 -1.09 .13 .23 .60 
Marital .15 .19 .81 .05 .20 .24 
Race .19 .54 .36 -.55 .56 -.97 
Employ .05 .09 .55 .03 .10 .29 
Income .00 .05 .07 -.06 .05 -1.14 
Education .14 .11 1.31 -.03 .11 -.24 
  R2=.12   R2=.09  
Outcome variable model 
 Attitude (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) 
-.21 .07 -3.09**    
M2 (Perceived Vuln) .03 .12 .22    
M3 (Intrinsic 
Rewards) 
.47 .12 4.07***  
M4 (Extrinsic 
Rewards) 
-.04 .07 -.57  
X (Vignette) .18 .10 1.83    
Age .00 .01 .34    
Gender -.12 .19 -.67    
Marital .11 .17 .66    
Race .31 .47 .66    
Employ -.12 .08 -1.43    
Income -.05 .04 -1.14    
Education .02 .10 .21    
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    R2=.39     
 Effect 95% CI     
Direct effect XY .18 (-.01, .37)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influence both mediators Perceived 
Vulnerability, Intrinsic Rewards, and Extrinsic Rewards. Perceived Severity and Intrinsic 
Rewards influences Attitude. There was no direct effect of vignette on Attitude. There was a 
significant conditional indirect effect of vignette on Attitude towards WITHDRAWAL and 




Table B.5 Model 4 Intention Full Model - Often & Dose 
Process Model 4 Regression findings for Full Model Intention (Y) by Perceived Severity (M1), 
Perceived Vulnerability (M2), Intrinsic Rewards (M3), Extrinsic Rewards (M4), Subjective Norm 
(M5), and Attitude (M6) OFTEN and DOSE misuse types 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .09 .12 .77 .66 .09 6.95*** 
Age -.01 .01 -1.23 -.01 .01 -1.74 
Gender .22 .25 .89 -.11 .20 -.55 
Marital -.19 .23 -.81 .17 .19 .91 
Race -.95 .57 -1.67 -.32 .45 -.69 
Employ .10 .11 .95 .09 .09 1.06 
Income .02 .06 .35 .08 .05 1.76 
Education .37 .13 2.81** .07 .11 .65 
  R2=.13   R2=.34  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. t b s.e. t 
X (Vignette) .46 .10 4.60*** .24 .13 1.85 
Age .00 .01 .39 -.01 .01 -.55 
Gender -.30 .21 -1.39 .13 .27 .49 
Marital -.10 .20 -.48 .15 .25 .60 
Race .09 .48 .19 -.63 .61 -1.02 
Employ -.10 .09 -1.03 .06 .12 .48 
Income -.08 .05 -1.49 -.04 .06 -.64 
Education .00 .11 .00 -.12 .14 -.83 
  R2=.21   R2=.08  
 Subjective Norm (M5) Attitude (M6) 
Model b s.e. t b s.e. t 
X (Vignette) .08 .06 1.35 .26 .11 2.39* 
Age .01 .00 2.01* .00 .01 .35 
Gender -.37 .12 -2.99** -.53 .23 -2.31* 
Marital -.22 .11 -1.91 .24 .21 1.14 
Race -.05 .28 -.17 .17 .52 .33 
Employ -.08 .05 -1.43 -.12 .10 -1.17 
Income -.01 .03 -.29 -.04 .05 -.66 
Education -.08 .06 -1.31 .03 .12 .27 
  R2=.20   R2=.14  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) 
.03 .05 .50    





-.01 .08 -.19  
M4 (Extrinsic 
Rewards) 
.08 .05 1.57  
M5 (Subjective 
Norm) 
-.14 .12 -1.24 
M6 (Attitude) .26 .07 3.84*** 
X (Vignette) -.09 .07 -1.29    
Age -.00 .01 -.76    
Gender -.26 .13 -1.98    
Marital .06 .12 .46    
Race .12 .29 .40    
Employ .02 .06 .35    
Income .01 .03 .46    
Education -.05 .07 -.71    
    R2=.63     
 Effect 95% CI     
Direct effect XY -.09 (-.23, .05)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influence mediators Perceived 
Vulnerability, Intrinsic Rewards, and Attitude. Perceived Vulnerability and Attitude influence 
Intention towards OFTEN and DOSE misuse. There was no direct effect of vignette on Intention. 
There was a significant conditional indirect effect of vignette on Intention towards OFTEN and 





Table B.6 Model 4 Intention Full Model - Withdrawal & Feel Good 
Process Model 4 Regression findings for Full Model Intention (Y) by Perceived Severity (M1), 
Perceived Vulnerability (M2), Intrinsic Rewards (M3), Extrinsic Rewards (M4), Subjective Norm 
(M5), and Attitude (M6) WITHDRAWAL and FEEL GOOD misuse types 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .10 .12 .88 .57 .10 5.76*** 
Age -.01 .01 -1.22 -.02 .01 -2.60* 
Gender .33 .25 1.34 -.17 .21 -.79 
Marital -.22 .22 -1.03 .07 .19 .39 
Race -.46 .68 -.68 .45 .58 .77 
Employ .09 .11 .82 .13 .09 1.40 
Income .08 .06 1.39 .03 .05 .64 
Education .30 .13 2.36* .15 .11 1.41 
  R2=.12   R2=.24  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. t b s.e. t 
X (Vignette) .39 .10 3.70*** .22 .11 2.03* 
Age -.01 .01 -1.78 -.01 .01 -1.49 
Gender -.20 .22 -.91 .11 .23 .47 
Marital .14 .20 .69 .05 .20 .24 
Race .36 .61 .59 -.33 .64 -.52 
Employ .06 .10 .64 .06 .10 .58 
Income .01 .05 .17 -.05 .05 -.87 
Education .11 .11 1.00 -.08 .12 -.70 
  R2=.18   R2=.10  
 Subjective Norm (M5) Attitude (M6) 
Model b s.e. t b s.e. t 
X (Vignette) .16 .06 3.00** .38 .11 3.58*** 
Age .01 .00 1.49 -.00 .01 -.28 
Gender -.14 .12 -1.15 -.23 .23 -1.03 
Marital -.10 .10 -.94 .18 .20 .91 
Race .31 .32 .96 .79 .62 1.27 
Employ -.08 .05 -1.56 -.12 .10 -1.24 
Income -.03 .03 -1.19 -.06 .05 -1.04 
Education -.05 .06 -.86 .01 .12 .05 
  R2=.13   R2=.13  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) 
-.01 .05 -.12    





.27 .09 3.08**  
M4 (Extrinsic 
Rewards) 
.08 .05 1.46  
M5 (Subjective 
Norm) 
-.06 .11 -.58 
M6 (Attitude) .25 .07 3.88*** 
X (Vignette) .04 .07 .61    
Age -.01 .01 -1.27    
Gender -.01 .14 -.06    
Marital .22 .12 1.85    
Race -.01 .37 -.02    
Employ .01 .06 .15    
Income .04 .03 1.32    
Education -.05 .07 -.72    
    R2=.61     
 Effect 95% CI     
Direct effect XY -.04 (-.10, .19)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influence mediators Perceived 
Vulnerability, Intrinsic Rewards, Extrinsic Rewards, Subjective Norm and Attitude. Perceived 
Vulnerability, Intrinsic Rewards, and Attitude influence Intention towards WITHDRAWAL and 
FEEL GOOD misuse. There was no direct effect of vignette on Intention. There was a significant 
conditional indirect effect of vignette on Intention towards WITHDRAWAL and FEEL GOOD 




Table B.7 Model 4 Theory of Reasoned Action All Misuse Types 
Process Model 4 Regression findings for Intention (Y) by Subjective Norm (M1) and Attitude 
(M2) all misuse types 
Mediator variable models 
 Subjective Norm (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
X (Vignette) .11 .05 2.07* .33 .10 3.40*** 
Age .01 .00 1.94 .00 .01 .09 
Gender -.16 .11 -1.40 -.30 .21 -1.44 
Marital -.17 .10 -1.70 .21 .19 1.14 
Race .20 .30 .67 .50 .57 .87 
Employ -.05 .05 -1.10 -.14 .09 -1.51 
Income -.20 .03 -.78 -.05 .05 -.96 
Education -.05 .06 -.79 .02 .11 .16 
  R2=.11   R2=.15  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Subjective 
Norm) 
.01 .13 .11    
M2 (Attitude) .39 .07 5.46***    
X (Vignette) .18 .07 2.52*    
Age -.01 .01 -1.72    
Gender -.10 .15 -.67    
Marital .19 .14 1.36    
Race -.21 .41 -.51    
Employ .09 .06 1.33    
Income .03 .03 .97    
Education .04 .08 .53    
    R2=.36     
 Effect 95% CI     
Direct effect XY .18* (.04, .33)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influence both mediators Subjective Norm 
and Attitude. Attitude influences Intention to misuse prescriptions for all misuse types. There 
was a significant direct effect of vignette on Intention. Attitude is a significant mediator between 











X (vignette) = Pain, drug seeking, misuse influences Mediator (Mi), if significant. 
M1M2 = Mediator (M1) influences Mediator (M2), if significant. 
Mi = Mediator (Mi) influences Dependent (Y), if significant. 
Direct XY = Vignette (X) directly influences Dependent (Y), if significant. 
Indirect XMiY  = Vignette (X) indirectly influences Dependent (Y) through Mediator (Mi), 
if significant. 
Indirect XMiMi Y  = Vignette (X) indirectly influences Dependent (Y) through Mediator 
(M1) and Mediator (M2), if significant. 
Types of misuse:  
• Taking prescription more OFTEN than prescribed.  
• Taking prescription in higher DOSE than prescribed.  
• Taking prescription to avoid WITHDRAWAL symptoms.  
• Taking prescription to “FEEL GOOD.” 
Combined misuse cases 
• ALL TYPE MISUSE combines results for all four misuse types 
• OFTEN and DOSE combines results for those two medication-related types of misuse. 
• WITHDRAWAL and FEEL GOOD combines results for those two symptom/feeling-
based types of misuse 
 
  
Vignette (X) Intention (Y) 




Table B.8 Model 6 Perceived Vulnerability Often & Dose 
Process Model 6 Regression findings for Intention (Y) by Perceived Vulnerability (M1) and 
Attitude (M2) OFTEN and DOSE misuse types 
Mediator variable models 
 Perceived Vulnerability (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - .39 .11 3.63*** 
X (Vignette) .66 .10 6.91*** .02 .13 .14 
Age -.01 .01 -1.58 .01 .01 1.19 
Gender -.08 .20 -.38 -.42 .23 -1.86 
Marital .24 .19 1.28 .24 .21 1.15 
Race -.30 .47 -.65 .29 .52 .56 
Employ .10 .09 1.08 -.15 .10 -1.47 
Income .08 .05 1.73 -.08 .05 -1.52 
Education .04 .11 .39 -.01 .12 -.13 
  R2=.34   R2=.23  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .52 .06 8.29***    
M2 (Attitude) .18 .05 3.30**    
X (Vignette) -.06 .07 -.91    
Age -.01 .01 -1.33    
Gender -.26 .13 -2.03*    
Marital .08 .12 .65    
Race .05 .29 .17    
Employ .03 .06 .48    
Income .01 .03 .46    
Education -.01 .07 -.22    
    R2=.60     
Direct and Indirect Effect 95% CI     
Direct XY -.06 (-.21, .08)     
Indirect Total .39 (.23, .60)     
Indirect1 XPVY .35 (.19, .54)     
Indirect2 
XPVAttY .05 (.00, .14) 
    
Indirect3 XAttY .00 (-.05, .05)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences mediator Perceived 
Vulnerability. Perceived Vulnerability influences Attitude. Perceived Vulnerability and Attitude 
influence Intention towards OFTEN and DOSE misuse. There was no direct effect of vignette on 
Intention. Perceived Vulnerability mediates the indirect effect of vignette on Intention towards 
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OFTEN and DOSE misuse. Perceived Vulnerability also mediates Attitude which in turn 




Table B.9 Model 6 Perceived Vulnerability Withdrawal & Feel Good 
Process Model 6 Regression findings for Intention (Y) by Perceived Vulnerability (M1) and 
Attitude (M2) WITHDRAWAL and FEEL GOOD misuse types 
Mediator variable models 
 Perceived Vulnerability (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - .38 .09 4.42*** 
X (Vignette) .58 .10 6.00*** .14 .11 1.27 
Age -.01 .01 -2.21* -.00 .01 .62 
Gender -.14 .21 -.68 -.21 .21 -1.02 
Marital .01 .18 .08 .15 .18 .83 
Race .41 .58 .71 .62 .58 1.07 
Employ .10 .09 1.07 -.16 .09 -1.76 
Income .02 .05 .33 -.06 .05 -1.28 
Education .19 .11 1.83 -.07 .11 -.64 
  R2=.24   R2=.24  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .40 .06 6.49***    
M2 (Attitude) .33 .06 5.67***    
X (Vignette) .00 .07 .00    
Age -.01 .01 -1.41    
Gender -.00 .14 -.03    
Marital .20 .12 1.69    
Race -.13 .38 -.34    
Employ .02 .06 .35    
Income .03 .03 .99    
Education -.04 .07 -.58    
    R2=.55     
Direct and Indirect Effect 95% CI     
Direct XY .00 (-.14, .14)     
Indirect Total .35 (.22, .49)     
Indirect1 XPVY .23 (.12, .37)     
Indirect2 
XPVAttY .07 (.03, .16) 
    
Indirect3 XAttY .05 (-.00, .13)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influence mediator Perceived 
Vulnerability.  Perceived Vulnerability influences Attitude. Perceived Vulnerability and Attitude 
both influence Intention towards WITHDRAWAL and FEEL GOOD misuse. There was no 
direct effect of vignette on Intention. Perceived Vulnerability mediates an indirect effect of 
vignette on Intention towards WITHDRAWAL and FEEL GOOD misuse. Perceived 
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Vulnerability mediates Attitude which in turn mediates an indirect effect of vignette on Intention 
towards WITHDRAWAL and FEEL GOOD misuse.   
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Table B.10 Model 6 Perceived Severity Often & Dose 
Process Model 6 Regression findings for Intention (Y) by Perceived Severity (M1) and Attitude 
(M2) OFTEN and DOSE misuse types 
Mediator variable models 
 Perceived Severity (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - -.35 .08 -4.22*** 
X (Vignette) .04 .11 .40 .33 .10 3.38*** 
Age -.01 .01 -.49 -.00 .01 -.33 
Gender .32 .23 1.42 -.38 .21 -1.78 
Marital -.29 .21 -1.39 .24 .19 1.23 
Race -.87 .56 -1.56 -.17 .52 -.33 
Employ .05 .10 .49 -.09 .09 -.95 
Income -.00 .05 -.06 -.03 .05 -.61 
Education .29 .12 2.47* .10 .11 .91 
  R2=.10   R2=.25  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Sevrity) .05 .07 .68    
M2 (Attitude) .34 .07 5.00***    
X (Vignette) .26 .08 3.26**    
Age -.01 .01 -1.66    
Gender -.12 .15 -.68    
Marital .20 .15 1.34    
Race -.12 .40 -.29    
Employ .08 .07 1.18    
Income .03 .04 .72    
Education .02 .09 .18    
    R2=.33     
Direct and Indirect Effect 95% CI     
Direct XY .26 (.10, .41)     
Indirect Total .14 (.03, .23)     
Indirect1 XPSY .00 (-.01, .04)     
Indirect2 
XPSAttY -.01 (-.04, .02) 
    
Indirect3 XAttY .11 (.03, .24)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences mediator Attitude and Attitude 
influences Intention towards OFTEN and DOSE misuse. Perceived Severity influences mediator 
Attitude and Attitude influences Intention towards OFTEN and DOSE misuse. There was a 
significant direct effect of vignette on Intention. Attitude partially mediates an indirect effect of 
vignette on Intention OFTEN and DOSE misuse.  
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Table B.11 Model 6 Perceived Severity Withdrawal & Feel Good 
Process Model 6 Regression findings for Intention (Y) by Perceived Severity (M1) and Attitude 
(M2) WITHDRAWAL and FEEL GOOD misuse types 
Mediator variable models 
 Perceived Severity (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - -.27 .08 -3.50*** 
X (Vignette) .08 .11 .71 .40 .10 4.00*** 
Age -.01 .01 -1.57 -.01 .01 -.79 
Gender .35 .24 1.43 -.17 .21 -.78 
Marital -.20 .22 -.93 .13 .19 .67 
Race -.48 .68 -.72 .68 .59 1.14 
Employ .10 .10 1.00 -.09 .09 -.94 
Income .08 .06 1.48 -.03 .05 -.57 
Education .30 .12 2.41* .07 .11 .65 
  R2=.12   R2=.21  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Sevrity) .00 .06 .00    
M2 (Attitude) .45 .06 6.99***    
X (Vignette) .20 .08 2.60*    
Age -.02 .01 -2.63**    
Gender -.04 .16 -.25    
Marital .24 .14 1.74    
Race -.01 .43 -.03    
Employ .08 .07 1.20    
Income .06 .04 1.58    
Education .01 .08 .09    
    R2=.42     
Direct and Indirect Effect 95% CI     
Direct XY .20 (.05, .35)     
Indirect Total .17 (.07, .31)     
Indirect1 XPSY .00 (-.02, .02)     
Indirect2 
XPSAttY -.01 (-.04, .01) 
    
Indirect3 XAttY .18 (.08, .32)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences mediator Attitude. Perceived 
Severity influences Attitude. Attitude influences Intention towards WITHDRAWAL and FEEL 
GOOD misuse. There was a significant direct effect of vignette on Intention. There was also a 
significant partial conditional indirect effect of vignette on Intention towards WITHDRAWAL 
and FEEL GOOD misuse as mediates by Attitude.   
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Table B.12 Model 6 Perceived Intrinsic Rewards Often & Dose 
Process Model 6 Regression findings for Intention(Y) by Intrinsic Rewards (M1) and Attitude 
(M2) OFTEN and DOSE misuse types 
Mediator variable models 
 Intrinsic Rewards (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - .45 09 5.25*** 
X (Vignette) .46 .10 4.77*** .09 .10 .91 
Age -.00 .01 -.47 .00 .01 .19 
Gender -.36 .21 -1.75 -.33 .21 -1.59 
Marital -.03 .19 -.14 .32 .18 1.73 
Race .03 .51 .06 .10 .50 .20 
Employ -.04 .09 -.43 -.09 .09 -1.04 
Income -.07 .05 -1.38 -.01 .05 -.11 
Education .03 .11 .25 .01 .10 .07 
  R2=.19   R2=.29  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic Rewards) .22 .07 3.10**    
M2 (Attitude) .24 .07 3.56***    
X (Vignette) .18 .08 2.33*    
Age -.01 .01 -1.67    
Gender -.07 .16 -.47    
Marital .23 .14 1.64    
Race -.15 .38 -.39    
Employ .08 .07 1.22    
Income .04 .04 1.16    
Education .02 .08 .28    
    R2=.37     
Direct and Indirect Effect 95% CI     
Direct XY .18 (.03, .34)     
Indirect Total .18 (.09, .29)     
Indirect1 XIRY .10 (.02, .23)     
Indirect2 
XIRAttY .05 (.01, .13) 
    
Indirect3 XAttY .02 (-.02, .10)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences mediator Intrinsic Rewards. 
Intrinsic Rewards influences Attitude. Intrinsic Rewards and Attitude both influence Intention 
towards OFTEN and DOSE misuse. There was a significant direct effect of vignette on Intention. 
There was a significant partial conditional indirect effect of vignette on Intention towards 
OFTEN and DOSE misuse as mediates by Intrinsic Reward. Intrinsic Rewards partially mediates 
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Attitude which in turn partially mediates an indirect effect of vignette on Intention towards 




Table B.13 Model 6 Perceived Intrinsic Rewards Withdrawal & Feel Good 
Process Model 6 Regression findings for Intention(Y) by Intrinsic Rewards (M1) and Attitude 
(M2) WITHDRAWAL and FEEL GOOD misuse types 
Mediator variable models 
 Intrinsic Rewards (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - .50 .08 6.57*** 
X (Vignette) .37 .10 3.62*** .17 .09 1.86 
Age -.01 .01 -1.35 .00 .01 .53 
Gender -.19 .22 -.86 -.17 .19 -.89 
Marital .05 .19 .28 .13 .18 .77 
Race .31 .62 .50 .62 .53 1.16 
Employ .03 .09 .35 -.14 .08 -1.66 
Income -.01 .05 -.18 -.05 .04 -1.14 
Education .16 .11 1.43 -.07 .10 -.75 
  R2=.11   R2=.35  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic Rewards) .44 .06 7.35***    
M2 (Attitude) .24 .06 4.03***    
X (Vignette) .10 .07 1.50    
Age -.01 .01 -1.89    
Gender .00 .13 .01    
Marital .20 .12 1.71    
Race -.04 .37 -.10    
Employ .03 .06 .59    
Income .04 .03 1.20    
Education -.03 .07 -.51    
    R2=.58     
Direct and Indirect Effect 95% CI     
Direct XY .10 (-.03, .23)     
Indirect Total .25 (.13, .39)     
Indirect1 XIRY .16 (.07, .30)     
Indirect2 
XIRAttY .05 (.01, .11) 
    
Indirect3 XAttY .04 (.00, .12)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences mediator Intrinsic Rewards. 
Intrinsic Rewards influences Attitude. Intrinsic Rewards and Attitude both influence Intention 
towards WITHDRAWAL and FEEL GOOD misuse. There was no direct effect of vignette on 
Intention. Intrinsic Reward mediates an indirect effect of vignette on Intention towards 
WITHDRAWAL and FEEL GOOD misuse. Likewise, Intrinsic Reward mediates Attitude  
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which in turn mediates an indirect effect of vignette on Intention towards WITHDRAWAL and 
FEEL GOOD misuse. Though the relationship between vignette and Attitude was not significant 
(p=.06) the bootstrapped indirect effect model indicated that Attitude mediates an indirect effect 
of vignette on Intention towards WITHDRAWAL and FEEL GOOD misuse.  
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Table B.14 Model 6 Perceived Extrinsic Rewards Often & Dose 
Process Model 6 Regression findings for Intention(Y) by Extrinsic Rewards (M1) and Attitude 
(M2) OFTEN and DOSE misuse types 
Mediator variable models 
 Extrinsic Rewards (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - .12 .08 1.56 
X (Vignette) .23 .12 1.98* .25 .10 2.51* 
Age -.01 .01 -1.28 -.00 .01 .01 
Gender .11 .25 .45 -.57 .21 -2.67** 
Marital .09 .23 .39 .19 .19 .99 
Race -.64 .62 -1.03 .17 .53 .32 
Employ .01 .11 .09 -.12 .09 -1.28 
Income -.03 .06 -.46 -.03 .05 -.60 
Education -.08 .13 -.63 .08 .11 .72 
  R2=.08   R2=.16  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Extrinsic Rewards) .11 .06 1.88    
M2 (Attitude) .33 .07 5.03***    
X (Vignette) .24 .08 3.12**    
Age -.01 .01 -1.51    
Gender -.11 .16 -.65    
Marital .21 .14 1.45    
Race -.08 .39 -.21    
Employ .08 .07 1.22    
Income .03 .04 .88    
Education .02 .08 .29    
    R2=.35     
Direct and Indirect Effect 95% CI     
Direct XY .24 (.09, .39)     
Indirect Total .12 (.04, .23)     
Indirect1 XERY .02 (.00, .07)     
Indirect2 
XERAttY .01 (-.00, .04) 
    
Indirect3 XAttY .08 (.02, .20)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences both mediators Extrinsic 
Rewards and Attitude.  Attitude influences Intention towards OFTEN and DOSE misuse. There 
was a significant direct effect of vignette on Intention. Attitude partially mediates the indirect 
effect of vignette on Intention towards OFTEN and DOSE misuse. Though the relationship 
between Extrinsic Rewards and Intention was not significant (p=.06) the bootstrapped indirect 
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effect model indicated that Extrinsic Rewards partially mediates the indirect effect of vignette on 





Table B.15 Model 6 Perceived Extrinsic Rewards Withdrawal & Feel Good 
Process Model 6 Regression findings for Intention(Y) by Extrinsic Rewards (M1) and Attitude 
(M2) WITHDRAWAL and FEEL GOOD misuse types 
Mediator variable models 
 Extrinsic Rewards (M1) Attitude (M2) 
Model b s.e. t b s.e. t 
M1M2 - - - .04 .09 .48 
X (Vignette) .24 .11 2.22* .34 .11 3.29** 
Age -.01 .01 -1.35 -.00 .01 -.20 
Gender .15 .23 .67 -.27 .22 -1.22 
Marital .06 .20 .28 .16 .20 .80 
Race -.30 .64 -.47 .78 .62 1.27 
Employ .04 .10 .39 -.12 .10 -1.23 
Income -.04 .05 -.75 -.05 .05 -.98 
Education -.07 .12 -.65 .01 .11 .06 
  R2=.09   R2=.13  
Outcome variable model 
 Intention (Y)  
Model b s.e. t    
M1 (Extrinsic Rewards) .13 .06 2.12*    
M2 (Attitude) .46 .06 7.46***    
X (Vignette) .15 .08 1.98*    
Age -.01 .01 -2.19*    
Gender -.04 .16 -.27    
Marital .18 .14 1.35    
Race -.03 .43 -.08    
Employ .07 .07 1.09    
Income .06 .04 1.44    
Education .04 .08 .54    
    R2=.42     
Direct and Indirect Effect 95% CI     
Direct XY .15 (.00, .30)     
Indirect Total .19 (.09, .33)     
Indirect1 XERY .03 (.00, .08)     
Indirect2 
XERAttY .00 (-.01, .03) 
    
Indirect3 XAttY .16 (.06, .30)     
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences both mediators Extrinsic 
Rewards and Attitude. Extrinsic Rewards and Attitude both influence Intention towards 
WITHDRAWAL and FEEL GOOD misuse. There was a significant conditional indirect effect of 
vignette on Intention towards WITHDRAWAL and FEEL GOOD misuse as mediates by 
Attitude. There was a significant direct effect of vignette on Intention. There was a significant 
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partial conditional indirect effect of vignette on Intention towards WITHDRAWAL and FEEL 
GOOD misuse as mediates by Extrinsic Rewards. There was also a significant partial conditional 
indirect effect of vignette on Intention towards WITHDRAWAL and FEEL GOOD misuse as 










X (vignette) = Pain, drug seeking, misuse influences Mediator (Mi), if significant. 
W (moderator) = Moderator (W) influences Mediator (Mi), if significant. 
X*W = Moderator (W) interacts with Vignette (X) to influence Mediator (Mi), if significant. 
Mi = Mediator (Mi) influences Dependent (Y), if significant. 
Direct XY = Vignette (X) directly influences Dependent (Y), if significant. 
W = -1SD = When perceived Moderator (W) is at a LOW level it influences the conditional 
indirect effect of Vignette (X) on Dependent (Y) as mediated by Mediator (Mi), if significant. 
W = 0 = When perceived Moderator (W) is at a MODERATE level it influences the conditional 
indirect effect of Vignette (X) on Dependent (Y) as mediated by Mediator (Mi), if significant. 
W = 1SD =  When perceived Moderator (W) is at a HIGH level it influences the conditional 
indirect effect of Vignette (X) on Dependent (Y) as mediated by Mediator (Mi), if significant. 
Types of misuse:  
• Taking prescription more OFTEN thank prescribed.  
• Taking prescription in higher DOSE than prescribed.  
• Taking prescription to avoid WITHDRAWAL symptoms.  
• Taking prescription to “FEEL GOOD.” 
Combined misuse cases 
• ALL TYPE MISUSE combines results for all four misuse types 
• OFTEN and DOSE combines results for those two medication-related types of misuse. 
• WITHDRAWAL and FEEL GOOD combines results for those two symptom/feeling-
based types of misuse 
  
Vignette (X) Dependent 
 
Mediator (Mi) Moderator (W) 
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Table B.16 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Attitude(Y) 
Often & Dose Misuse 
Mediator variable models 
 Perceived Vulnerability (M1)  
Model b s.e. t    
X (Vignette) .34 .08 4.07***    
W (Risk Add) .19 .04 5.13***    
X*W .18 .04 5.00***    
Age -.00 .01 -.52    
Gender -.12 .15 -.79    
Marital .20 .14 1.49    
Race -.21 .35 -.60    
Employ .04 .07 .58    
Income .05 .04 1.51    
Education .01 .08 .14    
  R2=.63     
Outcome variable models 
 Attitude (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .40 .11 3.75***    
X (Vignette) -.01 .13 -.04    
Age .01 .01 1.27    
Gender -.45 .22 -2.01*    
Marital .28 .21 1.38    
Race .27 .52 .52    
Employ -.14 .10 -1.44    
Income -.09 .05 -1.61    
Education .00 .12 .03    
  R2=.24     
Direct  Effect 95% CI     
Direct XY -.01 (-.26, .25)     
Conditional Indirect Perceived 
Vulnerability 
  
W = -1SD(-2.49) -.04 (-.15, .01)    
W = 0 .14 (.04, .26)    
W = 1SD(2.49) .31 (.08, .57)    
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Perceived Vulnerability. Risk 
of Addiction has a moderating effect on Perceived Vulnerability. Risk of Addiction interacts 
with vignette to influence mediator Perceived Vulnerability and Perceived Vulnerability 
influences Attitude towards Combined Often and Dose Misuse. There was no significant direct 
effect of vignette on Attitude. There was also a significant conditional indirect effect of vignette 
on Attitude towards Combined Often and Dose Misuse as mediated by Perceived Vulnerability 
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and moderated by Risk of Addiction. Specifically, at perceived moderate and high levels of Risk 
of Addiction then pain, drug seeking and misuse will influence the perception of Perceived 





Table B.17 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Often & Dose Misuse 
Mediator variable models 
 Perceived Vulnerability (M1)  
Model b s.e. t    
X (Vignette) .36 .08 4.29***    
W (Risk Add) .20 .04 5.46***    
X*W .18 .04 4.98***    
Age -.00 .01 -.73    
Gender -.08 .16 -.55    
Marital .17 .14 1.21    
Race -.21 .36 -.58    
Employ .06 .07 .84    
Income .04 .04 1.21    
Education .04 .08 .54    
  R2=.63     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .53 .06 8.27***    
X (Vignette) -.00 .08 -.06    
Age -.01 .01 -1.34    
Gender -.30 .14 -2.10*    
Marital .15 .13 1.19    
Race .09 .33 .29    
Employ -.04 .06 -.58    
Income .00 .03 .08    
Education -.04 .07 -.51    
  R2=.50     
Direct  Effect 95% CI     
Direct XY -.01 (-.16, .15)     
Conditional Indirect Perceived 
Vulnerability 
  
W = -1SD(-2.47) -.04 (-.15, .04)    
W = 0 .19 (.10, .31)    
W = 1SD(2.47) .43 (.24, .65)    
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Perceived Vulnerability. Risk 
of Addiction has a moderating effect on Perceived Vulnerability. Risk of Addiction interacts 
with vignette to influence mediator Perceived Vulnerability and Perceived Vulnerability 
influences Intention towards Combined Often and Dose Misuse. There was no significant direct 
effect of vignette on Intention. There was also a significant conditional indirect effect of vignette 
on Intention towards Combined Often and Dose Misuse as mediated by Perceived Vulnerability 
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and moderated by Risk of Addiction. Specifically, at perceived moderate and high levels of Risk 
of Addiction then pain, drug seeking and misuse will influence the perception of Perceived 




Table B.18 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Attitude(Y) 
Withdrawal & Feel Good 
Mediator variable models 
 Perceived Vulnerability (M1)  
Model b s.e. t    
X (Vignette) .27 .09 2.95**    
W (Risk Add) .22 .04 5.48***    
X*W .19 .04 4.71***    
Age -.01 .01 -1.29    
Gender -.22 .16 -1.38    
Marital -.02 .14 -.14    
Race .09 .41 .23    
Employ .06 .07 .81    
Income .00 .04 .11    
Education .17 .08 2.11*    
  R2=.53     
Outcome variable models 
 Attitude (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .40 .09 4.68***    
X (Vignette) .12 .11 1.10    
Age .01 .01 .93    
Gender -.25 .21 -1.23    
Marital .19 .18 1.05    
Race .56 .51 1.10    
Employ -.15 .09 -1.64    
Income .07 .05 -1.48    
Education -.04 .10 -.40    
  R2=.25     
Direct  Effect 95% CI     
Direct XY .12 (-.09, .32)     
Conditional Indirect Perceived 
Vulnerability 
  
W = -1SD(-2.43) -.08 (-.19, -.01)    
W = 0 .11 (.04, .21)    
W = 1SD(2.43) .29 (.13, .51)    
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Perceived Vulnerability. Risk 
of Addiction has a moderating effect on Perceived Vulnerability. Risk of Addiction interacts 
with vignette to influence mediator Perceived Vulnerability and Perceived Vulnerability 
influences Attitude towards Combined Withdrawal and Feel Good. There was no significant 
direct effect of vignette on Attitude. There was also a significant conditional indirect effect of 
vignette on Attitude towards Combined Withdrawal and Feel Good Misuse as mediated by 
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Perceived Vulnerability and moderated by Risk of Addiction. Specifically, at perceived low, 
moderate and high levels of Risk of Addiction then pain, drug seeking and misuse will exert a 
conditional indirect effect on Attitude towards Combined Withdrawal and Feel Good mediated 
by Perceived Vulnerability. At lower Risk of Addiction, Perceived Vulnerability will decrease 





Table B.19 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M)  Intention(Y) 
Withdrawal & Feel Good 
Mediator variable models 
 Perceived Vulnerability (M1)  
Model b s.e. t    
X (Vignette) .25 .10 2.67**    
W (Risk Add) .25 .04 6.04***    
X*W .15 .04 3.67***    
Age -.01 .01 -1.27    
Gender -.06 .17 -.35    
Marital .00 .15 .02    
Race .44 .48 .92    
Employ .06 .07 .85    
Income -.00 .04 -.03    
Education .14 .09 1.67    
  R2=.51     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .54 .06 8.84***    
X (Vignette) .02 .08 .29    
Age -.01 .01 -.90    
Gender -.08 .15 -.52    
Marital .22 .13 1.71    
Race .03 .42 .08    
Employ -.04 .07 -.63    
Income .01 .03 .24    
Education -.06 .08 -.81    
  R2=.45     
Direct  Effect 95% CI     
Direct XY .02 (-.13, .18)     
Conditional Indirect Perceived 
Vulnerability 
  
W = -1SD(-2.47) -.06 (-.17, .02)    
W = 0 .14 (.03, .25)    
W = 1SD(2.47) .34 (.12, .55)    
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Perceived Vulnerability. Risk 
of Addiction has a moderating effect on Perceived Vulnerability. Risk of Addiction interacts 
with vignette to influence mediator Perceived Vulnerability and Perceived Vulnerability 
influences Intention towards Combined Withdrawal and Feel Good Misuse. There was no 
significant direct effect of vignette on Intention. There was also a significant conditional indirect 
effect of vignette on Intention towards Combined Withdrawal and Feel Good Misuse as 
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mediated by Perceived Vulnerability and moderated by Risk of Addiction. Specifically, at 
perceived moderate and high levels of Risk of Addiction then vignette will exert a conditional 





Table B.20 Model 7 Risk of Addiction(W) with Perceived Vulnerability(M1) and Attitude(M2) 
 Intention(Y) Withdrawal & Feel Good 
Mediator variable models 
 Perceived Vulnerability (M1) Attitude(M2) 
Model b s.e. t b s.e. t 
X (Vignette) .31 .09 3.42*** .30 .12 2.49* 
W (Risk of 
Addiction) .23 .04 5.79*** .06 .05 1.16 
X*W .18 .04 4.62*** .14 .05 2.65** 
Age -.01 .01 -1.29 .00 .011 .32 
Gender -.14 .16 -.85 -.27 .21 -1.27 
Marital -.05 .14 -.36 .12 .19 .66 
Race .41 .45 .92 .70 .59 1.18 
Employ .06 .07 .84 -.14 .09 -1.49 
Income .01 .04 .17 -.06 .05 -1.22 
Education .16 .08 1.96 -.01 .11 -.14 
  R2=.56   R2=.21  
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived Vuln) .40 .06 6.57***    
M2 (Attitude) .33 .06 5.74***    
X (Vignette) -.01 .07 -.16    
Age -.01 .01 -1.52    
Gender .01 .14 .05    
Marital .21 .12 1.74    
Race -.14 .38 -.37    
Employ .01 .06 .19    
Income .03 .03 1.02    
Education -.05 .07 -.65    
  R2=.56     
Direct  Effect 95% CI     
Direct XY -.01 (-.15, .13)     
Conditional Indirect Perceived 
Vulnerability 
 Attitude 
W = -1SD(-2.45) -.06 (-.16, .0) W = -1SD(-2.45) -.01 (-.10, .07) 
W = 0 .12 (.06, .22) W = 0 .10 (.04, .20) 
W = 1SD(2.45) .30 (.15, .49) W = 1SD(2.45) .21 (.10, .38) 
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences both Perceived Vulnerability 
and Attitude. Risk of Addiction has a moderating effect on Perceived Vulnerability. Risk of 
Addiction interacts with vignette to influence both mediators Perceived Vulnerability and 
Attitude Perceived Vulnerability and Attitude both influence Intention towards WITHDRAWAL 
and FEEL GOOD Misuse.  There was no direct effect of vignette on Intention. There was a 
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significant conditional indirect effect of vignette on Intention towards WITHDRAWAL and 
FEEL GOOD Misuse as mediated by both Perceived Vulnerability and Attitude and moderated 
by Risk of Addiction. Specifically, at perceived moderate and high levels of Risk of Addiction 
then vignette will exert a conditional indirect effect on Intention towards WITHDRAWAL and 




Table B.21 Model 7 Self-Efficacy(W) with Perceived Severity(M)  Attitude(Y) Often Misuse 
Mediator variable models 
 Perceived Severity (M1)  
Model b s.e. t    
X (Vignette) .40 .15 2.66**    
W (Self-Efficacy) .41 .14 2.99**    
X*W -.34 .14 -2.46*    
Age -.01 .01 -1.06    
Gender .30 .22 1.36    
Marital -.33 .20 -1.66    
Race -.73 .56 -1.32    
Employ .07 .10 .76    
Income -.02 .05 -.47    
Education .28 .11 2.48*    
  R2=.17     
Outcome variable models 
 Attitude (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) -.41 .08 -5.21*** 
   
X (Vignette) .25 .09 2.60*    
Age -.01 .01 -1.06    
Gender -.30 .21 -1.46    
Marital .29 .19 1.52    
Race -.33 .52 -.65    
Employ -.08 .09 -.91    
Income -.03 .05 -.72    
Education .12 .11 1.12    
  R2=.26     
Direct  Effect 95% CI     
Direct XY .25 (.06, .43)     
Conditional Indirect Perceived Severity   
W = -1SD(-1.41) -.36 (-.72, -.11)    
W = 0 -.16 (-.33, -.04)    
W = 1SD(1.19) .00 (-.12, .14)    
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Perceived Severity. Self-
Efficacy has a moderating effect on Perceived Severity. Self-Efficacy interacts with vignette to 
influence mediator Perceived Severity. Perceived Severity influences Attitude towards OFTEN 
Misuse. There was a significant direct effect of vignette on Attitude. There was a significant 
partial conditional indirect effect of vignette on Attitude towards OFTEN Misuse as mediated by 
Perceived Severity and moderated by Self-Efficacy. Specifically, at perceived low and moderate 
levels of Self-Efficacy then vignette will exert a partial conditional indirect effect on Attitude 
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towards OFTEN misuse mediated by Perceived Severity. When Self-Efficacy is LOW and 




Table B.22 Model 7 Self-Efficacy(W) with Perceived Severity(M)  Intention(Y) Withdrawal 
Misuse 
Mediator variable models 
 Perceived Severity (M1)  
Model b s.e. t    
X (Vignette) .32 .14 2.31*    
W (Self-Efficacy) .27 .12 2.24*    
X*W -.25 .12 -2.01*    
Age -.01 .01 -1.01    
Gender .23 .24 .98    
Marital -.30 .21 -1.45    
Race -.45 .66 -.69    
Employ .07 .10 .68    
Income .05 .06 .96    
Education .24 .12 1.94    
  R2=.12     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) -.14 .07 -2.00* 
   
X (Vignette) .35 .09 3.83***    
Age -.02 .01 -2.45*    
Gender -.12 .20 -.61    
Marital .29 .18 1.63    
Race -.11 .18 1.63    
Employ .07 .08 .80    
Income .03 .05 .70    
Education .09 .10 .91    
  R2=.16     
Direct  Effect 95% CI     
Direct XY .35 (.17, .53)     
Conditional Indirect Perceived Severity   
W = -1SD(-1.41) -.09 (-.24, -.01)    
W = 0 -.05 (-.13, -.00)    
W = 1SD(1.19) -.00 (-.07, .04)    
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Perceived Severity. Self-
Efficacy has a moderating effect on Perceived Severity. Self-Efficacy interacts with vignette to 
influence mediator Perceived Severity. Perceived Severity influences Intention towards 
WITHDRAWAL Misuse. There was a significant direct effect of vignette on Intention. There 
was a significant partial conditional indirect effect of vignette on Intention towards 
WITHDRAWAL Misuse as mediated by Perceived Severity and moderated by Self-Efficacy. 
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Specifically, at perceived low and moderate levels of Self-Efficacy then vignette will exert a 
partial conditional indirect effect on Intention towards WITHDRAWAL misuse mediated by 
Perceived Severity. When Self-Efficacy is LOW and MODERATE, then vignette influences 




Table B.23 Model 7 Self-Efficacy(W) with Intrinsic Rewards(M)  Attitude(Y) Often and Dose 
Misuse 
Mediator variable models 
 Intrinsic Rewards (M1)  
Model b s.e. t    
X (Vignette) .07 .13 .55    
W (Self-Efficacy) -.48 .12 -4.01***    
X*W .30 .12 2.52*    
Age .00 .01 .09    
Gender -.23 .20 -1.13    
Marital -.03 .18 -.17    
Race -.10 .49 -.20    
Employ -.07 .09 -.81    
Income -.08 .05 -1.63    
Education .05 .10 .48    
  R2=.28     
Outcome variable models 
 Attitude (Y)  
Model b s.e. t    
M1 (Intrinsic 
Rewards) .47 .09 5.51*** 
   
X (Vignette) .06 .10 .60    
Age .00 .01 .47    
Gender -.36 .21 -1.78    
Marital .33 .18 1.83    
Race .06 .50 .12    
Employ -.09 .09 -.99    
Income -.01 .05 -.17    
Education .01 .10 .08    
  R2=.31     
Direct  Effect 95% CI     
Direct XY .06 (-.14, .26)     
Conditional Indirect Intrinsic Rewards   
W = -1SD(-1.37) -.16 (-.54, .13)    
W = 0 .03 (-.12, .20)    
W = 1SD(1.16) .20 (.07, .40)    
* p<.05, ** p<.01, *** p<.001 
Description: Self-Efficacy has a moderating effect on Intrinsic Rewards. Self-Efficacy interacts 
with vignette to influence mediator Intrinsic Rewards and Intrinsic Rewards influences Attitude 
towards Combined Often and Dose Misuse.  There was no significant direct effect of vignette on 
Attitude. There was a significant conditional indirect effect of vignette on Attitude towards 
Combined Often and Dose Misuse as mediated by Intrinsic Rewards and moderated by Self-
Efficacy. Specifically, at perceived high levels of Self-Efficacy then vignette will exert a 
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conditional indirect effect on Attitude towards Combined Often and Dose Good mediated by 
Intrinsic Rewards.  
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Table B.24 Model 7 Self-Efficacy(W) with Intrinsic Rewards(M)  Intention(Y) Often and 
Dose Misuse 
Mediator variable models 
 Intrinsic Rewards (M1)  
Model b s.e. t    
X (Vignette) .18 .12 1.49    
W (Self-Efficacy) -.41 .10 -3.90***    
X*W .27 .11 2.55*    
Age -.01 .01 -.76    
Gender -.17 .20 -.83    
Marital -.04 .18 -.22    
Race -.02 .51 -.03    
Employ -.06 .09 -.72    
Income -.09 .05 -1.83    
Education .06 .10 .62    
  R2=.27     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic 
Rewards) .33 .06 5.09*** 
   
X (Vignette) .23 .08 2.86**    
Age -.01 .01 -1.84    
Gender -.11 .16 -.69    
Marital .30 .14 2.20*    
Race -.11 .40 -.29    
Employ .05 .07 .74    
Income .05 .04 1.30    
Education .01 .08 .17    
  R2=.33     
Direct  Effect 95% CI     
Direct XY .23 (.07, .38)     
Conditional Indirect Intrinsic Rewards   
W = -1SD(-1.36) -.06 (-.29, .10)    
W = 0 .06 (-.02, .17)    
W = 1SD(1.15) .16 (.07, .31)    
* p<.05, ** p<.01, *** p<.001 
Description: Self-Efficacy has a moderating effect on Intrinsic Rewards. Self-Efficacy interacts 
with vignette to influence mediator Intrinsic Rewards and Intrinsic Rewards influences Intention 
towards Combined Often and Dose Misuse.  There was a significant direct effect of vignette on 
Intention. There was a significant partial conditional indirect effect of vignette on Intention 
towards Combined Often and Dose Misuse as mediated by Intrinsic Rewards and moderated by 
Self-Efficacy. Specifically, at perceived high levels of Self-Efficacy then vignette will exert a 
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Table B.25 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M)  Attitude(Y) 
Withdrawal and Feel Good Misuse 
Mediator variable models 
 Intrinsic Rewards (M1)  
Model b s.e. t    
X (Vignette) .08 .11 .74    
W (Risk Add) .22 .05 4.86***    
X*W .12 .05 2.48*    
Age -.00 .01 -.34    
Gender -.23 .19 -1.24    
Marital .03 .17 .18    
Race .28 .47 .59    
Employ .01 .08 .09    
Income -.02 .04 -.53    
Education .15 .09 1.63    
  R2=.35     
Outcome variable models 
 Attitude (Y)  
Model b s.e. t    
M1 (Intrinsic 
Rewards) .52 .08 6.77*** 
   
X (Vignette) .15 .09 1.58    
Age .01 .01 .82    
Gender -.23 .19 -1.17    
Marital .16 .17 .98    
Race .49 .48 1.02    
Employ -.13 .08 -1.54    
Income -.06 .04 -1.29    
Education -.05 .10 -.53    
  R2=.35     
Direct  Effect 95% CI     
Direct XY .15 (-.04, .33)     
Conditional Indirect Intrinsic Rewards   
W = -1SD(-2.43) -.10 (-.25, -.01)    
W = 0 .04 (-.06, .15)    
W = 1SD(2.43) .19 (.01, .41)    
* p<.05, ** p<.01, *** p<.001 
Description: Risk of Addiction influences Intrinsic Rewards. Risk of Addiction interacts with 
vignette to influence Intrinsic Rewards. Intrinsic Rewards influences Attitude towards Combined 
Withdrawal and Feel Good Misuse. There was no significant direct effect of vignette on Attitude. 
There was also a significant conditional indirect effect of vignette on Attitude towards Combined 
Withdrawal and Feel Good Misuse as mediated by Intrinsic Rewards and moderated by Risk of 
Addiction. Specifically, at perceived low and high levels of Risk of Addiction then pain, drug 
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seeking and misuse will exert a conditional indirect effect on Attitude towards Combined 
Withdrawal and Feel Good mediated by Intrinsic Rewards. At lower Risk of Addiction, Intrinsic 





Table B.26 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M)  Intention(Y) 
Withdrawal and Feel Good Misuse 
Mediator variable models 
 Intrinsic Rewards (M1)  
Model b s.e. t    
X (Vignette) .08 .11 .77    
W (Risk Add) .24 .05 5.20***    
X*W .10 .05 2.12*    
Age -.00 .01 -.38    
Gender .17 .19 -.88    
Marital .04 .17 .24    
Race .40 .54 .74    
Employ .01 .08 .17    
Income -.03 .04 -.60    
Education .12 .10 1.29    
  R2=.35     
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic 
Rewards) .58 .05 10.55*** 
   
X (Vignette) .10 .07 1.52    
Age -.01 .01 -1.56    
Gender -.02 .14 -.11    
Marital .21 .12 1.68    
Race .07 .39 .17    
Employ -.01 .06 -.20    
Income .02 .03 .73    
Education -.05 .07 -.74    
  R2=.53     
Direct  Effect 95% CI     
Direct XY .10 (-.03, .24)     
Conditional Indirect Intrinsic Rewards   
W = -1SD(-2.42) -.09 (-.22, .03)    
W = 0 .05 (-.07, .17)    
W = 1SD(2.42) .19 (-.03, .41)    
* p<.05, ** p<.01, *** p<.001 
Description: Risk of Addiction has a moderating effect on Intrinsic Rewards. Risk of Addiction 
interacts with vignette to influence Intrinsic Rewards. Intrinsic Rewards influences Intention 
towards Combined Withdrawal and Feel Good Misuse. There was no significant direct effect of 
vignette on Intention. There was a significant conditional indirect effect of vignette on Intention 
towards Combined Withdrawal and Feel Good Misuse as mediated by Intrinsic Rewards and 
moderated by Risk of Addiction. Specifically, with Risk of Addiction moderating then pain, drug 
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seeking and misuse will exert a conditional indirect effect on Intention towards Combined 




Table B.27 Model 7 Risk of Addiction(W) with Intrinsic Rewards(M1) and Attitude(M2)  
Intention(Y) All Type Misuse 
Mediator variable models 
 Intrinsic Rewards (M1) Attitude(M2) 
Model b s.e. t b s.e. t 
X (Vignette) .23 .10 2.31* .17 .11 2.31* 
W (Risk of 
Addiction) .15 .04 3.58*** .04 .05 .88 
X*W .09 .04 2.21* .11 .05 2.20* 
Age -.00 .01 -.26 .00 .01 .36 
Gender -.28 .17 -1.61 -.31 .20 -1.54 
Marital -.05 .16 -.31 .19 .18 1.07 
Race .22 .48 .46 .45 .55 .80 
Employ -.01 .08 -.13 -.14 .09 -1.55 
Income -.05 .04 -1.14 -.04 .05 -.91 
Education .09 .09 1.05 -.02 .10 -.16 
  R2=.34   R2=.20  
Outcome variable models 
 Intention (Y)  
Model b s.e. t    
M1 (Intrinsic 
Rewards) .41 .07 6.06*** 
   
M2 (Attitude) .22 .06 3.44***    
X (Vignette) .06 .07 .95    
Age -.01 .00 -1.44    
Gender -.04 .13 -.31    
Marital .22 .12 1.94    
Race -.20 .35 -.55    
Employ .06 .06 1.13    
Income .04 .03 1.49    
Education -.01 .07 -.17    
  R2=.51     
Direct  Effect 95% CI     
Direct XY .06 (-.07, .19)     
Conditional Indirect Intrinsic Rewards  Attitude 
W = -1SD(-2.47) -.00 (-.09, .08) W = -1SD(-2.47) -.00 (-.07, .06) 
W = 0 .09 (.02, .21) W = 0 .06 (.01, .15) 
W = 1SD(2.47) .19 (.07, .39) W = 1SD(2.47) .12 (.01, .28) 
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences both Intrinsic Rewards and 
Attitude. Risk of Addiction has a moderating effect on Intrinsic Rewards. Risk of Addiction 
interacts with vignette to influence both mediators Intrinsic Rewards and Attitude. Intrinsic 
Rewards and Attitude both influence Intention towards All-Type Misuse.  There was no direct 
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effect of vignette on Intention. There was a significant conditional indirect effect of vignette on 
Intention towards All-Type Misuse as mediated by both Intrinsic Rewards and Attitude and 
moderated by Risk of Addiction. Specifically, at perceived moderate and high levels of Risk of 
Addiction then vignette will exert a conditional indirect effect on Intention towards All-Type 





Table B.28 Model 7 Risk of Addiction(W) Full Model Attitude(Y) All Misuse Types 
Process Model 7 Regression findings for Full Model Attitude (Y) x Perceived Severity (M1), 
Perceived Vulnerability (M2), Intrinsic Rewards (M3), and Extrinsic Rewards (M4) x Risk of 
Addiction(W) all misuse types 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) -.05 .13 -.39 .06 .07 .81 
W (Risk Add) .13 .05 2.37* .11 .03 3.91*** 
X*W -.10 .05 -1.80 -.02 .03 -.80 
Age -.01 .01 -.99 -.01 .01 -1.67 
Gender .43 .23 1.88 .19 .12 1.54 
Marital -.22 .28 -.80 -.09 .14 -.61 
Race -.57 .72 -.79 -.27 .38 -.71 
Employ .03 .09 .30 .03 .05 .54 
Income .02 .05 .33 .04 .03 1.25 
Education .29 .13 2.22* .15 .07 2.07* 
  R2=.16   R2=.27  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. T b s.e. t 
X (Vignette) .21 .09 2.37* .18 .15 1.21 
W (Risk Add) .16 .04 4.29*** .03 .06 .58 
X*W .10 .04 2.67** -.02 .06 -.28 
Age -.00 .01 -.25 -.01 .01 -.69 
Gender -.33 .17 -1.99* .14 .25 .58 
Marital .04 .19 .24 .06 .28 .23 
Race .19 .48 .39 -.54 .46 -1.19 
Employ -.01 .09 -.17 .03 .10 .26 
Income -.04 .04 -.81 -.06 .06 -1.14 
Education .08 .10 .87 -.04 .13 -.31 
  R2=.35   R2=.09  
Outcome variable model 
 Attitude (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) 
-.41 .17 -2.50*    
M2 (Perceived Vuln) .46 .29 1.60    
M3 (Intrinsic 
Rewards) 
.47 .13 3.52***  
M4 (Extrinsic 
Rewards) 
-.01 .07 -.13  
X (Vignette) .07 .08 .75    
Age .01 .01 .74    
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Gender -.16 .19 -.84    
Marital .14 .19 .78    
Race .12 .52 .23    
Employ -.14 .09 -1.61    
Income -.05 .04 -1.23    
Education .08 .09 .86    
    R2=.45     
 Effect 95% CI     
Direct effect XY .06 (-.10, .23)     
Conditional Indirect Perceived Severity  Perceived Vulnerability 
W = -1SD(-2.50) -.08 (-.30, .05) W = -1SD(-2.50) .05 (-.02, .25) 
W = 0 .02 (-.08, .16) W = 0 .03 (-.02, .16) 
W = 1SD(2.50) .03 (-.01, .36) W = 1SD(2.50) .00 (-.10, .13) 
Conditional Indirect Intrinsic Rewards  Extrinsic Rewards 
W = -1SD(-2.50) -.02 (-.12, .07) W = -1SD(-2.50) -.00 (-.05, .03) 
W = 0 .10 (.03, .21) W = 0 -.00 (-.04, .02) 
W = 1SD(2.50) .21 (.07, .41) W = 1SD(2.50) -.00 (-.04, .02) 
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Intrinsic Rewards. Risk of 
Addiction shows a moderating effect on Perceived Severity, Perceived Vulnerability and 
Intrinsic Reward. However, Risk of Addiction only interacts with pain, drug seeking, and misuse 
(vignette) to influence Intrinsic Rewards which in turn influences Attitude. There was a 
significant conditional indirect effect of vignette on Attitude towards all type misuse as mediated 
by Intrinsic Rewards and moderated by Risk of Addiction. Specifically, at perceived moderate 
and high levels of Risk of Addiction interacts with pain, drug seeking and misuse to influence 





Table B.29 Model 7 Risk of Addiction(W) Full Model Intention(Y) All Misuse Types 
Process Model 7 Regression findings for Full Model Intention (Y) x Perceived Severity (M1), 
Perceived Vulnerability (M2), Intrinsic Rewards (M3), Extrinsic Rewards (M4), Subjective Norm 
(M5), and Attitude (M6) x Risk of Addiction(W) all misuse types 
Mediator variable models 
 Perceived Severity (M1) Perceived Vulnerability (M2) 
Model b s.e. t b s.e. t 
X (Vignette) -.03 .13 -.23 .07 .07 1.00 
W (Risk Add) .12 .05 2.10* .10 .03 3.61*** 
X*W -.08 .05 -1.55 -.02 .03 -.60 
Age -.01 .01 -.72 -.01 .01 -1.50 
Gender .39 .23 1.65 .18 .13 1.38 
Marital -.19 .28 -.68 -.08 .15 -.56 
Race -.22 .74 -.30 -.06 .38 -.17 
Employ .05 .09 .54 .04 .05 .69 
Income .04 .05 .67 .05 .03 1.62 
Education .26 .14 1.89 .13 .08 1.68 
  R2=.13   R2=.25  
 Intrinsic Rewards (M3) Extrinsic Rewards (M4) 
Model b s.e. t b s.e. t 
X (Vignette) .21 .09 2.25* .16 .15 1.07 
W (Risk Add) .17 .04 4.26*** .04 .06 .71 
X*W .09 .04 2.38* -.03 .06 -.50 
Age -.00 .02 -.42 -.01 .01 -1.16 
Gender -.32 .18 -1.80 .10 .25 .41 
Marital .02 .19 .12 .08 .28 .27 
Race .26 .63 .41 -.29 .48 -.60 
Employ -.01 .09 -.06 .07 .10 .63 
Income -.03 .05 -.66 -.05 .06 -.85 
Education .06 .10 .54 -.11 .13 -.81 
  R2=.36   R2=.10  
 Subjective Norm (M5) Attitude (M6) 
Model b s.e. t b s.e. t 
X (Vignette) .04 .07 .54 .27 .09 2.99** 
W (Risk Add) .07 .03 2.23* .05 .04 1.15 
X*W -.04 .03 -1.30 .10 .04 2.60** 
Age .01 .00 1.82 .00 .01 .41 
Gender -.15 .13 -1.17 -.33 .21 -1.53 
Marital -.14 .11 -1.25 .17 .20 .81 
Race .29 .52 .56 .43 .99 .43 
Employ -.04 .05 -.76 -.16 .11 -1.52 
Income -.02 .03 -.73 -.05 .05 -1.13 
Education -.05 .06 -.79 .05 .11 .40 
  R2=.15   R2=.22  
Outcome variable model 
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 Intention (Y)  
Model b s.e. t    
M1 (Perceived 
Sevrity) 
-.37 .19 -1.94    
M2 (Perceived Vuln) .81 .33 2.42*    
M3 (Intrinsic 
Rewards) 
.26 .12 2.29*  
M4 (Extrinsic 
Rewards) 
.04 .05 .70  
M5 (Subjective 
Norm) 
-.07 .16 -.40 
M6 (Attitude) .28 .14 1.97* 
X (Vignette) -.03 .06 -.54    
Age -.00 .01 -.70    
Gender -.10 .14 -.73    
Marital .14 .12 1.24    
Race -.18 .18 -1.01    
Employ .06 .05 1.05    
Income .04 .03 1.11    
Education -.04 .07 -.55    
    R2=.60     
 Effect 95% CI     
Direct effect XY -.03 (-.14, .08)     
Conditional Indirect Perceived Severity  Perceived Vulnerability 
W = -1SD(-2.52) -.07 (-.30, .04) W = -1SD(-2.52) .09 (-.04, .32) 
W = 0 .01 (-.08, .15) W = 0 .06 (-.03, .22) 
W = 1SD(2.52) .09 (-.03, .33) W = 1SD(2.52) .02 (-.11, .22) 
Conditional Indirect Intrinsic Rewards  Extrinsic Rewards 
W = -1SD(-2.52) -.01 (-.07, .05) W = -1SD(-2.52) .01 (-.01, .07) 
W = 0 .05 (.01, .15) W = 0 .01 (-.01, .05) 
W = 1SD(2.52) .12 (.02, .28) W = 1SD(2.52) .00 (-.01, .05) 
Conditional Indirect Subjective Norm  Attitude 
W = -1SD(-2.52) -.01 (-.08, .02) W = -1SD(-2.52) .00 (-.08, .08) 
W = 0 -.00 (-.04, .01) W = 0 .08 (.01, .20) 
W = 1SD(2.52) .00 (-.02, .08) W = 1SD(2.52) .15 (.02, .36) 
* p<.05, ** p<.01, *** p<.001 
Description: Pain, drug seeking, and misuse (vignette) influences Intrinsic Rewards and Attitude.  
Risk of Addiction shows a moderating effect on Perceived Severity, Perceived Vulnerability, 
Intrinsic Rewards, and Subjective Norms. However, Risk of Addiction only interacts with pain, 
drug seeking, and misuse (vignette) to influence Intrinsic Rewards and Attitude. Perceived 
Vulnerability and Intrinsic Rewards both influence Intention. There was a significant conditional 
indirect effect of vignette on Intention towards all type misuse as mediated by Intrinsic Rewards 
and moderated by Risk of Addiction. Specifically, at perceived moderate and high levels Risk of 
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Addiction interacts with vignette to influence the perception of Intrinsic Rewards, which, in turn, 
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